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The work in this dissertation summarizes the development of a nitric oxide producing 
prodrug, JS-K in a polymeric Pluronic® P123 micelle formulation. This work is an 
attempt to advance the formulation development and provide the preclinical rationale by 
studying: a) formulation stability and toxicity in vitro and in vivo and plasma protein 
binding of the drug and the formulation in vitro; b) cell distribution of the free drug (JS-
K) and the formulation (P123/JS-K) in vitro; c) mechanistic pathways triggered by JS-K 
and P123/JS-K leading to apoptosis and finally; d) development and validation of an 
analytical method for detection of the drug or formulation and biological metabolites 
when used in clinical settings. 
Except for the mechanistic studies performed where the method employed was 
Western blot or fluorescence analysis, all the other studies were conducted using 
analytical methods developed on high performance liquid chromatography (HPLC) 
equipped with ultra violet (UV) detector. The available method lacked metabolite 
detection and sensitivity with low drug concentration. Therefore, a more robust, sensitive 
and elaborate method was developed using ultra performance liquid chromatography 
(UPLC) equipped with a UV detector. The method was also validated as per United 
States Pharmacopoeia (USP). The validated method could be used for studying 
biodistribution, pharmacokinetics and potential toxicity in clinical settings.
iv	  
The major findings of the dissertation could be succinctly described by stating JS-K 
in the Pluronic P123 formulation was comparatively more stable than in the free-JS-K 
formulation. There was no major toxicity observed due to the designed formulation when 
tested both in vitro and in vivo. P123/JS-K showed preferential distribution in the cell 
nucleus, indicating some effect produced by the Pluronic® micelle. Mechanistically, not 
much difference was observed between JS-K and P123/JS-K and both were shown to 
produce stress response in leukemia cells. Both JS-K and P123/JS-K were nontoxic to 
CD34+ hematopoietic cells. 
The work described in this dissertation is an attempt to showcase “Bench to Bedside” 
research in laboratory settings. An attempt has been made to incorporate all the studies 
required by the regulatory agencies such as US Food and Drug Administration (FDA). 
The studies performed and the method developed will lay the platform for future studies 
that are required for filing an Investigational New Drug (IND) application following 
current Good Manufacturing Practices (cGMP). 
	  	  	  	  	  	  	  	  	  	  	  
I would like to dedicate this dissertation to my parents, 
 Gurinder Pal Singh and Satwant Kaur 
for their unconditional support and encouragement 
and 
the omnipresent Almighty for anything and everything! 	  
  




LIST OF TABLES............................................................................................................. ix 
LIST OF FIGURES ........................................................................................................... xi 
PREFACE........................................................................................................................ xiv 
CHAPTER 
1. INTRODUCTION AND BACKGROUND ....................................................................1 
 
1.1 Leukemia ......................................................................................................................1 
1.2 Glutathione (GSH) ........................................................................................................2 
1.3 Glutathione-S-transferases (GST) .................................................................................5 
1.4 Nitric Oxide (NO) .........................................................................................................6 
1.5 Nitric Oxide Donors (NOD) and Arylated Diazeniumdiolates (ADZD) ....................10 
1.6 O2-(2,4-Dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-  1,2-       
diolate or JS-K ...................................................................................................................12 
1.7 Poloxamers...................................................................................................................16 
1.8 Pluronic® P123 (P123).................................................................................................19 
1.9 Unmet Needs................................................................................................................20 
1.10 References..................................................................................................................21 
 
2. DEVELOPMENT AND CHARACTERIZATION OF A PLURONIC® P123 
FORMULATION FOR THE NITRIC OXIDE-GENERATING AGENT JS-K ..............51 	  
2.1 Abstract ........................................................................................................................51 
2.2 Introduction..................................................................................................................52 




2.7 Future Perspectives ......................................................................................................74 
2.8 References....................................................................................................................75 
3. CELLULAR DISTRIBUTION STUDIES OF THE NITRIC OXIDE-GENERATING 
ANTINEOPLASTIC PRODRUG JS-K, FORMULATED IN PLURONIC P123 
MICELLE ..........................................................................................................................93 
	   vii	  
	  
3.1 Abstract ........................................................................................................................93 
3.2 Introduction..................................................................................................................94 




3.7 Authorship Contributions ..........................................................................................106 
3.8 Acknowledgements....................................................................................................106 
3.9 Disclosures.................................................................................................................106 
3.10 References................................................................................................................107 	  
4. MULTIPLE STRESS RESPONSES INDUCED BY THE NITRIC OXIDE- 
RELEASING PRODRUG JS-K ......................................................................................117 	  
4.1 Abstract ......................................................................................................................117 
4.2 Introduction................................................................................................................118 




4.7 References..................................................................................................................135 	  
5. DEVELOPMENT AND VALIDATION OF A METHOD TO MEASURE LEVELS 
OF THE NITRIC OXIDE-PRODUCING PRODRUG JS-K USING ULTRA 
PERFORMANCE LIQUID CHROMATOGRAPHY.....................................................147 	  
5.1 Abstract ......................................................................................................................147 
5.2 Introduction................................................................................................................148 
5.3 Methods .....................................................................................................................149 






6. SUMMARY OF RESEARCH, CRITIQUES AND SUGGESTED FUTURE  
WORK .............................................................................................................................178 
 
6.1 Chapter 2- Development and Characterization of a Pluronic® P123 Formulation for 
the Nitric Oxide-generating agent JS-K...........................................................................178 
6.2 Chapter 3 − Cellular Distribution Studies of the Nitric Oxide-generating 
Antineoplastic Prodrug JS-K, Formulated in Pluronic® P123 Micelles ..........................182 
6.3 Chapter 4- Multiple Stress Response Induced by the Nitric Oxide-releasing Prodrug 
JS-K. ................................................................................................................................187 
	   viii	  
6.4 Chapter 5- Development and Validation of a Method to Measure Levels of the NO-
producing Prodrug JS-K Using Ultra Performance Liquid Chromatography (UPLC) ...195 
6.5 Reference ...................................................................................................................198 	  
APPENDIX: ACTIVATION OF JNK PROTEIN BY JS-K OR P123/JS-K- A 
POTENTIAL MISSING LINK BETWEEN ENDOPLASMIC RETICULUM STRESS 
AND OXIDATIVE STRESS...........................................................................................202 
 
 
 LIST OF TABLES 
 
Table 
1.1 Estimated number of new cases of different Leukemia in United States (2013) ........43 	  
1.2 JS-K studies performed in various tumor types and the mechanism of action  
proposed in each study.......................................................................................................44 	  
2.1 MTS cytotoxicity assay on HL-60 and U-937 cells comparing JS-K and  
P123/JS-K ..........................................................................................................................87 
2.2 Size measurement of blank micelles and P123 loaded with JS-K at different 
percentages.........................................................................................................................88 	  
2.3 Stability studies of JS-K. Percent recovery of JS-K or P123/JS-K calculated at the 
indicated time points ..........................................................................................................89 	  
2.4 Binding Constants (Ka) obtained from equilibrium dialysis and fluorescence 
quenching and Stern Volmer constant (Ksv) obtained from fluorescence quenching at 
room temperature ...............................................................................................................90 
 
2.5 Stern Volmer quenching constant (Ksv) and HSA association binding constant (Ka) 
of JS-K and P123/JS-K at three temperatures: 298, 303 and 310 K..................................91 	  
2.6 Thermodynamic parameters for HSA and JS-K or HSA and P123/JS-K at three 
temperatures- 298, 303 and 310 K.....................................................................................92 
 
5.1 Drug loss with solid phase extraction (SPE) .............................................................173 	  
5.2 Comparison of solid phase extraction (SPE) and direct extraction method     
efficiency .........................................................................................................................174 	  
5.3 Intra-day accuracy of JS-K measurements ................................................................175 	  





5.5 Intermediate precision for Richman JS-K samples (formulated in DMSO) prepared 
and analyzed on two different days .................................................................................177 
A.1 JNK, pJNK and actin levels in two separate experiments. ......................................214 
LIST OF FIGURES 
Figure 
1.1 Etiology of Leukemia. In myeloid leukemias, the differentiation block occurs along 
the myeloid lineage while in lymphoid leukemias this occurs along the lymphoid  
lineage. ...............................................................................................................................35 
1.2 Multiple facets of Nitric Oxide ...................................................................................36 
1.3 Pro and anti apoptotic effects produced by NO...........................................................37 
1.4 Different classes of nitric oxide donors. Adapted from G.R.J.Thatcher, S. Anand. 
Nitric Oxide-Releasing Molecules for Cancer Therapy and Chemoprevention. ..............38 
1.5 NO release from ADZD...............................................................................................39 
1.6 Structure and activation of JS-K..................................................................................40 
1.7 Targets of JS-K’s action in hematological malignancies. AML relapse could be 
attributed to survival of leukemic stem cells (LSC) ..........................................................41 
1.8 Basic structure of block copolymer .............................................................................42 
2.1 Structure of JS-K .........................................................................................................79 
2.2 TEM image (magnification 667x) of 1mM JS-K loaded in 2.25% P123 micelles......80 
2.3 Critical micelle concentration (CMC) value of Pluronic® P123 as determined by 
plotting Absorbance (AU) with log Pluronic® % weight/volume .....................................81 
2.4 Stern Volmer Plot for JS-K and HSA or P123/JS-K and HSA at room temperature ..82 
2.5 Stern Volmer plot for JS-K and AGP or P123/JS-K and AGP at room temperature ..83 
2.6 Stern volmer plot for JS-K and HSA at 298, 303 and 310 K. ....................................84 
2.7 Stern volmer plot for P123/JS-K at 298, 303 and 310 K. ...........................................85 
	   xii	  
2.8 In vivo tumor regression analysis: NOD/SCID IL2Rgnull mice were injected with HL-
60 cells subcutaneously .....................................................................................................86 
 
3.1 Structure of JS-K .......................................................................................................111 
3.2 Percent recovery of JS-K from cytoplasmic and nuclear fractions when cells were 
incubated in PBS..............................................................................................................112 
 
3.3 Percent recovery of JS-K from the nuclear fraction when cells were incubated in 
PBS/10% FBS..................................................................................................................113 
 
3.4 Percent recovery of JS-K from the nuclear fraction when cells were incubated in 
RPMI/10% FBS ...............................................................................................................114 
 
3.5 S-glutathionylation of cytosolic proteins by JS-K: HL-60 cells were treated with 5 
µM JS-K and incubated for 30 minutes ...........................................................................115 
 
3.6 S-glutathionylation of nuclear proteins by JS-K. HL-60 cells were treated with 5 µM 
JS-K and incubated for 30 minutes..................................................................................116 
 
4.1 Phases and conditions of ER stress............................................................................142 
 
4.2 Activation of ER stress by JS-K. ...............................................................................143 
 
4.3 Actin band seen on HSC cells....................................................................................144 
 
4.4 Intracellular ROS levels after treatment with JS-K , P123/JS-K, P123, H2O2, or 
H2O2+P123/JS-K at 30, 60 and 120 min. ......................................................................145 
 
4.5 Proposed mechanism of stress response induced by JS-K ........................................146 
 
5.1 Structure and metabolism of JS-K .............................................................................165 
 
5.2 Chromatogram of JS-K and its metabolites. .............................................................166 
 
5.3 2,4-DNP standard curve using UV absorbance at 300 nm ........................................167 
 
5.4 GS-2,4-DNP standard curve using UV absorbance at 300 nm. ................................168 
 
5.5 Linearity of Richman JS-K compared to NCI JS-K samples at 5, 50, 100, 150 and 200 
µM at 1 µL injection volume. ..........................................................................................169 
 
5.6 Linearity of JS-K standards compared to JS-K samples at 5, 50, 100, 150 and 200 µM 
at 5 µL injection volume..................................................................................................170 
 
	   xiii	  
5.7 Specificity of JS-K at 1 µL injection. JS-K standards at 5, 50, 100, 150 and 200 µL 
were run in triplicate. Each set was injected twice. ........................................................171 
 
5.8 Specificity of JS-K at 5 µL injection: JS-K standards at 5, 50, 100, 150 and 200 µL 
were run in triplicates ......................................................................................................172 
 
A.1 Activation of ER stress by JS-K ..............................................................................211 
 
A.2 JNK protein phosphorylation after 4 hr or 6 hr treatment of HL-60 cells with JS-K or    
P123/JS-K. ......................................................................................................................212 
 
A.3 JNK protein phosphorylation after 4 hr or 6 hr treatment of HL-60 cells with JS-K or 






Work in this dissertation attempts to provide the preclinical rationale for the 
development of a nitric oxide (NO)-releasing prodrug, JS-K. Conventional 
chemotherapeutics suffer from several drawbacks, including drug resistance resulting in 
relapse. NO has shown activity against leukemia cells. It has also been found to induce 
differentiation in acute myeloid leukemia (AML) cells. JS-K, a NO donor (NOD) has 
shown activity against human leukemia (HL-60 cells) cells. The major limitations of the 
drug are its insolubility in addition to its quick degradation in blood. This is because the 
drug releases NO upon nucleophilic attack. The cysteines and thiols present in the blood 
degrade JS-K to release NO. Therefore, this dissertation focuses on the development of a 
JS-K formulation in polymeric Pluronic® P123 micelles. Each chapter can be considered 
as advancement in the JS-K development progressing steadily towards its clinical use.  
Chapter 2 discusses all the formulation development studies. JS-K was incorporated 
in Pluronic® P123 and I started development studies from there on. The studies 
encompassed Pluronic® P123 characterization using established methodologies to analyze 
the size, shape, specific gravity, viscosity and critical micelle concentration. The studies 
proceeded further with cell viability assays to test toxicity in vitro. Following in vitro 
cytotoxicity, the formulation stability study was carried out comparing nonformulated 
free JS-K with JS-K incorporated in P123 (P123/JS-K). The next set of studies was 
carried out to test the interaction of JS-K and P123/JS-K with major blood proteins- 
xv	  
human serum albumin and acid glycoprotein using techniques of equilibrium dialysis 
and/or fluorescence quenching. For the first time, to our knowledge, a study was 
conducted comparing two different techniques, i.e., equilibrium dialysis and fluorescence 
quenching in terms of accuracy and sensitivity. Finally, an in vivo tumor regression study 
was performed in NOD/SCID IL2Rgnull mice. The drug and the formulation effectiveness 
were established with greater tumor regression observed in the treated group as compared 
to the untreated control groups. 
Chapter 3 presents the cellular uptake of the free drug compared to formulated drug. 
HL-60 cells were used to study whole cell uptake and distribution of drug to the cytosol 
and to the nucleus. The drug uptake was analyzed using high performance liquid 
chromatography (HPLC). A sensitive JS-K detection method using an HPLC/UV 
detector was available for the analysis. This proved cost effective and advantageous, as 
the fluorescent/radio labeled JS-K was not available. Also, it would have added to the 
cost of analysis. The drug distribution studies established preferential distribution of 
P123/JS-K inside the nucleus. This result was tested in terms of the possible effect that 
could have been produced by the drug when distributed into the nucleus. S-
glutathionylation of cytosolic proteins was compared with the nuclear protein 
glutathionylation when HL-60 cells were treated with JS-K or P123/JS-K. Consistent 
with the uptake study, nuclear protein glutathionylation was greater than cytosolic protein 
glutathionylation. The results in this chapter laid the foundation for the mechanistic study 
of JS-K as summarized in Chapter 4. 
With nuclear protein glutathionylation established, it was clear that JS-K could induce 
glutathionylation. Such a posttranslational modification can work in favor or against the 
xvi	  
cell function and cell survival. We hypothesized that JS-K induced posttranslational 
modification and JS-K-released NO could pose stress to the tumor cell, leading to 
apoptosis. Chapter 4 summarizes results obtained when endoplasmic reticulum (ER) 
stress and oxidative stress were studied. This was an extensive study as ER stress was 
studied on HL-60 cells, primary AML cells and hematopoietic stem cells. We studied the 
rise in intracellular levels of reactive oxygen/reactive nitrogen species to test oxidative 
stress. Both ER stress and oxidative stress were induced by JS-K or P123/JS-K in HL-60 
cells. The study also showed that JS-K or P123/JS-K did not produce any ER stress in 
normal CD34+ hematopoietic cells, reflecting specificity of the drugs action on the tumor 
cells. 
Chapter 5 finally lays down the method to analyze the drug in the clinical settings. 
Although there was a HPLC method to analyze the drug, the method lacked sensitivity. 
Also, the drug is prone to degradation; therefore, a method was required to test small 
amounts of JS-K. In this study as well, to the best of our knowledge, two sample 
extraction techniques were compared for the first time. We compared the direct protein 
precipitation method with protein precipitation followed by solid phase extraction. The 
UPLC method development was carried out on spiked mouse blood samples. The 
development study was also executed on mouse organs. The developed method was 
qualitatively analyzed using mass spectrometry. After the method development, method 
validation study was performed. USP parameters (linearity, accuracy, precision and 
ruggedness) were studied to validate the method. This method is important as it allows 
measurement of JS-K byproducts as well. This is important in the clinical setting to test 
for the drug or its metabolites.  
xvii	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INTRODUCTION AND BACKGROUND 
 
1.1 Leukemia 
Leukemia is bone marrow cancer resulting from accumulation of uncontrolled, non-
functional hematopoietic cells. The term can be used to describe four major types based 
on the type and time of accumulation of the blood cells. While chronic leukemia results 
from a differentiation block at a later stage of differentiation, acute leukemia stems from 
an earlier differentiation block. Myeloid leukemia results from accumulation of myeloid 
blasts while lymphoid leukemia is manifested by accumulation of lymphoid blasts (5). 
According to the Leukemia and Lymphoma Society, nearly 291,521 people are currently 
suffering from or recovering from leukemia in the USA (6). Fig. 1.1 illustrates the 
involvement of the stem cells and development of different types of leukemia. Table 1.1 
shows the incidence of different types of leukemia. 
 
1.1.1 Acute myeloid leukemia (AML) 
1.1.1.1 Disease and incidence 
AML is a blood malignancy characterized by uncontrolled expansion of myeloid blast 
cells in the bone marrow and peripheral blood or other tissues (7). AML is the most 
common adult acute leukemia (8) and progresses rapidly without treatment. This 
leukemia is diagnosed commonly in older patients with a median age of 67 years. In older 
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patients, the response to chemotherapy is lower than in younger patients, making it a 
particularly challenging disease in the older age group (9).  
 
1.1.1.2 Treatment options available and the impact 
Currently AML is treated with cytotoxic chemotherapeutics aimed at killing leukemic 
blasts. The induction therapy includes anthracycline/cytarabine combinations followed by 
consolidation therapy. In certain cases, autologous or allogenic hematopoietic stem cell 
transplantation is performed to achieve complete eradication and generate immune 
response (10).  
 
1.2 Glutathione (GSH) 
Glutathione or L-γ-glutamyl-L-cysteinyl-glycine is composed of three amino acids 
and synthesized de-novo by the action of two energy dependent enzymes, γ-glutamate-
cysteine ligase and GSH synthase (11).  It is the most abundant nonprotein thiol present 
in the cell with 85-90 % localized in the cytosol (12). GSH is an essential antioxidant and 
is necessary for cell survival. It is involved in a plethora of functions, including cell 
signaling, cell detoxification by xenobiotic efflux response, thiol-disulfide reversible 
reaction and providing a reservoir for the cysteine pool (13). The redox status in the cell 
is maintained by a delicate equilibrium between reduced GSH and the oxidized/disulfide 
form of GSH (GSSG). Such an equilibrium is important for providing a reducing 
environment for maintaining proteins in the reduced form and also allowing reversible 
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1.2.1 Glutathione as redox regulator 
The ratio of GSH/GSSG is critical for maintaining the redox balance of the cells. 
Proteins are generally kept in reduced form by GSH (15). In addition to changes in 
GSH/GSSG levels, the cellular redox status could be changed by depletion of GSH levels 
due to xenobiotics/drug metabolism and reactive oxygen or reactive nitrogen species 
generation (16). Redox sensitive proteins have a thiol moiety on the side chain of the 
cysteine (Cys) residue that is sensitive to the redox status of the cell and prone to S-
glutathionylation. These Cys residues can exist as thiolate anions at physiological pH and 
can have charge interactions with the basic amino acid residues. This makes them more 
prone to oxidation. While reversible oxidation can result in the formation of sulfenic acid 
and protein or formation of mixed disulfides, irreversible oxidation (more detrimental) 
results in the formation of sulfinic acid and sulfonic acid (17). 
 
1.2.2 Glutathione and protein posttranslational modification 
Protein glutathionylation is a reversible reaction (except in the cases where sulphonic 
acid moieties are formed) occurring under physiological conditions and under conditions 
of oxidative and nitrosative stress (17). It can occur between two proteins (interprotein) 
or within a protein (intraprotein disulfide) (18). Protein glutathionylation is determined 
by the availability of the cysteine residue that is dependent on its three-dimensional (3D) 
conformation and reactivity. Also, modification of protein thiol can affect the protein 
activity, depending on the cysteine residue involved. Broadly, protein glutathionylation 
can occur in five different ways (19): 
a) Thiol-disulphide exchange 
PSH + GSSG  P-S-S-G + GSH 
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This reaction is mainly determined by the GSH/GSSG ratio. 
PSH: protein sulfhydryl. PSSG: protein disulfide. 
b) Direct oxidation 
GSH + PSH  PSSG 
PSH: protein sulfhydryl. PSSG: protein disulfide. 
c) Formation via intermediates: Sulfinic acid- and sulphonic acid-formed oxidized 
products are stable and irreversible. They are formed under oxidizing conditions.  
The cysteine-sulfenic acid (SOH) can also react with GSH. It forms a reversible 
product. This two step reaction can be represented as: 
PSH + H2O2  PSOH + H2O 
PSOH + GSH  P-S-S-G + H2O 
PSOH: protein-sulphenic acid 
d) S-nitrosothiols: Protein-S-nitrosothiols react with GSH to form S-
nitrosoglutathione (GSNO) releasing free protein. The S-nitrosoglutathione then reacts 
with GSH again  
PS-NO + GSH  GSNO + Protein 
GSNO + GSH  GS-SG + HNO 
GS-SG + PSH  PS-SG + GSH 
e) Thiyl radicals: Hydroxyl radicals (OH°) react with GSH to form thiyl radicals 
(GS°). The reaction of glutathionylated protein could be catalyzed by glutaredoxin. 
PSH + HO°  PS° + H2O 
PS° + GS°  PS-SG 
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The primary method of formation of gluatathionylated protein is by thiol-disulfide 
exchange. This generally occurs when GSH/GSSG equilibrium is disturbed and the 
GSSG form exceeds the GSH form. Exchange occurs between the thiol group of the 
protein and the disulfide group of the GSSG to form protein disulfide and glutathione 
(20). Protein glutathionylation also results during the conditions of oxidative stress where 
protein sulfhydryl can directly be oxidized to protein disulfide in the reaction catalyzed 
by oxidants. Glutathionylated proteins can also be formed irreversibly via sulfenic acid 
intermediates. S-nitrosothiols and thiyl radicals can also form reversible or irreversible 
glutathionylated proteins (21).  
 
1.2.3 Glutathione in cell survival 
GSH has been found to be important for cell survival. In the past, studies have shown 
that GSH deficient cells are prone to apoptosis (22). Apoptosis or programmed cell death 
has been found to be modulated by GSH levels or by the posttranslational modifications 
of proteins induced by GSH. Early stages of apoptosis are therefore considered the 
hallmark of the cell death process. Oxidation of GSH to GSSG could occur due to the 
reactive species generated by the chemotherapeutics or metals and xenobiotics. This later 
leads to apoptotic response (23-26). 
 
1.3 Glutathione-S-transferases (GST) 
GST constitute a family of phase –II detoxification enzymes involved in catalytic and 
noncatalytic functions. They are divided into cytosolic or microsomal classes. While the 
microsomal GST are involved in leukotriene and prostaglandin metabolism, the cytosolic 
GST are divided into seven isotypes: GST α (A), GST µ (M), GST π (P), GST σ, GST θ, 
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GST ω and GST ζ. GST A, M and P have been found to be involved with tumor 
progression and chemotherapy resistance (27). The catalytic function of GST involves the 
catalysis of reaction between glutathione and xenobiotics and thus efflux of the conjugate 
by rendering it more water-soluble. The reaction takes place at the S atom of the 
glutathione with an electrophilic group (from the xenobiotic). The noncatalytic function 
of GST includes their inhibition of c-Jun-N-terminal-kinase protein (cJNK) (a stress-
induced mitogen activated protein kinase (MAPK) protein), thus inhibiting apoptotic 
response (28). Therefore, drug resistance induced by GST could be attributed to either 
direct detoxification response or indirect response by inhibiting the MAP kinase pathway. 
 
1.4 Nitric Oxide (NO) 
NO is a free radical involved in a variety of physiological functions of the cell. The 
physiological functions of NO encompass smooth muscle relaxation, neuronal 
transmission and platelet aggregation. It is involved in cell signaling by inducing post-
translational modifications (29). NO moieties could be incorporated into protein groups 
and lead to reversible or irreversible protein modification, as explained later in detail. NO 
is also involved in inflammation, mutagenesis and carcinogenesis (30). On the other 
hand, NO has also shown antitumoral properties. It can lead to apoptosis by targeting 
various cellular sites and bringing about posttranslational modifications such as S-
Nitrosylation, S-Glutathionylation and ribosylation (2). Also, NO was found to induce 
differentiation in AML cells (31, 32). Thus NO enacts as the double-edged sword where 
the function of NO is dependent on source of NO (endogenously generated or 
exogenously supplied), cell type, concentration, rate of delivery and production (if 
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endogenous source) (4). Due to the diverse and pleiotropic effects of NO, it is important 
to deliver it at the target site. Fig. 1.2 shows the multiple facets of NO. 
 
1.4.1 Nitric oxide as a free radical 
Endogenously, NO is generated by three isoforms of the nitric oxide synthase (NOS): 
inducible NOS (iNOS), endothelial NOS (eNOS) and neuronal NOS (nNOS) (33). NO 
can react with oxygen to form reactive nitrogen species (RNS) or with glutathione to 
form S-nitrosoglutathione (GSNO called as S-nitrosylation) (34) or with heavy metals 
(35) or with macromolecules such as DNA (36) and proteins. NO also leads to S-
thiolytion, disulfide bond formation, sulfenic, sulfinic and sulfonic acid derivatives. 
Under normal physiological conditions, the cells maintain a reducing environment with 
antioxidants (such as GSH, superoxide dismutase, Vitamins A, E and C) present. This 
keeps reactive oxygen and reactive nitrogen species at low levels, thus protecting the 
cells from oxidative damage. In a broad sense, RNS includes nitric oxide radical (NO°), 
peroxynitrite (ONOO-) and nitrogen dioxide radical (NO2°) (2). Alternatively, NO can 
also act as antioxidant and react with ROS such as superoxide (37).  
 
1.4.2 Nitric oxide and protein modification 
NO modulates cell signaling by inducing posttranslational modifications that affect 
protein structure, activity and function. Such modifications can be brought about by 
direct interaction of NO with proteins or by producing RNS. Such an addition occurs 
generally at the Cys residues of the proteins (38). S-nitrosylation affects cell signaling 
and major processes such as phosphorylation, acetylation, palmitoylation and 
ubiquitylation, affecting cell survival (39). Nitration of proteins also occurs at the 
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tyrosine residues (to form protein 3-nitrotyrosine) as a response to oxidative stress. This 
generally occurs through peroxynitrite generation. Such a nitration serves as a biomarker 
for nitrosative stress (40). The posttranslational modification induced affects the 
hydrophobicity, redox potential, pKa and volume of the affected protein (41, 42). NO can 
also induce intermolecular and intramolecular disulfide bonds affecting structure and 
reactivity of proteins (43). 
 
1.4.3 Nitric oxide and glutathione 
S-nitrosylation, a posttranslational modification, occurs after oxidation of NO to 
dinitrogen trioxide (N2O3) that acts as source of nitrosonim ion (NO+). In addition to 
N2O3, other sources of NO+ include nitrous acid (HNO2), alkylnitrite and dinitrogen 
tetraoxide (N2O4) (44). S-Nitrosylation reactions can then proceed through reactions of 
NO with thiolates, thiyl radicals and transition metals (45). S-nitrosylation is enhanced 
with high hydrophobicity of proteins (46). It has been found that S-nitrosylation of 
proteins enhances glutathionylation (47). S-nitrosyltion has been found to be abnormal in 
pathological conditions, including cancer (46). Cys residues of proteins are prone to 
redox-based modifications and electrophilic substitution reactions. Glutathionylation of 
Cys is one such redox-based modification. S-nitroso-GSH or GSNO is the most abundant 
non-protein thiol in the cell and undergoes group transfer reaction to glutathionylate 
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1.4.4 Nitric oxide and cell survival 
Nitric oxide promotes cell growth but has also been found to induce cell senescence 
(1). In general, the cell survival pathways of NO are linked with protumorigenesis effects. 
Therefore, NO can produce both pro- and antitumorigenic effects. This has been 
explained in Figures 1.2 and 1.3.  
 
1.4.5 Nitric oxide and cancer 
NO has been implicated in cancer. This radical can be both procancerous and anti-
cancerous, depending on the concentration, the cell type affected and the type of tumor 
microenvironment (49, 50). Several studies have been performed with NO or NO donors 
with or without chemotherapeutic agents and mixed responses have been observed (49). 
NO has been shown to be involved with cancer progression through tumor migration, 
invasion, angiogenesis and metastasis (1). Studies have suggested that NO, iNOS and 
sometimes eNOS are involved in solid tumors such as lung cancer, melanoma, colon 
cancer and pancreatic cancer (51-55). On the other hand, solid tumors have also been 
shown to become sensitive to chemotherapeutics when NO (by itself or in the form of 
NO donor) is included with regular chemotherapy or other drugs targeting cancer cells 
(56-60). Thus, NO can act as a chemosensitizing agent (37). Mitochondria, the energy 
store of the cell, gets nitrated under basal and diseased conditions (61), thus affecting cell 
survival. The mechanisms of protumorigenesis and antitumorigenesis effects of NO have 
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1.5 Nitric Oxide Donors (NOD) and Arylated 
 Diazeniumdiolates (ADZD) 
As explained in the text, millimolar concentrations of NO can induce apoptosis. 
Therefore, NO donors hold great potential as effective chemotherapeutic agents. To date, 
various NO donors are available clinically or are in process of development (organic 
nitrates, metal-NO complexes, diazeniumdiolates or drug conjugated to NO) (30, 58, 60, 
62, 63).  The different classes of NOD are shown in Fig. 1.4.  
Generally, the nitrate and the furoxan classes of NOD have been studied in 
chemoprevention and the diazeniumdiolates class has been studied in chemotherapy. 
Therefore, with use of NOD, generally one of the purposes is achieved that includes 
either direct chemotherapy or use of NOD for chemoprevention or using the NOD for 
attenuating the side effects produced due to chemotherapy (64). Diazeniumdiolates 
(DZD) could be regarded as NOD acting as prodrugs releasing NO spontaneously or due 
to some enzymatic reactions (65, 66).  Generally, a diazeniumdiolate ion (or the sodium 
salt) is first prepared by exposing a solution of a suitable nucleophilic compound (X-) to 
5 atmospheres of NO under anaerobic conditions (67).  Structural studies confirmed the 
substantial double bond character of the N=N linkage of many X-N(O)=NO- ions, with 
the oxygen atoms being cis to one another; this and other features of their structures led 
to their formal designation as “diazeniumdiolates”. A structural example of such a DZD 
salt would be X-N(O)=NO- Na+, where one of the oxygen atoms (O2 ) can form a salt 
(66).  
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Also, when X is a secondary amine residue, these products were found to yield 2 
mol/mol NO at physiological temperature and pH, with half-lives ranging from 2 s to 20 
h, depending on the type of the amine moiety attached (66). 
It was further discovered that for X-N(O)=NO- Na+, the ionized oxygen, (O2 ), can be 
further derivatized (i.e., alkylated) to provide additional stability to the entire compound.  
The addition of various moieties to the O2 oxygen of the DZD is generally called “O2 - 
alkylation”, and forms the protecting/shielding group (68) as explained later in the text.   
In contrast to other NO donors, DZD are easy to manage and study, as they release 
NO at first order rate in simple aqueous solutions or buffered solutions without requiring 
any redox activation. This allows the study to be carried out easily with steady NO 
generation (66). Also, they offer potentially site-selective NO release. Their rate and 
duration of NO release could be altered and modified (69). In the arylated 
diazeniumdiolates (ADZD), the O2 position of the diazeniumdiolate is derivatized by an 
aryl shielding group to form a prodrug (70) (Fig. 1.5). ADZD are NO-generating 
prodrugs (JS-K, an ADZD has 2,4-dinitrophenyl as the shielding group). They are 
designed to be activated by GSH or other nucleophiles; the reaction can be catalyzed by 
GST. As explained before, GST enzymes catalyze the reaction between the S atom of 
GSH and the electrophilic center of xenobiotics, making the formed complex more water-
soluble.  
ADZD provide an electrophilic center for the GST enzyme and release NO upon 
attack by cellular nucleophiles, including GSH (71). As stated before, the GST-π isoform 
is over-expressed in several tumors and α and µ forms are expressed to a lesser extent 
comparatively (28). Therefore, ADZD were designed to be activated by upregulated 
	   12	  
isoforms. Out of the several ADZD, PABA/NO (70-73) and JS-K (74-93) have been 
studied extensively for their anticancer effects. Molecular modeling studies showed that 
PABA/NO structure was designed to fit GST-π whereas the JS-K structure fits well to the 
GST-α and µ forms (71). In our lab, we continued our studies with JS-K.  
 
1.6 O2-(2,4-Dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1- 
yl]diazen-1-ium-1,2-diolate or JS-K 
1.6.1 Need for development 
Cancer cells have been found to be sensitive to the effect of NO (94). Also, in 
previous studies, it was shown that AML cells showed unusual sensitivity to NO (32, 95). 
Because of the above stated reasons, a library of the ADZD was tested using HL-60 
human AML cells and JS-K was found to be the most potent inhibitor in vitro and in vivo 
with an IC50 ranging from 0.2-0.5 µM. JS-K is a prodrug and releases NO upon action by 
GSH or other cellular thiols with or without GST catalysis. 
 
1.6.2 Chemistry 
JS-K (Fig. 1.6) chemistry shows that this ADZD can release NO upon nucleophilic 
attack on the dinitrophenyl (DNP) ring. The DNP ring stabilizes the whole structure. 
During the development of the compound, structure activity relationship studies were 
performed and the metabolites of JS-K were studied and tested for their in vitro cytotoxic 
potential on the HL-60 cells. It was found that in addition to NO, the other metabolites, 
namely N-(ethoxycarbonyl)piperazine (IC50 8.6 µM) and glutathione-dinitrophenyl ( IC50 
8.4 µM) were cytotoxic as well (89).  JS-K is a very labile compound and it slowly 
hydrolyzes to release dinitrophenol.  
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1.6.3 Potential chemotherapeutic 
JS-K has shown toxicity towards a broad spectrum of cancer cell types. Several in 
vitro studies have been performed on various cell types to study the cytotoxic effects of 
JS-K, as detailed later in the text. As stated before, the initial screening of ADZD was 
carried out with leukemia cells. JS-K’s cytotoxic effect has been tested on hematological 
malignancies, including myeloid leukemia (88-91), lymphoid leukemia (86) and 
myeloma (79). JS-K’s cytotoxicity was also tested on solid tumors, including prostate 
(90), breast (84), lung (82), colon (76), liver (87) and glioma (93). The mechanism of JS-
K action was also studied in several tumor types (Table 1.2). Conclusion of these studies 
was that JS-K has a broad spectrum of activity and is cytotoxic through different 
mechanisms, thus holding promise as a drug candidate. In our lab, JS-K in vitro 
cytotoxicity and in vivo tumor regression was studied using prostate cancer cells and 
AML cells. Although JS-K possessed cytotoxic potential in both the cancer types, higher 
sensitivity was observed in AML cells. It was inferred that JS-K showed higher 
sensitivity towards rapidly dividing liquid cancers as compared to slowly proliferating 
solid cancers (90). 
 
1.6.4 Mechanism of JS-K cytotoxicity 
Several studies have been performed with an attempt to delineate the mechanism of 
JS-K toxicity. Some common mechanisms have been reported in both solid and liquid 
tumor models. Table 1.2 outlines the proposed mechanisms in different tumor models. 
Recent literature has suggested that the relapse of AML could be attributed to the 
presence of a subpopulation of leukemic stem cells (LSC). Factors leading to survival of 
LSC could be divided into “extrinsic” factors (EF) and the “intrinsic” factors (IF) (96). 
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While the IF includes the cell cycle regulators, prosurvival pathways (NFκB), cell stress 
(oxidative, genotoxic etc) and self renewal components/pathways (β-catenin) (97), the EF 
encompasses the factors relating to the tumor microenvironment (bone marrow in the 
case of AML) and broadly includes chemokine receptors (CXCR4), adhesion molecules 
(CD44) and proteins involved in the maintenance of the hypoxic tumor environment (96). 
Mechanistic studies of JS-K have been performed with respect to both IF and EF. 
Although most studies were performed on tumor cells and not the tumor stem cells, the 
studies lay the foundation for future experiments that could be performed in tumor stem 
cells. The IF’s such as the cell cycle regulation (86, 90), survival pathways (NFκB) (77), 
cell stress (79, 82, 84, 87) and self renewal pathway (86) have been explored in liquid 
cancers and some solid cancers. Also, the EF such as angiogenesis (78) and survival and 
growth factors required for the maintenance of the tumor have been studied (79). In our 
lab, we studied mainly the IF affected by JS-K in leukemia. An effective 
chemotherapeutic is required to possess broad mechanism and nontoxicity towards 
normal cells. In our lab and in other labs, JS-K was found to be nontoxic to normal cells. 
(75, 79, 84)  Another important aspect of JS-K revealed its potential use in personalized 
medicine. In the lung cancer model, JS-K was found to be particularly toxic to a subset of 
a panel of various lung cancer cell lines (82). The cell lines with basally higher levels of 
reactive oxygen or reactive nitrogen species were most sensitive to JS-K’s effect. Fig 1.7 
shows factors related to AML relapse and JS-K’s potential effects on those factors. 
 
1.6.5 JS-K synergy with other drugs 
With its broad mechanisms of action, JS-K was tried in combination studies. This is 
important for the future clinical application of the drug. The combination studies were 
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performed with cytarabine (ARA-C), daunorubicin and etoposide in AML. JS-K showed 
strong synergy with ARA-C in HL-60 cells. On the other hand, it showed antagonism 
with daunorubicin and etoposide (88). In another study, JS-K showed the reversal of 
resistance by making cells more sensitive to clinical chemotherapeutics like arsenic and 
platinum. JS-K also resulted in the increased accumulation of these chemotherapeutics 
(80). In yet another study, JS-K combination with the proteasome inhibitor Bortezomib 
was studied (79). The study showed that low doses of Bortezomib were synergistic with 
JS-K. Bortezomib is now used for the treatment of relapsed multiple myeloma (98) and 
refractory mantle cell lymphoma (99). One of the possible mechanisms could be the 
triggering of the endoplasmic reticulum (ER) stress. Bortezomib, being a proteosome 
inhibitor, causes ER stress (100) due to accumulation of proteins. In our lab, we studied 
ER stress triggered by JS-K (positive). Therefore, it could be argued that along the same 
lines, the combination might show synergism with JS-K in AML cells as well. Recently, 
Bortezomib has been tried in combination with experimental drugs in vitro (101) and 
with clinical chemotherapeutic in AML patients (102, 103). Another reason we propose 
for the possible synergism between JS-K and Bortezomib is the induction of oxidative 
stress by both drugs (100). Also, Bortezomib has been found to inhibit the NFκB survival 
pathway (104).  
 
1.6.6 Pitfalls in JS-K development and alternatives 
One of the major drawbacks in the use of JS-K is its extremely short half life. Half 
life is an important factor for JS-K development as the release of NO affects 
physiological function. The immediate release of NO not only prevents the drug 
distribution to the site of action but also could result in potential hypotension. Although 
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the studies performed showed no such hypotensive effects at therapeutic doses, 
hypotension could occur at higher doses. Another major hurdle in the JS-K development 
was its extreme hydrophobicity. Therefore, a polymer Pluronic® formulation of JS-K was 




1.7.1 Polymers and drug delivery 
“Polymer therapeutics” refers to the use of the polymer in evoking or modifying 
pharmaceutical drug availability and/or mechanism of action (105). Drug delivery of 
hydrophobic drugs using polymeric nanoparticles is a promising strategy. In addition to 
solubility of the drugs, drug incorporation also offers stability, targeting, controlled 
release, prolonged duration, reduced toxicity and some extent of biological activity 
imparted by the polymer itself (106, 107). The field has progressed significantly in the 
delivery of anticancer drugs. This is because of the systemic toxicity and extensive 
clearance due to action of drug efflux proteins on nonformulated chemotherapeutics. 
Therefore, polymeric systems offer the advantages of drug encapsulations and limited 
interaction with the healthy cells, thus enabling dose increase and reduced toxicity (108). 
Polymeric systems could be prepared and used according to need. They could be used for 
passive targeting or active targeting. They could also be designed for site-directed 
delivery or site-triggered delivery. They could be made pH responsive or temperature 
responsive (109-114). Nine polymeric anticancer (nanomedicine) drugs have been 
approved for clinical use so far (115). 
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1.7.2 Polymeric micelles/Pluronic® or poloxamers 
Polymeric micelles obtained from block copolymers are nano-sized drug delivery 
systems possessing a hydrophilic shell (providing steric stability and targeting ability) 
and drug encapsulating hydrophobic core (encapsulation could be nonionic or ionic or 
covalent). The size range of these systems usually fall from 10-100 nm, which offers the 
advantage of bypassing both renal clearance and the reticuloendothelial system (116). 
Also, the abnormal tumor vasculature allows enhanced permeability and retention of the 
chemotherapeutic when encapsulated in polymeric micelles (117). Polymeric micelles 
have been used to deliver chemotherapeutics, imaging agents, small proteins and 
peptides, DNA and siRNA (111, 118-125) 
Amphiphilic block copolymers can form polymeric micelles. They consist of a basic 
unit comprised of ethylene oxide (EO) and propylene oxide (PO) arranged as EO-PO-EO 
units (Fig. 1.8). The number of EO and PO can be altered, resulting in polymeric micelle 
of varying hydrophobicity (high PO content), chain length, hydrophilic-lipophilic balance 
and critical micelle concentration (105). 
 
1.7.3 Advantages and disadvantages offered by poloxamers 
Poloxamers have been used extensively as drug excipients, thus enhancing drug 
solubility and delivery (105). They have shown activity against drug efflux transporters 
due to their ability to form micelles. The unimers interact with the cancer cells and inhibit 
the drug efflux transporters, thus leading to sensitization of the cell to enhance drug 
accumulation (126, 127).  The formed micelles have prolonged circulation due to their 
stability against dilution. As explained before, the shell and the core of the formed 
micelle can be designed based on the need. Due to the above advantages, poloxamers 
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could be considered as potential drug delivery systems with low toxicity (128). The use 
of Pluronic in the clinic has also highlighted some disadvantages offered by this miceller 
system. These include compromised drug loading capacity, poor blood stability as 
compared to other polymeric systems and limited information about their interaction with 
cells and effects produced (129). 
 
1.7.4 Physical properties of poloxamers affecting drug delivery 
The properties affecting the poloxamer structure, drug incorporation capability and 
bioactivity could be summarized as following: 
 
1.7.4.1 Critical micelle concentration (CMC) 
The individual block copolymers of the poloxamer possess the potential of self-
assembly into micelles.  The concentration at which micellization occurs is termed the 
critical micelle concentration or CMC. When the concentration exceeds the CMC, there 
exists a dynamic equilibrium between the unimers and the micelles. The chain length 
affects CMC as increase in the PO length reduces the CMC (130). CMC is important 
from a drug delivery aspect as it determines the stability of the micelle. This is explained 
in the following section. Also, it affects the biological response produced by the 
poloxamers (105). 
 
1.7.4.2 Thermodynamic stability 
The thermodynamic stability of polymeric micelles could be defined in terms of 
standard free energy change for the micellization process as: 
dG= RTln(CMC) 
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The CMC of block copolymer is usually in the range of 10-6-10-7 M, which is nearly 
three-four times lower when compared to small molecule surfactants. Due to this, 
poloxamers offer increased stability. This prevents extensive dilution of the micelles in 
the body fluids; thus, there is a reduced probability of these micelles to disassemble at 
small concentrations (128). The poloxamers also possess kinetic stability that provides 
protection to the micelle structure enabling a slow disassembly into unimers at extreme 
dilutions (131). 
 
1.7.4.3 Micelle size 
Generally, micelles preferred for pharmaceutical applications are less than 100 nm 
(105). The size of the micelle is an important consideration as it affects circulation in the 
blood and biodistribution (132). 
 
1.8 Pluronic® P123 (P123) 
P123 is an amphiphilic polymeric micelle with a molecular weight of 5750. The 
average number of EO and PO units are 40 and 70, respectively, with a CMC value of 4.4 
µM (105). P123 possess higher stability due to longer hydrophobic block and low CMC 
value (133). Several studies have been performed where P123 alone or in combination 
with other poloxamer has been used to deliver chemotherapeutics. In one such study, 
Paclitaxel (PTX) was incorporated in P123 and the studies revealed higher accumulation 
of the drug in the tumor tissue. It also showed improved pharmacokinetic profile when 
compared to nonformulated PTX (134). Although P123 is not FDA approved like F127 
and F68 (133), the increasing number studies performed with this poloxamer (133-139) 
illustrate its potential therapeutic and clinical application. 
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1.9 Unmet Needs 
Treatment of acute myeloid leukemia is still an unmet need because of the high 
incidence of relapse in spite of aggressive therapy (140). Treatment failure combined 
with the development of drug resistance makes remission challenging.  Leukemia relapse 
has been attributed to the presence of leukemia stem cells (LSC) or leukemia initiating 
cells (LIC) that were discovered over a decade ago (141). Recent data suggest that one 
could target LSCs by targeting surface antigens expressed on LSC or by affecting the 
microenvironment supporting LSC interaction or by inhibiting the signaling pathways 
that provides growth signals and self-renewal potential to the LSC (96). 
Cancer cells acquire resistance due to development of the multidrug resistance 
phenotype (MDR phenotype) by activation of efflux proteins such as MRP1, ABC and 
BCRP; due to repair of damaged DNA; gene mutations such as that of p53 or by over-
expressing detoxification enzymes such as GST. As stated by Townsend et al., one of the 
most effective way of targeting resistance and thus cancer is to exploit the therapeutic 
potential of GST. They suggest three ways to target GST. GST’s could be targeted with 
GST inhibitors, drugs that promote GST oligomerization and thus JNK activated 
apoptotic pathway or by exploiting the elevated GST expression in the tumors by 
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Myeloid	  type	  leukemia Lymphoid	  type	  leukemia 
Fig. 1.1: Etiology of Leukemia. In myeloid leukemias, the 
differentiation block occurs along the myeloid lineage while 
in lymphoid leukemias this occurs along the lymphoid 
lineage. See text for detail. Adapted from cancer.gov. 
	   	  































(ER Stress): a) 
Disturbance of Ca 
homeostasis. b) By 
producing 
oxidative stress via 
cytochrome c 
pathway 
Formation of OONO- can 
oxidize nuclear DNA and 
cause DNA damage 
S-nitroso glutathionylation 
depletes cell GSH leading to 
apoptosis (oxidizing 
environment)  condition of 
Oxidative Stress 
S-Nitrosylation can 







c, NFKB inhibition, 
reduced BCL2 
expression and high 
p53 expression 
Fig. 1.2: Multiple facets of Nitric Oxide. Data from (1-4). 
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a) Due to overexpression of
endogenous NO nitrosative 
stress is induced and cell 
death pathways activated. 
b) Overexpression of NO
produces anti-angiogenic 
effect.  
c) NO alters mitochondrial
membrane permeabilization 
thus sensitizing cells to 
apoptosis. 
d) It causes DNA damage.
e) Transcription factors such
as NFKB, zinc fingers and 
AP1 can be post-
translationally modified by 
NO and lead to apoptosis. 
Proapoptotic effect 
a) Overexpression of
endogenous NO. NOS 
inhibitors induce tumor 
regression. 
b) Evidence suggesting tumor
progression by elevated NO 
due to matrix 
metalloproteinase.             
c) Metastatic potention of NO
has been linked to reaction of 
peroxynitrite with superoxide 
leading to increased vascular 
permeability.                     
d) Elevated NO in tumor has
also been linked with 
overproduction of VEGF 
Antiapoptotic effect 
	  Fig. 1.3: Pro- and antiapoptotic effects produced by NO. Data 









True NO donors. JS-K 
belongs to this class
Fig. 1.4: Different classes of nitric oxide donors. Adapted from G.R.J. Thatcher, S. 
Anand. Nitric Oxide-Releasing Molecules for Cancer Therapy and 
Chemoprevention. In B. Bonavida (ed.), Nitric Oxide (NO) and Cancer, Vol. Part 
VII, Springer, New York, 2010, pp. 362. 





























Fig. 1.5: NO release from ADZD 














Fig. 1.6:  Structure and activation of JS-K 



























































in HL-60 cells 
Fig. 1.7: Targets of JS-K’s action in hematological malignancies. AML relapse 
could be attributed to survival of leukemic stem cells (LSC). Factors 
supporting LSC survival are in red, pathways related to those factors are in 

































Fig. 1.8: Basis structure of block copolymer. Number of “a” and 
“b” units differs in the different types of block copolymers. 
































Table 1.1: Estimated number of new cases of different Leukemia in United 
States (2013) 
Type Total Male Female 
Acute lymphoblastic leukemia 6,070 3,350 2,720 
Chronic lymphocytic leukemia 15,680 9,720 5,960 
Acute myeloid leukemia 14,590 7,820 6,770 
Chronic myeloid leukemia 5,920 3,420 2,500 
Other leukemia 6,350 3,570 2,780 
Total estimated new cases 48,610 27,880 20,730 
Source: Cancer Facts and Figures 2013, American Cancer Society; 2013, 
cancer.org 








Table 1.2: JS-K studies performed in various tumor types and the mechanism of action 
proposed in each study 
JS-K 
formulation 
Tumor type In vitro cell 
line/ 
IC50 
In vivo Proposed MOA 












treated at dose 














necrosis (90).  
a) Intrinsic (caspase 3 & 
9) and extrinsic apoptotic 
pathway (caspase 8) 
(92) 
b) Differentiation of 
leukemia (HL-60 cells) 
cells (90). 
c) Oxidative stress 
d) ER stress 
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Table 1.2 continued 
JS-K 
formulation 
Tumor type In vitro cell 
line/ 
IC50 
In vivo Proposed MOA 
P123/JS-K AML HL-60 
cells, 
U937 cells  
 a) Oxidative stress 







IC50 = 9 
µM (48 
hrs) 
 a) JS-K modulated the b-
catenin pathway by 
reducing b-catenin/TCF-
4 inhibitory activity. 
b) Nuclear b-catenin S-
nitrosylation was 
observed. 
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Table 1.2 continued 
JS-K 
formulation 
Tumor type In vitro cell 
line/ 
IC50 

































a) Up to 2.5 µM JS-K 
was found to be non 
toxic in healthy 
peripheral blood 
mononuclear cells. 
b) Induction of apoptosis 
through PARP, caspase 8 
and 9 cleavage (time 
course and dose 
dependent study (0.6-2.5 
µM). This study was 
carried out in MM.1S 
cells. 
c) JS-K treatment 
overcame the survival 
advantages conferred by 
growth factors such as 
IL-6 and IGF-1. 
d) Cytotoxicity produced 
by JS-K is mediated by 
NO• 
e) JS-K produces 
genotoxicity by inducing 
DNA double strand 
breaks and activating 
DNA damage response. 
f) JS-K caused activation 
of JNK protein. 
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Table 1.2 continued 
JS-K 
formulation 
Tumor type In vitro cell 
line/ 
IC50 
In vivo Proposed MOA 
JS-K 
0.5 or 1 µM 
Breast Cancer MDA-MB-









 a) Anti-invasive effects 
by affecting mitogen-
activated protein kinase 
(MAPK) and by 
increasing TIMP-2 
production. 
b) 0.5 µM JS-K did not 
affect p38, ERK or JNK 
phosphorylation in any 
cell line except F10. 
c) 1 µM JS-K decreased 
p38 phosphorylation in 
all cells and ERK 
phosphorylation in F10 
cells. 
d) Confirmed the 
involvement of NO• for 
producing apoptotic 
effects   
 












treated at dose 










a) Extensive necrosis in 
the excised tumors was 
observed. 
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Table 1.2 continued 
JS-K 
formulation 
Tumor type In vitro cell 
line/ 
IC50 
In vivo Proposed MOA 
JS-K and 
P123/JS-K. 












K at a dose of 
6µ mol/kg 
thrice/week. 
a) JS-K showed 
cytotoxicity towards a 
subset of human NSCLC. 
The most sensitive cells 
lines showed higher level 
of basal reactive 
oxygen/nitrogen species. 
b) Study confirmed 
release of NO by JS-K. 
c) Study showed that 
ROS/RNS levels 
increased in the cells 
after JS-K treatment 
suggesting oxidative 
stress. Also, with basal 
levels of ROS/RNS 
present in the cell 
system, JS-K increased 
the levels of ROS/RNS. 
d) Intrinsic apoptotic 
pathway activated. 
e) JS-K caused DNA 
damage. 
JS-K Hepatoma (87) Hep-3b 
cells. IC50: 
8 µM (72 
hrs) 
 a) Activation of MAPK 
pathway by inducing 
ERK, p38 and JNK 
phosphorylation. 
b) JS-K induced MAPK 
activation is NO 
mediated. 
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Table 1.2 continued 
JS-K 
formulation 
Tumor type In vitro cell 
line/ 
IC50 
In vivo Proposed MOA 











treated with 6 
mg/kg/d s.c. 









a) NO release from U87 






















treated with 4 
µM JS-K 










a) JS-K inhibited cord 
formation and endothelial 
cell migration in HUVEC 
thus indicating anti-
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Tumor type In vitro cell 
line/ 
IC50 
In vivo Proposed MOA 







 a) Inhibition of ubiquitin-
E1 thioester. 





DEVELOPMENT AND CHARACTERIZATION OF  
A PLURONIC® P123 FORMULATION FOR THE  




or JS-K is a nitric oxide-producing prodrug belonging to the class of arylated 
diazeniumdiolates. JS-K has shown promising antitumor activity in vitro and in vivo. The 
major obstacle in clinical use of JS-K is its challenging solubility and stability. We have 
developed a Pluronic® P123 formulation for JS-K. The present study aims to characterize 
and compare Pluronic® P123-formulated JS-K (P123/JS-K) with free JS-K in vitro and in 
vivo. 
We analyzed micelle size using dynamic light scattering, shape by transmission 
electron microscopy and critical micelle concentration using UV analysis. We performed 
our efficacy study in vitro and in vivo by cytotoxicity analysis on HL-60 and U937 
myeloid leukemia cells. We also implanted HL-60 cells in NOD/SCID IL2Rγnull mice and 
performed a tumor regression study. We also assessed JS-K or P123/JS-K stability by 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  Adapted from manuscript: Development and characterization of a Pluronic® formulation for the nitric 
oxide-generating agent JS-K. Imit Kaur, Moises Terrazas, Ken M. Kosak, James N Herron, Steven E. Kern, 
Kenneth M. Boucher and Paul J. Shami. Submitted to Nanomedicine. 	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analyzing JS-K or P123/JS-K recovery from RPMI media/10% FBS, human plasma, 
human whole blood and 4 mM glutathione. Finally, we analyzed plasma protein binding 
of JS-K or P123/JS-K using equilibrium dialysis and fluorescence quenching. We 
analyzed binding constant, Stern Volmer constant and thermodynamic parameters 
including enthalpy, entropy and free energy. 
We conclude that Pluronic® P123 solubilizes JS-K and stabilizes it as indicated by 
higher recovery from physiological media. The Pluronic® formulation also showed 
different protein binding characteristics as compared to free drug. Finally, P123/JS-K 
showed higher tumor regression when compared to free JS-K. 
 
2.2 Introduction 
Acute myeloid leukemia (AML) is the second most common type of adult leukemia. 
Estimated new cases and deaths from AML in the United States in 2010 were 12,330 and 
8,950, respectively (1). The success of conventional chemotherapeutic agents is 
frequently limited by the development of drug resistance and severe toxicity of current 
treatments (2).  
Nitric oxide (NO), a biologically occurring pleiotropic molecule, is involved in a 
plethora of physiological, biological and pathological functions (3), (4). NO has shown 
promising therapeutic activity against multiple diseases, including cardiovascular and 
pulmonary diseases (5). 
NO has shown in vitro tumoricidal activity (6). It can lead to apoptosis by targeting 
various cellular sites and bringing about posttranslational modifications such as S-
nitrosylation, S-glutathionylation, DNA nitration	  or deamination and ADP ribosylation 
(7). NO induces differentiation in acute myeloid leukemia (AML) cells (8). Due to 
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instability of the NO radical and its hypotensive effects, NO cannot be administered 
directly or in high doses. NO donors such as diazeniumdiolates generate NO 
spontaneously. They induce apoptosis and differentiation in AML cells (9). However, 
these compounds cannot be used clinically for the treatment of malignant diseases 
because of the pleiotropic effects of NO, and particularly NO-induced vasodilatation 
through activation of the soluble guanylate cyclase/cGMP pathway (10). Alternatively, 
arylated diazeniumdiolates react with glutathione (GSH) to release NO. Although the 
reaction can occur spontaneously, it is catalyzed by the glutathione S-transferases (GST). 
GSTs are often elevated in malignant cells (11). O2-(2,4-dinitrophenyl)1-[(4-
ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] or JS-K  (Fig. 2.1), an arylated 
diazeniumdiolate, has potent antileukemic activity in vitro and in vivo (12), (13), (14). In 
in vivo murine models, JS-K was also found to be effective against prostate cancer (11), 
hepatoma (15), multiple myeloma (13) and non-small cell lung cancer (14). JS-K also 
possesses anti-angiogenic activity both in vitro and in vivo (16). In multiple myeloma and 
breast cancer studies, JS-K did not affect the growth of normal human peripheral blood 
mononuclear cells (13) and normal mammary epithelial cells (17). 
Pluronic® block copolymers are widely used for the solubilization of hydrophobic 
chemotherapeutic agents. These are amphiphilic molecules arranged as A-B-A blocks of 
hydrophilic poly(ethylene oxide) (PEO or A) and hydrophobic poly(propylene oxide) 
(PPO or B). The block copolymers possess different hydrophilic-lipophilic balance 
(HLB) due to varying concentrations of ethylene oxide and propylene oxide units. HLB is 
important for critical micelle concentration (CMC), i.e., the concentration above which 
these copolymers self-assemble into micelles in an aqueous solution (18), (19). 
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Plasma protein binding is an important parameter of the drug development process 
that needs to be established to predict drug distribution characteristics. Drug bound to 
plasma proteins acts as a reservoir or drug depot and is not available for its effect. Only 
the free drug molecules are available at the target site (20). Therefore, in preclinical 
settings, it is important to determine the plasma protein binding characteristics of an 
active pharmaceutical ingredient (API) to assess safety, efficacy and bioavailability (21). 
Two major plasma proteins involved in drug binding are human serum albumin (HSA) 
and alpha1-acid glycoprotein (AGP) (22). Plasma protein binding could be analyzed via 
conventional equilibrium dialysis technique or the comparatively new technique of 
fluorescence quenching.  
In the present study, a novel Pluronic® P123 micelle formulation of JS-K was 
developed and preliminary preclinical studies were carried out. We performed in vitro 
cytotoxicity analysis and also an in vivo tumor regression study in a mouse model. The 
Pluronic® micelle was characterized in its size, shape, surface charge and critical micelle 
concentration. Finally, we performed serum-binding analysis and compared two different 
techniques of binding, namely equilibrium dialysis and fluorescence quenching. While 
both the techniques provided valuable information in terms of binding characteristics, we 
were able to assess thermodynamic parameters associated with drug-protein binding 
using fluorescence quenching. 
 
2.3 Materials and Methods 
2.3.1  Materials 
JS-K was synthesized as previously described (23) and provided by Dr. Joseph 
Saavedra (SAIC Frederick). Pluronic® polymers were obtained from BASF (Florham 
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Park, NJ). Human serum albumin (HSA) and alpha 1 acid glycoprotein (AGP) used for 
protein binding studies were from Sigma (St. Louis, MO).  Low binding SpectraPor 
dialysis membrane [MWCO: 12,000-14,000] was from Spectrum Laboratories Inc (Los 
Angeles, CA). All the other chemicals were from Sigma (St. Louis, MO) unless 
otherwise indicated. 
 
2.3.2  Cell culture 
Human myeloid leukemia HL-60 cells and human monocytic leukemia cells U937 
(ATCC, Manassas, VA) were cultured in RPMI-1640 supplemented with 10% fetal 
bovine serum (FBS), penicillin/streptomycin and mycozap. Cells were cultured at 37◦C in 
a 5% CO2 humidified atmosphere. Five micromolar JS-K stocks in dimethyl sulfoxide 
(DMSO) were serially diluted in phosphate buffered saline (PBS) before addition to the 
cultures. The final concentration of DMSO added to the cultures was 0.1% or less. For 
each experiment, JS-K was added at the time of culture initiation, cells were harvested at 
the indicated time points, washed in PBS and assays conducted.  
 
2.3.3  Preparation of JS-K loaded P123 micelles 
11.25% of P123 micelle stock solution was prepared in deionized water. The solution 
was further diluted to 2.25% in PBS (pH 6.5). 1 mM micelle JS-K (P123/JS-K) was 
prepared by heating 980 µL of 2.25% P123 at 50°C and adding 20 µL of 50 mM JS-K 
stock in DMSO. The weight loading of drug in P123 micelles was 1.7%. Further dilution 
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2.3.4  P123 JS-K drug retention and loading 
JS-K was loaded in P123, P105 and F127 Pluronic® polymers. The proportion of JS-
K to Pluronic® polymer in solution was 3.84% by weight. The JS-K micelle preparations 
were dialyzed for 5.5 h or 17 h. The different Pluronic® formulations (before and after 
dialysis) were incubated with HL-60 cells for three days. The MTS cytoxicity analysis 
was performed (see below).  
 
2.3.5  In vitro cytotoxic activity 
The in vitro cytotoxic activity of JS-K, P123/JS-K micelles and blank P123 micelles 
was assessed by MTS assay (Promega, Madison, WI) in HL-60 and U-937 cells.  Briefly, 
cells were seeded in a 96-well plate at a density of 104 cells per well per 100µL. Cells 
were treated with 0, 0.09 µM, 0.2 µM, 0.4 µM, 0.6 µM and 0.8 µM of free JS-K or 
P123/JS-K or blank P123 in triplicates. After incubating for 72 h, 20 µL of MTS reagent 
was added to each well and incubated further for 1.5 h. Absorbance was read at 490 nm 
in a microplate reader (Modulus Microplate, Turner Biosystems). Untreated cells were 
taken as 100% viable. A media blank was used to correct for background absorbance. 
Results were expressed as a growth percent of control and IC50 values were derived from 
growth vs. drug concentration curves. 
 
2.3.6  P123 Pluronic® micelle formulation of JS-K 
JS-K stocks (50 mM) in DMSO were mixed with stocks of Pluronic® P123 polymers 
prepared in PBS. Micellization was allowed to occur spontaneously with gentle heating 
(50°C). The proportion of JS-K to P123 in solution was 1.7% by weight. For experiments 
with free JS-K, DMSO stocks of JS-K (50 mM) were diluted to a final concentration of 
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JS-K of 1 mM in PBS/80% DMSO in stability experiments or PBS/40% DMSO for 
protein binding experiments or only PBS for other experiments. 
 
2.3.7  P123/JS-K formulation characterization 
2.3.7.1 Particle size measurement 
 Particle mean size measurements were performed using the dynamic light scattering 
method using a MalvernNano zeta sizer. The size analysis was performed on blank P123 
micelles (2.25%) in PBS and JS-K incorporated P123 micelles (final loading 1.7%). 
 
2.3.7.2 Transmission electron microscopy (TEM) analysis 
The morphology of P123 micelles was studied by TEM after negative staining with 
phosphotungstic acid solution (2% w/v). 1 mM of JS-K formulation in 2.25% of P123 
micelle was prepared. TEM images were obtained only with P123/JS-K micelles as the 
empty micelles were found to be comparatively less stable without drug. 
 
2.3.7.3 Critical micelle concentration (CMC) 
 CMC of Pluronic® P123 micelles was analyzed using the Iodine UV-absorption 
spectra method using iodine as hydrophobic probe as previously reported (24). Briefly, 
KI/I2 solution was prepared by dissolving 0.5 g Iodine (I2) and 1 g Potassium Iodide (KI) 
in 50 mL water for injection (WFI). P123 concentrations ranging from 0.000005% to 
0.1% were prepared in WFI. To each 5 mL solution, 25µL of KI/I2 solution was added. 
The vials were covered with foil to avoid photo-degradation. The samples were incubated 
for nearly 12 h at room temperature. The measurements were performed at 366 nm using 
a UV-vis spectrometer (Ultrospec 2000, Pharmacia Biotech). Triplicate readings were 
performed for each sample. CMC value was analyzed by plotting absorbance vs log% 
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Pluronic® weight and was interpreted at the point where a sharp increase in absorbance 
was observed. The data were analyzed by a piece-wise linear model with a single change 
in slope. A grid search method was used to determine the optimal change point. The 
statistical analysis was performed using R statistical computing software version 2.15.0 
(Vienna, Austria). 
 
2.3.8  P123/JS-K formulation stability in physiological media 
The stability of JS-K formulated in DMSO was compared to JS-K formulated in P123 
Pluronic® micelle in various physiological media. JS-K recovery in either formulation 
was tested in 4 mM GSH (formulated in PBS; pH 7.4); RPMI media, human plasma and 
human whole blood. At the indicated time points, aliquots from the relevant test solution 
were collected in 95% Acetonitrile/Formate in water (ACN/Formate in water) in 
polypropylene vials. The extracts were spin filtered (0.2 µm, low binding nylon filters) 
for 2 min. JS-K levels were measured by HPLC using an isocratic mobile phase 
consisting of 25% 0.025 M ammonium formate (pH 4.2), 25% ACN and 50% methanol 
at a flow rate of 1 mL/min for 6-8 min. 
 
2.3.9  P123/JS-K protein binding studies 
The two most common proteins in the blood are human serum albumin (HSA) and 
alpha 1 acid glycoprotein  (AGP). While HSA preferentially binds with acidic drugs, 
AGP binds mainly with basic or neutral drugs (25). We studied interaction of free drug 
and micelle formulated drug with these two proteins by fluorescence quenching of 
tryptophan present in these proteins. Free or P123-formulated JS-K was prepared at 
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concentrations 20 µM-700 µM or 100µM-700µM for temperature controlled fluorometric 
studies.  
We compared the equilibrium dialysis technique with fluorescence quenching in our 
preliminary experiments. Both preliminary experiments were carried out at room 
temperature. The purpose of these experiments was to test the sensitivity and closeness of 
results obtained from either of the technique. Also, with the dialysis technique, since 
higher drug volumes were used for extended hours, free JS-K precipitation was observed 
and therefore, saturation/equilibrium was not attained. Dialysis was carried out using 
Spectra/Por dialysis membranes (MWCO:12,000-14,000) which were activated for 30 
min. in HPLC grade water and rinsed before use. The membranes were held in a 20 mL 
glass vial. The glass vial was covered with aluminum foil so as to prevent photo- 
degradation of JS-K. The drug preparation (JS-K in DMSO or JS-K in P123) with 4% 
final HSA was added in the dialysis bag and a similar sink (i.e., HSA and DMSO or 
P123) was created in the glass vial. The whole apparatus was kept at constant stirring 
position and the samples were collected from both sides of the membrane after 2, 4, 6 and 
8 h. We found that for P123/JS-K, equilibrium was achieved after 2 h. For free JS-K, we 
could not achieve equilibrium due to possible degradation of the drug over time. 
Therefore, 2 h of equilibrium dialysis was selected for both formulations. The samples 
were then soaked for 30 min. in 95% acetonitrile/5% ammonium formate in water (pH~3) 
and then spin filtered (0.2 micron, low binding nylon) for 2 min. JS-K levels in the bag 
and the glass vial were measured by HPLC or UPLC. For quantitation, AUC values were 
calculated. Percent recovery from each fraction was calculated based on the total initial 
amount of JS-K added. The association and dissociation constants were calculated using 
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the SigmaPlot (Systat, Chicago, IL) software with the in-built equation for Ligand 
Binding. 
For the fluorometric analysis, the formulation was prepared as described above. Final 
protein concentration was 4% for HSA and 0.09% for AGP. Drug and protein were added 
in 96-well black opaque plates to avoid the inner filter effect. Fluorescence was read at an 
excitation of 280 nm and emission of 360 nm. Necessary blank fluorescence was read 
and subtracted as background from the fluorescence of interest.  For the temperature-
controlled studies, plates were incubated at the desired temperature in a PCR thermal 
controller (PTC-100™, MJ Research, Inc) for 30 min. and read within 10 min. on the 
fluorescent reader (Synergy 4, BioTek) previously adjusted to the same temperature. 
Fluorometric analysis was carried out using the Stern Volmer equation. In case of HSA, 
Ksv and Ka were obtained at 298, 303 and 310 K. The thermodynamic parameters such 
as enthalpy, entropy and free energy were calculated to assess the nature of binding 
involved. 
 
2.3.10  In vivo studies of JS-K and P123/JS-K 
To study the in vivo antineoplastic potency of JS-K and P123/JS-K, NOD/SCID 
IL2Rgnull mice were injected subcutaneously with 2.5 x 106 HL-60 cells. When tumors 
became palpable, treatment with JS-K (4 µmol/kg) or P123/JS-K (4 µmol/kg or 5 
µmol/kg) or P123 only (volume equivalent to a P123/JS-K dose of 5 µmol/kg) was 
started. Dose selection was made based on the prior exploratory experiments. 
Historically, we have shown that 4 µmol/kg dose of free JS-K could be administered 
without producing any hypotensive effects (11). We were able to escalate the dose with 
P123/JS-K without any observable hypotensive effects. Treatments were administered 
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intravenously every other day. For the no treatment group, only body weight and tumor 
size were measured. Mouse weight and tumor size were measured every other day using 
a Vernier caliper. Tumor volume was calculated using the formula: width x length x 
[(width + length)/2] x 0.5236. Animals were sacrificed after 8 treatments using 
isofluorane inhalation and tumors were collected for histochemical analysis. The protocol 
was approved by the University of Utah Institutional Animal Care and Use Committee. 
 
2.3.11  High performance liquid chromatography and ultra  
performance liquid chromatography 
HPLC to measure JS-K levels was conducted on a Water’s Alliance HPLC system 
controlled by Empower software. We used an isocratic mobile phase consisting of A = 
30% 0.02 M ammonium formate (pH 3), 40% acetonitrile (ACN) and 30% methanol and 
D = 100% methanol. Flow rate was kept constant at 1 mL/min for 6-8 min. During 
chromatographic separation, JS-K was monitored by absorbance at 300 nm. The method 
results in a standard detection curve over a linear range of 6.1 – 49.1 ng with a lower 
limit of quantitation of 6.4 ng. Very low amounts of JS-K were measured using Water’s 
UPLC Empower 2 software. The samples were run on gradient of 0.02 M formic acid, pH 
~2.7 and 100% acetonitrile at a flow rate of 0.6 mL/min. 
 
 2.3.12  Statistical analysis 
The omnibus null hypothesis of no difference in mean tumor volume between any of 
the groups was tested using one-way analysis of variance. Tukey’s Honest Significant 
Difference test was used to adjust the p-values for the individual differences for multiple 
comparisons. Statistical analysis was performed using R statistical computing software 
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version 2.13.0 (Vienna, Austria). At specific time points, individual tumor volumes were 
compared using the Student’s t-test assuming a 2-tailed distribution with unequal 
variance. Differences were considered significant for P values below 0.05. 
We also performed statistical analysis using trapezoid method. For each mice group 
cumulative area under the curve (AUC) of the tumor volume was calculated starting from 
the first treatment to the last eighth treatment. Cumulative AUC (for the last treatment) of 
each group was used for running one-way analysis of variance. Differences were 
considered significant for P values below 0.05. 
 
2.4 Results 
2.4.1 P123 JS-K drug retention and loading 
We performed some preliminary experiments to analyze the efficacy of JS-K loading 
in different pluronic systems and cytotoxicity produced by different poloxamers. JS-K 
was loaded in P123, P105 and F127 as explained in the methods section. We tested the 
cytoxicity of three different Pluronic micelles. The three micelles tested have different 
HLB values (F127>P105>P123) (26). The micelles were dialyzed and tested for 
cytotoxicity as explained in the materials and methods section. The order of efficacy 
obtained against HL-60 cells after dialysis was P123>P105>F127 (results not shown). To 
determine the extent of JS-K loading and retention in micelles, JS-K was loaded in P123. 
The proportion of JS-K to Pluronic® polymer in solution was 10% by weight. The percent 
of JS-K retained after 2 h of dialysis was determined by HPLC. Percent retention of JS-K 
in P123 was 75 ± 10%. These preliminary experiments showed that JS-K in a micellar 
formulation is retained after dialysis.  
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2.4.2 P123 micelle JS-K in vitro cytotoxicity 
P123 micelle JS-K (1.7% JS-K/P123 by weight) in vitro cytotoxicity was analyzed 
using two different acute myeloid leukemia cell lines, HL-60 and U-937. Both the cell 
lines are for AML with different phenotypes. While HL-60 cells are myeloid derived, U-
937 cells are monocytic. We used two different cell lines two analyze the sensitivity of 
AML cells with variable phenotypes against JS-K or P123/JS-K treatment. In HL-60 
cells, IC50 values obtained from free JS-K treatment are similar to IC50 value obtained 
from P123/JS-K formulation. P123 control showed negligible toxicity. In U-937 cells, 
IC50 value obtained from P123/JS-K is slightly lower than JS-K. The results indicate 
Pluronics® have negligible toxicity themselves and do not affect toxicity imparted by JS-
K. The results are shown in Table 2.1. 
 
2.4.3 P123 micelle JS-K characterization 
P123/JS-K formulation was characterized by particle size measurement, surface 
charge and morphology. These studies are important as particle size affects 
biodistribution and elimination. The mean diameter of blank P123 micelles was 29.2 ± 
1.36 nm. We observed a slight reduction in size on JS-K incorporation, suggesting 
stabilization of micelles (Table 2.2). TEM images suggested that P123/JS-K micelles are 
spherical in shape (Fig. 2.2). TEM images of blank micelles could not be obtained due to 
the dynamic character of the Pluronics® changing from unimers to micelles. JS-K 
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2.4.4 Critical micelle concentration (CMC) determination 
CMC is an important characterization parameter that influences micellar stability and 
solubilization characteristics. To measure CMC, we used a hydrophobic probe– Iodine 
(I2) as explained in the methods section. I2 gets solubilized in the hydrophobic micelle 
core. An excess KI solution aids conversion of triatomic I3-- to I2, maintaining the 
saturated solution of I2 (24). The absorption intensity of I2 was plotted against different 
weight percent of Pluronic® and CMC value was obtained from the point on the curve 
where an abrupt increase in absorbance was observed (Fig. 2.3). We obtained an average 
CMC value of 5.6 ± 1.3 µM (average and SEM of two independent experiments with 
three replicates each). This value is compatible with the value reported by Kabanov et al. 
for P123 (26). 
 
2.4.5 Stability of P123/JS-K in different physiological and biological media 
We compared the stability of unformulated JS-K and P123/JS-K in blood, 
glutathione, plasma and RPMI/10% FBS media. As shown in Table 2.3, the P123 
formulation extended the percentage recovery of JS-K as compared to the free drug. This 
likely reflect shielding of JS-K from proteins and nucleophiles by Pluronic® micelles. 
Also, the table highlights the recovery affected by the different suspending media. 
Although all treatments were carried out for 60 min., but the drug was not recovered from 
some of the suspending media like whole blood. The HPLC method used for JS-K 
quantification was sensitive to intact JS-K detection only. Therefore, only intact drug was 
measured. JS-K degraded to its metabolites was not detected by the HPLC method.  
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2.4.6 HSA and AGP binding with JS-K and P123/JS-K 
2.4.6.1 Equilibrium dialysis  
The equilibrium dialysis study was carried out to investigate the interaction of JS-K 
or P123/JS-K with HSA as explained in the material and methods section. JS-K showed 
affinity for HSA and the equilibrium time was obtained at 2 h. Although at that time 
point, some drug degradation/precipitation was seen with free JS-K, it was important to 
stick to 2 h for the achievement of steady state condition. We measured drug levels from 
both “in the dialysis bag” and “out of the bag” as explained before to determine the 
binding constant. The values were derived using the ligand binding equation. The results 
are reported in the Table 2.4. 
 
2.4.6.2 Fluorescence quenching study at room temperature  
In preliminary work, both HSA and AGP quenching by JS-K and P123/JS-K was 
analyzed at room temperature. A Stern Volmer plot was generated for both formulations 
and proteins. Equation 1 was used to obtain the Stern Volmer quenching constant: 
                          (1) 
(where Fo: Fluorescence in the absence of external quencher; F: Quenched Fluorescence; 
Q: Conc. of quencher/drug; Ksv: Stern Volmer Constant). 
Figures 2.4 and 2.5 show the Stern Volmer plots of HSA and AGP, respectively. 
The quenching data were used to determine the binding constant with HSA and compare 
the value obtained with equilibrium dialysis. Table 2.4 shows the binding parameters 
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As shown in Table 2.4, the binding constants obtained from the two techniques are 
acceptably close. This confirmed the sensitivity and accuracy of both techniques. For the 
subsequent experiments, we chose fluorescence quenching over equilibrium dialysis 
because the former is a rapid and sensitive technique. It also requires less material (µL as 
compared to mL for dialysis) and is relatively quicker than dialysis. This is particularly 
important for our studies, as nonformulated JS-K is prone to degradation.  
 
2.4.6.3 Determination of quenching mechanism 
 Fluorescence quenching was performed at 25°C, 30°C and 37°C as explained in the 
material and methods section in order to obtain the Stern Volmer constant at different 
temperatures. As shown in Table 2.5, a temperature effect was observed. With increase in 
temperature, the Stern Volmer constant is reduced. Such an inverse relationship with 
temperature could explain the quenching behavior (Figures 2.6 and 2.7). Fluorescence 
quenching could be caused by a number of factors leading to molecular interactions such 
as excited state reactions, ground state complex formation and collisional quenching. The 
decrease in Ksv value with a higher temperature suggests a static quenching mechanism 
(27), i.e., formation of complex between JS-K and HSA or P123/JS-K and HSA. The 
quenching rate constant (Kq) was calculated to further confirm formation of complex and 
static quenching mechanisms. The quenching rate constant can be calculated using the 
equation: 
                    (2) 
τo is the average lifetime of HSA molecule in absence of JS-K (quencher) or any other 
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The value of τo of HSA is 10-8 s (28). The Kq values calculated are shown in Table 
2.5. The Kq values obtained are higher than the maximum scatter collision quenching for 
HSA, i.e., 2x1010 L mol-1s-1. 
 We also performed a fluorescence study with HSA and P123 only. Interestingly, 
instead of quenching, fluorescence enhancement was observed (results not shown). 
 
2.4.6.4 Analysis of binding constants  
The association binding constant (Ka) was calculated using a modified Stern Volmer 
equation: 
              (3) 
where Fo = original unquenched fluorescence of HSA; dF = difference in the 
fluorescence in the absence and presence of JS-K or P123/JS-K at the concentration Q; f 
= fraction of initial fluorescence accessible to quencher. 
Binding constants obtained at different temperatures are shown in Table 2.5. 
 
2.4.6.5 Thermodynamic constants analysis  
Thermodynamic parameters are important for the determination of binding forces 
involved between the protein and the drug. The forces involved could be noncovalent 
bonds including hydrophobic interactions; electrostatic interactions; Van der Waals 
forces and/or hydrogen bonds. The thermodynamic parameters were evaluated using the 
Van’t Hoff equation: 










logKa = " dH2.303RT +
dS
2.303R
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                                    (5) 
The enthalpy change (dH) and entropy change (dS) were calculated from the slope and 
intercept of the binding constant vs. temperature curve, respectively. Free energy (dG) 
was calculated from the derived enthalpy and entropy at different temperatures. The 
results are shown in Table 2.6. 
 
2.4.7 In vivo tumor regression analysis 
We tested the in vivo efficacy of free JS-K and P123/JS-K using HL-60 cells 
implanted in NOD/SCID IL2Rgnull as detailed in the methods section. Five groups were 
compared as follows: no treatment control, P123 control, free JS-K at 4 µmol/kg, 
P123/JS-K at 4 µmol/kg and P123/JS-K at 5 µmol/kg. There were 12 to 13 animals per 
variable. Mice were treated intravenously every other day for a total of 8 doses. Tumor 
volume curves for each variable are shown in Fig. 2.8. When the curves were compared 
using two way analysis of variance (ANOVA) method, they were not statistically 
different. However, when comparing tumor volumes using the Student’s t-test at day 13, 
free JS-K at 4 µmol/kg and P123/JS-K at 5 µmol/kg induced a statistically significant 
reduction in tumor volume as compared to controls. Interestingly, at day 16, the 
difference between free JS-K-treated mice and controls was no longer significant. 
However, at day 16, P123/JS-K at 4 or 5 µmol/kg induced a statistically significant 
reduction in tumor volume. At day 16, tumor volume measurements were as follows 
(average and SEM): No treatment: 1.57 ± 0.22 cm3, P123 control: 1.62 ± 0.20 cm3, free 
JS-K (4 µmol/kg): 1.29 ± 0.23 cm3, P123/JS-K (4 µmol/kg): 0.89 ± 0.07 cm3, P123/JS-K 
(5 µmol/kg): 0.81 ± 0.06 cm3. Differences between P123/JS-K at 4 or 5 µmol/kg were not 
statistically significant. In the other set of analysis performed, we calculated the 
! 
dG = dH "TdS
	   69	  
cumulative area under the curve for tumor volumes plotted against the day of treatment. 
At day 16, we obtained statistically significant tumor reduction when all the treated 
groups were compared to control or no treatment. However, differences between 
P123/JS-K at 4 or 5 µmol/kg were not statistically significant. We could not carry the 
experiment beyond day 16 based on tumor volume guidelines of the IACUC. 
 
2.5 Discussion 
In this chapter, we describe a formulation for the prospective anticancer agent JS-K. 
Pluronic® block copolymers have been widely used as these are comparatively nontoxic 
and offer ease of preparation (29). Polymeric micelles do not offer high loading capacity, 
but seemed to work well for our purposes. In preliminary studies, we compared 
Pluronics® F127, P105 and P123. All three Pluronics® are different with respect to their 
physical characteristics, HLB value and solubility (26). The results indicated that for JS-
K, P123 was the best choice in terms of stability and enhancing solubility of this 
extremely hydrophobic drug. JS-K in P123 micelles was more stable than in the other 2 
formulations and P123 by itself did not have significant toxicity. Although most of our 
studies were performed on HL-60 cells, we also tested P123/JS-K in U-937 cells at the 
same drug loading percentage and obtained similar in vitro cytotoxicity results. 
We conducted studies to characterize P123/JS-K since it is a clinical candidate. As 
evident from the size measurements, not much difference in the size was observed before 
and after incorporation of JS-K. Also, the TEM images of P123/JS-K reflect stability 
achieved by incorporation of JS-K. It has been suggested that for Pluronic® micelles, at 
concentrations significantly above the CMC, micelle stability diminishes (30). Our 
studies support this observation as we were unable to get TEM images of blank micelles, 
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but with JS-K incorporation, spherical micelles were observed. JS-K, being extremely 
hydrophobic, stabilized the dynamic nature of the micelles with physical interactions.  
We also measured the CMC of the Pluronic® P123 using the KI/I2 method. The value we 
obtained is in agreement with what has been obtained by others (24, 26). 
Upon testing, free JS-K and P123/JS-K in various physiological media P123/JS-K 
showed enhanced recovery and extended stability as compared to JS-K alone. Human 
plasma, RPMI/FBS media and PBS were chosen as matrices of different complexity. 
Stability of JS-K was also tested in the presence of GSH because JS-K is cleaved in the 
presence of GSH. Higher stability of JSK in plasma as compared to whole blood could be 
attributed to higher GSH in blood as compared to plasma (31, 32). The relative 
stabilization of JS-K with P123 micelles could be attributed to shielding of JS-K in the 
micelle, thus preventing interaction with GSH.  
A drug’s interaction with serum proteins is an important PK/PD parameter that needs 
to be studied as this provides the basis for dosage regimen and other related PK analyses.  
The two major serum proteins are HSA and AGP. While it is generally observed that 
acidic drugs tend to bind with HSA and basic drugs tend to bind with AGP, the 
hypothesis is not absolute (33). We studied interaction of JS-K with HSA and AGP and 
P123/JS-K with HSA and AGP. We tried to compare our results obtained from 
equilibrium dialysis with the results obtained from spectrometric analysis. Equilibrium 
dialysis is an old and reliable technique but suffers from drawbacks such as requirement 
of high volumes, extensive time for equilibrium, volume shift and extensive preliminary 
studies. Nevertheless, it is the most widely used method and is still used to analyze 
plasma protein binding of various drugs (22). We initially performed the equilibrium 
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dialysis study for 8 h. For such a long time, P123/JS-K was relatively stable but free JS-K 
degradation was observed. In the P123/JS-K system, equilibrium was observed within 2 
h. Complete equilibrium was not obtained for free JS-K probably due to drug instability. 
Nevertheless, the 2 h point was selected for the equilibrium dialysis for both 
formulations. Using SigmaPlot, we analyzed the binding constant and possible number of 
binding sites using an in-built ligand binding equation. As free JS-K is prone to 
degradation, we validated our results using spectrophotometric analysis. Also, none of the 
binding analysis techniques provide complete information. Therefore, a combination of 
two different techniques can provide valuable datasets (22). With the use of fluorescence 
quenching, we were able to analyze the Stern Volmer constant, binding constant and 
thermodynamic constants such as enthalpy, entropy and free energy. Fluorescence 
quenching of tryptophan upon binding of drug can yield useful information. This 
technique is fast and reliable, and requires less sample (28), (34), (35). In a complex 
system where the drug (JS-K) is incorporated inside the micelle core, protein binding can 
take place between JS-K and tryptophan residues of protein, P123/JS-K micelle and the 
tryptophan residues and finally between the unimers/ micelles and the tryptophan 
residues. As observed from the results, the association constant (Ka) obtained from the 
two techniques is slightly different. Comparing equilibrium constants at room 
temperature, for P123/JS-K, Ka obtained from equilibrium dialysis and fluorescence 
quenching was close whereas nearly ten times higher Ka was calculated for free JS-K 
when fluorescence quenching analysis was performed. This difference could be explained 
by considering the stability of free JS-K. While P123/JS-K was allowed to attain 
equilibrium, free JS-K might have degraded during the experiment. Although it could be 
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argued that the stern volmer plot obtained has various data points that could be 
considered as outliers, we consider it due to the lack of technique optimization. The 
results were promising and therefore, a more optimized temperature controlled study was 
performed. When a temperature controlled study was performed with fluorescence 
quenching technique, both the formulations showed increase in binding constant or 
binding strength with temperature although the increase observed for free JS-K was more 
marked than P123/JS-K (Figures 2.6 and 2.7). This could be explained by reduced 
binding property of Pluronic® polymers. In order to be effective, the drug should be 
released from the polymer to produce its therapeutic effect. How early JS-K is released 
from the micelle core needs to be established. The thermodynamic parameters obtained 
from the fluorescence quenching study holds significance as well. The negative free 
energy possessed by both free JS-K and P123/JS-K binding with HSA at different 
temperatures indicates a spontaneous reaction that is thermodynamically favorable. 
Again, both free JS-K and P123/JS-K possess positive enthalpy and entropy but the 
values are about ten times higher with free JS-K interaction with serum protein. Although 
it is hard to speculate, the relevance of such an observation as the specific heat capacity is 
not considered, but according to studies carried out by Ross and Subramanian (36), the 
positive value of both enthalpy and entropy indicate hydrophobic interactions. 
Protein binding analysis can also be extended to hypothesize JS-K stability and 
interaction with HSA. As the protein binding is occurring, it could be hypothesized that 
JS-K stability can be enhanced with HSA interaction. A depot can be formed between JS-
K and HSA. Some studies have shown interaction of NO residues (such as nitrosothiols) 
with albumin (37, 38). Also, the major metabolite of JS-K, S-glutathione-2,4-
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dinitrophenyl can also interact with albumin via glutathione moiety. Therefore, either JS-
K as a whole or the metabolites of JS-K can interact with albumin to form a depot of 
either whole JS-K or the metabolites of JS-K that are instrumental in producing cytotoxic 
effects of the drug. 
The in vivo tumor regression study carried out justifies the use of the Pluronic® 
formulation of JS-K showing significant tumor regression after 8 treatments. It is 
interesting that both JS-K and P123/JS-K showed nearly equal tumor regression up to 
seven injections but P123/JS-K treated mice showed maximum regression after 8 
treatments. One could speculate that the P123 formulation allowed JS-K accumulation in 
the tumor to a greater extent and that a critical threshold of antineoplastic activity was 
reached as a result. Another point is that the micelles prevented the drug from interacting 
with proteins and as a result allowed more drug to interact with leukemic cells. Finally, 
the micelles probably enhanced penetration of the drug in the leukemic cells as we have 
previously demonstrated (39). It would have been informative to be able to carry the 




Overall, our study demonstrated that JS-K formulated in Pluronic® P123 has a more 
favorable in vitro and in vivo profile. The polymeric micelle formulation stabilizes the 
drug and diminishes its interaction with plasma proteins. The binding is 
thermodynamically favorable and points towards hydrophobic interactions. We also 
conclude that P123/JS-K is likely more therapeutically effective than free JS-K. 
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2.7 Future Perspectives 
JS-K has potential as a cancer chemotherapeutic agent. Its solubility and stability 
challenges can be overcome with a micelle formulation strategy. Such a strategy could 
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Fig. 2.1: Structure of JS-K 	  















Fig. 2.2: TEM image (magnification 667x) of 1mM JS-K loaded in 
2.25% P123 micelles. 	  











Fig. 2.3: Critical micelle concentration (CMC) value of Pluronic® P123 
as determined by plotting Absorbance (AU) with log Pluronic® % 
weight/volume. The CMC was obtained from the break point calculated 
on R statistical software. CMC was calculated from the average of two 
independent experiments with each concentration prepared in triplicates. 	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Fig. 2.4: Stern Volmer Plot for JS-K and HSA or P123/JS-K and HSA at 
room temperature 
y-axis: Fluorescence of HSA/Fluorescence of drug; x-axis: JS-K or 
P123/JS-K concentration. Plots obtained from averages of 3 independent 
experiments. 
 	  































Drug	  concentra.on	  (M)	  
P123/JS-­‐K	  
JS-­‐K	  
Fig. 2.5: Stern Volmer plot for JS-K and AGP or P123/JS-K and AGP 
at room temperature. 
y-axis : Fluorescence of HSA/Fluorescence of drug; x-axis: JS-K or 
P123/JS-K concentration. Plots obtained from averages of 3 
independent experiments. 	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Fig. 2.6: Stern volmer plot for JS-K and HSA at 298, 303 and 310 
K. Each point and standard error of mean (SEM) is a representative 
of two independent experiments with nine replicates.  
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Fig. 2.7: Stern volmer plot for P123/JS-K at temperatures 298, 303 and 
310 K. Each point and standard error of mean (SEM) is a 
representative of two independent experiments with nine replicates. 	  













Fig. 2.8: In vivo tumor regression analysis: NOD/SCID 
IL2Rgnull mice were injected with HL-60 cells subcutaneously. 
Treatments started after tumors became palpable. A total of 8 
injections were given. Treatment groups consisted of no 
treatment control, Pluronic® P123 treatment control, free JS-K 
injected at 4 µmol/kg, P123/JS-K injected at 4 µmol/kg, or 
P123/JS-K injected at 5 µmol/kg. See text for details. 	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Table 2.1: MTS cytotoxicity assay on HL-60 and U-937 cells comparing JS-K 
and P123/JS-K. 
System Formulation IC50 ± SEM* (µM) 
P123/JS-K 0.24 ± 0.059 
JS-K 0.24 ± 0.055 
HL-60 Cells 
P123 control -- 
P123/JS-K 0.3 ± 0 
JS-K 0.4 ± 0 
U-937 Cells 
P123 control -- 
*Average and standard error mean of at least two separate experiments. Each 
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Table 2.2: Size measurement of blank micelles and P123 loaded with JS-K at 
different percentages. The size of micelles decreases with increased loading. 
System Weight % drug loading Size ± SEM (nm)* 
Blank P123  0 29.24 ± 1.36 
0.17 27.8 ± 4.9 P123/JS-K 
1.7 17.6 ± 1.21 
*Averages and SEM of atleast two separate measurements. Each measurement 
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Table 2.3: Stability studies of JS-K. Percent recovery of JS-K or P123/JS-K calculated at 
the indicated time points. Percent Recovery of P123/JS-K is higher than JS-K, indicating 
drug stabilization.  
 
Solution (time) JS-K (% 
recovery±SEM*) 




FBS (60 min.) 
23 ± 0.4 48 ± 4 0.0015 
Human plasma (60 
min.) 
39 ± 1 59  ±1.5 0.012 
Whole blood (10 
min.) 
0 ± 0 6 ± 0 0.0284 
4 mM GSH (5 min.) 8.5 ± 4.6 51 ± 10.8 0.003 
*Average and SEM of atleast two independent experiments. **The Students t-test was 
used to obtain P values comparing both formulations. Results were considered 
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Table 2.4: Binding Constants (Ka) obtained from equilibrium dialysis and 
fluorescence quenching and Stern Volmer constant (Ksv) obtained from 
fluorescence quenching at room temperature. Concentration of drugs used in both 



















with AGP  
(M-1)*** 
JS-K 3.4 x 103 ± 2.2 
Ns** = 2.2; R2 
= 0.84 
1.2 x 103 
R2 = 0.59 
15 x 103 
R2 = 0.77 
3 x 103 
R2 = 0.91 
P123/JS-K 3.0 x 103 ± 3.6 
Ns** = 1.9; R2 
= 0.89 
2.2 x 103 
R2 = 0.805 
3.5 x 103 
R2 = 0.99 
2 x 103 
R2 = 0.67 
* Average and Standard error of mean (SEM) of atleast three independent 
experiments. **  Ns=No. of binding sites. *** Average of at least three independent 
experiments. 
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Table 2.5: Stern Volmer quenching constant (Ksv) and HSA association binding 









R2 = 0.983 
6.6 57.3 
R2 = 0.96 
303 6.9 
R2 = 0.94 
6.9 226.14 
R2 = 0.98 
JS-K 
310 3.1 
R2 = 0.98 
3.1 1052.3 
R2 = 0.99 
298 3.3 
R2 = 0.99 
3.3 608.2 
R2 = 0.988 
303 3.4 
R2 = 0.79 
3.4 615.2 
R2 = 0.986 
P123/JS-K 
310 2.2 
R2 = 0.93 
2.2 681.2 
R2 = 0.840 
* Calculated from the slope of the curve plotted. Two independent experiments were 
performed with nine replicates at each concentration. 
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Table 2.6: Thermodynamic parameters for HSA and JS-K or HSA and P123/JS-K at 










(J mol-1 K-1) 
298 57.3 
R2 = 0.96 
-10.14 
303 226.14 




R2 = 0.99 
-18.02 
185.46 
R2 = 0.99 
656.39 
R2 = 0.99 
298 608.2 
R2 = 0.988 
-15.93 
303 615.2 




R2 = 0.840 
-16.87 
7.4 
R2 = 0.88 
78.3 
R2 = 0.88 
Calculated from the slope of the curve plotted. Two independent experiments were 
performed with nine replicates at each concentration. 






CELLULAR DISTRIBUTION STUDIES OF THE NITRIC  
OXIDE-GENERATING ANTINEOPLASTIC PRODRUG  




Objective: Nitric oxide (NO) possesses anti-tumor activity. It induces differentiation and 
apoptosis in acute myeloid leukemia (AML) cells. The NO prodrug O2-(2,4-
dinitrophenyl)1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate, or JS-K, has 
potent antileukemic activity. JS-K is also active in vitro and in vivo against multiple 
myeloma, prostate cancer, non-small cell lung cancer, glioma and liver cancer. Using the 
Pluronic® P123 polymer, we have developed a micelle formulation for JS-K in order to 
increase its solubility and stability. The goal of the current study was to investigate the 
cellular trafficking of JS-K in AML cells. 
Methods: We investigated the intracellular distribution of JS-K (free drug) and JS-K 
formulated in P123 micelles (P123/JS-K) using HL-60 AML cells. We also studied the S-
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glutathionylating effects of JS-K on proteins in the cytoplasmic and nuclear cellular 
fractions.  
Key findings: Both free JS-K and P123/JS-K accumulate primarily in the nucleus. Both 
free JS-K and P123/JS-K induced S-glutathionylation of nuclear proteins, although the 
effect produced was more pronounced with P123/JS-K. Minimal S-glutathionylation of 
cytoplasmic proteins was observed.  
Conclusions: We conclude that a micelle formulation of JS-K increases its accumulation 
in the nucleus. Post-translational protein modification through S-glutathionylation may 
contribute to JS-K’s anti-leukemic properties. 
 
3.2 Introduction 
Nitric oxide (NO) is a naturally occurring biological molecule with multiple functions 
in the vascular, neurologic and immune systems (1). It has direct cytotoxic effects on 
tumor cells (2). It can lead to apoptosis by targeting various cellular sites and bringing 
about post-translational modifications of proteins through mechanisms such as S-
nitrosylation, S-glutathionylation and ADP ribosylation (3). NO has also been found to 
trigger apoptosis by inducing endoplasmic reticulum stress (4). We have previously 
shown that NO induces differentiation in acute myeloid leukemia (AML) cells (5). Also, 
diazeniumdiolates generate NO spontaneously and induce apoptosis in AML cells (6). 
However, these compounds cannot be used clinically for the treatment of malignant 
diseases because of the pleiotropic effects of NO, and particularly NO-induced 
vasodilatation through activation of the soluble guanylate cyclase/cGMP pathway (1). An 
alternative strategy relies on the use of prodrugs that target NO to the malignant cells. 
Arylated diazeniumdiolates react with glutathione (GSH) to release NO. The reaction is 
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catalyzed by glutathione S-transferases (GST) (7). This drug design exploits upregulation 
of GST in malignant cells (8).  Our initial screen of arylated diazeniumdiolates revealed 
that O2-(2,4-dinitrophenyl)1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] 
or JS-K (Fig. 3.1) has potent anti-leukemic activity in vitro and in vivo (7). JS-K inhibits 
the growth of HL-60 myeloid leukemia cells with a 50% growth inhibitory concentration 
(IC50) of 0.25 – 0.5 µM (7). In in vivo murine models, JS-K was also found to be 
effective against prostate cancer (7), hepatoma (9), multiple myeloma (10), non-small cell 
lung cancer (11) and glioma (12). JS-K also possesses anti-angiogenic activity both in 
vitro and in vivo (13). JS-K was shown to be selectively toxic towards tumor cells in 
multiple myeloma and breast cancer models. It did not affect the growth of normal 
human peripheral blood mononuclear cells (10) or normal mammary epithelial cells (14). 
Thus, JS-K is a promising candidate for development as an anti-neoplastic agent with a 
broad spectrum of activity. 
In preliminary studies, JS-K was found to have challenging pharmacologic properties 
that hinder its clinical development. These include poor solubility in aqueous media and 
reactivity with blood components resulting in a short half- life (t1/2). To solve these 
problems, we have developed a nanoscale formulation of JS-K using Pluronic® micelles. 
Pluronic® tri-block copolymers (poloxamers) are amphiphilic polymers composed of 
ethylene oxide (EO) and propylene oxide (PO) arranged in the sequence EOx-POy-EOx 
(15). Depending on the length of the EO and PO blocks, Pluronic® polymers form 
nanoscale micelles at different critical micelle concentrations (CMC) (16). These 
micelles have a hydrophobic core that traps sparingly soluble molecules and a 
hydrophilic shell that allows solubilization of the latter in aqueous media. Pluronic® 
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polymers are excellent candidates to solubilize anti-cancer agents because they have low 
toxicity, circumvent the multi-drug resistance phenotype and lead to higher intra-tumoral 
drug accumulation through the enhanced permeability and retention (EPR) effect (15-18). 
After screening multiple Pluronic® polymer candidates, we have developed a formulation 
for JS-K using the P123 Pluronic®. The purpose of the current study was to compare the 
intracellular trafficking of free JS-K as opposed to JS-K formulated in Pluronic® P123 
micelles (P123/JS-K). Results show that Pluronic® P123 micelles increase the penetration 
of JS-K in HL-60 AML cells. We also observed that JS-K induces S-glutathionylation of 
nuclear proteins. 
 
3.3 Materials and Methods 
3.3.1 Materials 
JS-K was synthesized at Richman Chemical (Lower Gwynedd, PA) as previously 
described (19). Pluronic® P123 polymers were obtained from BASF (Florham Park, NJ). 
All other chemicals were from Sigma (St. Louis, MO) unless otherwise noted. 
 
3.3.2 Cells and culture conditions 
Human myeloid leukemia HL-60 cells (ATCC, Rockville, MD) were cultured in 
RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and 
penicillin/streptomycin. Cells were cultured at 37 ºC in a 5% CO2 humidified 
atmosphere. For experiments in different media, cells were suspended in phosphate 
buffered saline (PBS) with or without 10% FBS, or RPMI/10% FBS as indicated in the 
individual experiment. For each experiment, JS-K was added at the time of culture 
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initiation, cells were harvested at the indicated time points, washed in PBS and assays 
conducted. 
 
3.3.3 Pluronic® micelle formulation of JS-K  
JS-K stocks (50 mM) in DMSO were mixed with stocks of Pluronic® P123 polymers 
prepared in PBS. Micellization was allowed to occur spontaneously with gentle heating at 
55-60°C. The Pluronic® stock concentration was 2.25%. The proportion of JS-K to P123 
in solution was 1.7% by weight. pH of the Pluronic® solution of JS-K was maintained at 
6.5. The final concentration of JS-K in the Pluronic® solution was 1 mM. For 
comparison, experiments were conducted with free JS-K. In the latter case, a DMSO 
stock (50 mM) of JS-K was serially diluted in PBS to a final concentration of JS-K of 1 
mM in PBS/60%DMSO. For the cellular uptake and cell distribution studies, the final JS-
K concentration in culture with either formulation was 50 µM. This high concentration 
was used in order to ensure detection of measurable levels of JS-K within the limitations 
of our assays. For the S-glutathionylation assays (see below), the final concentration of 
JS-K in culture using either formulation was 5 µM. 
 
3.3.4 High performance liquid chromatography (HPLC) 
HPLC analysis to measure JS-K levels was conducted on a Waters Alliance HPLC 
system consisting of a 2695 Separation Module, a 2996 Photodiode Array Detector using 
a Waters XTerra MS C18 chromatography column (4.6 X 150 mm; 3.5 mm particle size), 
controlled by Empower software. We used an isocratic mobile phase consisting of A= 
30% 0.02 M ammonium formate (pH 3), 40% acetonitrile (ACN) and 30% methanol, and 
D = 100% methanol.  Flow rate was kept constant at 1mL/min for 6 min. During 
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chromatographic separation, JS-K was monitored by absorbance at 300 nm. The method 
results in a standard detection curve over a linear range of 6.1-49.1 ng with a lower limit 
of detection of 6.4 ng. 
 
3.3.5 Cellular uptake and nuclei isolation 
HL-60 cells (5 x 106 cells per mL) were cultured in 6 well tissue culture plates. Free 
or P123/JS-K was added to HL-60 cells at final concentrations of 50 mM. At the 
indicated time points, cells were collected by centrifugation and washed with PBS at pH 
6.5. Cells were then lysed in lysis buffer. For whole cell lysates the lysis buffer consisted 
of 1% SDS formate. The lysis buffer for cytosolic and nuclear extraction consisted of 40 
mM sodium citrate, 1% Triton X-100 adjusted to pH 6.5 or lower in order to increase the 
stability of JS-K. The lysed samples were then vortexed for few seconds and refrigerated 
for 30 min. at 4ºC. Nuclei were then separated from the cytosol by centrifugation for 10 
min. at 600g. The efficiency of the nuclear isolation was verified by microscopic 
inspection of cytospins of the nuclear and cytoplasmic fractions stained with 
Wright/Giemsa stain. The isolated cellular fractions were then extracted with acetonitrile 
(60%)/formate (40%) for measurements of JS-K levels by HPLC as described above.  
 
3.3.6 Glutathionylation assays 
In order to evaluate protein S-glutathionylation, HL-60 cells (5x106 cells/mL) were 
treated with free JS-K or P123/JS-K or P123 only or DMSO only at a concentration of 5 
µM for 30 min. Cytosolic and nuclear protein isolation was performed using the 
Qproteome Nuclear Protein Isolation Kit (Qiagen, Valencia, CA) following the 
manufacturer’s protocol with the exception of excluding dithiothreitol (DTT) in order not 
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to confound results of the S-glutathionylation assay. Protein concentration of the samples 
was determined using the Bradford assay. Proteins were separated by SDS-PAGE on 4-
12% polyacrylamide gel under non-reducing conditions. Proteins were transferred to 
polyvinylidene fluoride (PVDF) membranes. After blocking in 5% nonfat dry milk in 
tris-buffered saline with 0.2% tween (TBST), the membrane was incubated overnight at 
4°C with anti-glutathione monoclonal antibody (1:1000, Virogen, Watertown, MA). 
Blots were developed by incubating the membrane with horseradish peroxidase 
conjugated secondary antibody (1:5000, Jackson Immuno Research Laboratories, INC, 
Westgrove, PA) and analyzed by enhanced chemiluminescence (GE Healthcare, 
Piscataway, NJ). 
 
3.3.7 Statistical analysis 
Two-way analysis of variance (ANOVA) was performed using SigmaPlots (Systat 
Software Inc, Chicago, IL). Results obtained for free JS-K or P123/JS-K were compared 
at different time points. Post-hoc analysis was performed using the Holm Sidak test. 
Differences were considered statistically significant for P values below 0.05.  
 
3.4 Results 
3.4.1 Cellular uptake studies 
We started by performing exploratory experiments to compare the recovery of JS-K 
from whole cell extracts when the drug was formulated in P123 micelles (P123/JS-K) as 
opposed to the unformulated compound (dissolve in PBS/DMSO). Cells were incubated 
in PBS or RPMI/10%FBS and JS-K added at a concentration of 50 µM for both 
formulations. After 15, 30 and 60 min., JS-K recovery from whole cell extracts was 
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conducted as detailed in the Methods. JS-K recovery was higher with the P123 micelles 
than with the free drug (data not shown for these exploratory experiments). Since with 
these exploratory experiments it seemed that the P123 formulation enhanced the cellular 
penetration of JS-K, we next sought to determine if it affected its intracellular 
distribution.  
We initially conducted the experiments with cells incubated in PBS in order to avoid 
the confounding effect of proteins or other elements in full media. For both formulations, 
recovery of JS-K from nuclei was higher than from the cytosol. However, P123 micelles 
increased the recovery of JS-K from nuclei. When cells were incubated in PBS, the 
percent recovery of free JSK from nuclei at 15, 30, 60 and 120 min. was 5.03±2.7; 
5.00±3.2; 10.83±6.1 and 0.58±0.2, respectively (Fig. 3.2). Under the same conditions and 
at the same time points, the percent recovery of P123-formulated JS-K from nuclei was 
9.05±4; 20.00±8.1; 21.15±3.6 and 27.73±4.9, respectively (Fig. 3.2). The differences 
between the 2 formulations were statistically significant when they were compared (P = 
<0.001), but the differences between the different time points of the same formulation 
were not significant. Also, the differences between the two formulations were statistically 
significant at 30 and 120 min. On the other hand, percent recovery of free JS-K from 
cytosol at 15, 30, 60 and 120 min. was 1.47±0.5; 0.87±0.5; 1.4±0.5 and 1.74±0.8, 
respectively (Fig. 3.2). Under the same conditions and at the same time points, the 
percent recovery of P123-formulated JS-K from cytosol was 2.73±1.5; 0.83±0.2; 
1.22±0.4 and 0.95±0.3 (Fig. 3.2). It is notable that with free JS-K, nuclear recovery 
peaked at 60 min. and was negligible afterwards. On the other hand, when JS-K was 
formulated in P123 micelles, nuclear recovery peaked at 120 min.  
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As the recovery from the cytosol was negligible when the cells were incubated in 
PBS, the cytosolic fraction was not tested for JS-K recovery in subsequent studies. In 
order to determine the effect of proteins in the culture medium on JS-K recovery, we then 
measured JS-K levels when the cells were incubated in PBS/10% FBS. When cells were 
incubated in PBS/10% FBS, the percent recovery of free JS-K from nuclei at 30, 60 and 
120 min. was 3.55±2.1, 3.15±1.5 and 2.13±1.1, respectively (Fig. 3.3). Under the same 
conditions and at the same time points, the percent recovery of P123/JS-K from nuclei 
was 20.74±7.2; 12.70±3.7 and 16.03±3.9, respectively (Fig. 3.3). The differences 
between the 2 formulations were statistically significant (P<0.001) but the differences 
between the different time points of the same formulation were not significant. When the 
formulations were compared at different time points, the differences were statistically 
significant at 30 and 120 min.  
In order to determine the effect of full media on JS-K recovery, we repeated the 
experiments when the cells were incubated in RPMI/10% FBS. When cells were 
incubated in RPMI/10% FBS, the percent recovery of free JS-K from nuclei at 15, 30, 60 
and 120 min. was 0.38±0.17; 0.45±0.23; 0.43±0.25 and 0.2±0.11, respectively (Fig. 3.4). 
Under the same conditions and at the same time points, the percent recovery of P123/JS-
K was 2.93±1.65, 4.68±1.62, 9.30±1.58 and 11.90±4.4, respectively (Fig. 3.4). Overall 
JS-K recovery from nuclei was lower than with the less complex matrices, but again, 
recovery was higher with P123/JS-K. The two formulations showed statistically 
significant differences (P<0.001) but the differences between the different time points of 
the same formulation were not significant. When the formulations were compared at 
different time points, the differences were statistically significant at 60 and 120 min. 
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3.4.2 S-Glutathionylation studies 
Protein S-glutathionylation is a well-established mechanism that controls protein 
function at the post-translational level (20,21). In that respect, NO has been shown to be a 
potent S-glutathionylating agent (3). We therefore sought to determine whether JS-K had 
the same effect in HL-60 cells. Based on our results showing increased levels of JS-K in 
the nucleus we also investigated whether JS-K had a differential S-glutathionylation 
effect on nuclear as opposed to cytoplasmic proteins. HL-60 cells were treated with JS-K 
at a concentration of 5 µM for 30 min. upon which nuclear and cytoplasmic proteins were 
isolated for assays of S-glutathionylation. Results showed that free JS-K induced minimal 
increase in the S-glutathionylation of cytosolic proteins (Fig. 3.5). The effect was similar 
when JS-K was formulated in P123 micelles (Fig. 3.5). When the soluble fraction of 
nuclear proteins was analyzed, free JS-K did not induce significant S-glutathionylation. 
However, for the same protein fraction, P123/JS-K induced significant S-
glutathionylation (Fig. 3.6). When the insoluble fraction of nuclear proteins was 
analyzed, both free and P123-formulated JS-K induced significant S-glutathionylation. 
The effect was slightly more pronounced with the P123 formulation (Fig. 3.6).   
 
3.5 Discussion 
In the current work we evaluated the cellular distribution of JS-K in HL-60 leukemia 
cells. When free JS-K was added to the leukemic cells, there was minimal drug recovery 
from the different cellular compartments. However, higher levels of JS-K were recovered 
from the nucleus. When JS-K was formulated in P123 micelles, recovery of JS-K was 
substantially increased. Again, the highest amounts of JS-K were recovered from the 
nucleus. Several factors could explain these observations. JS-K reacts with GSH to form 
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the secondary products dinitro-phenyl S-glutathione and the diazeniumdiolate 4-
carbethoxypiperazi-NO, which releases NO. Intracellular GSH levels are found mainly 
concentrated in the cytoplasm (22). One could therefore speculate that higher levels of 
JS-K were recovered from the nucleus because most of the JS-K in the cytoplasm reacted 
with GSH. However, the fact that JS-K was measured in the nucleus indicates that it does 
get transported into that compartment either passively or actively.  
When formulated in P123 micelles, JS-K was recovered at higher levels than when 
the drug was formulated in PBS/DMSO. It is to be noted that for these assays, we used 
high concentrations of JS-K (50 µM) in order to be able to measure drug levels using the 
assay we developed. Previous work has shown that the solubility limit of JS-K in aqueous 
solutions was around 10 µM (7). Consequently, a possible reason for which there was 
greater cellular recovery of JS-K with the P123 formulation is that, by increasing the 
solubility of JS-K in the culture media, P123 allowed more drug to reach the cells. 
However, P123 micelles enhance recovery of JS-K in particular from the nucleus. This 
may be due to the fact that the micelles temporarily shield JS-K and prevent it from 
reacting with cytoplasmic GSH and proteins in the cytoplasm. Furthermore, P123 
micelles by themselves may enhance the penetration of JS-K into the nucleus. Indeed, 
Rapoport et al. studied the effect of Pluronic® P105 on the cellular distribution of the 
lipophilic drug Ruboxyl. They showed that Ruboxyl accumulates in the nucleus at P105 
concentrations as high as 1% (23). It is therefore likely that a similar effect occurs when 
JS-K is formulated with P123 micelles. 
The recovery of JS-K from the different cellular compartments diminished when the 
cells were incubated with complex media such as PBS/10%FBS and RPMI/10%FBS. 
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This could be due to the fact that the stability of JS-K diminishes as it is exposed to 
proteins and other components of the media. P123 micelles yield to increased recovery of 
JS-K from the cells as compared to free JS-K in these media. Again, this is likely due to 
“protection” of JS-K by the micelles. 
From a mechanistic standpoint, we show that JS-K induces S-glutathionylation of 
mainly nuclear proteins. Such a post-translational modification can have important 
implications. An oxidative cellular environment is linked with cell death whereas a 
reducing environment promotes cell survival (24). Depletion of cellular GSH pool has 
been associated with apoptosis (22). Nuclear GSH depletion also triggers apoptosis (25). 
The transcription factor nuclear factor-kB (NF-kB) promotes AML survival (24). S-
glutathionylation of this protein can prevent its nuclear translocation, thus promoting 
apoptosis. NO inhibits directly the DNA binding activity of NF-kB (26). Whether, as an 
NO donor, JS-K affects AML cell survival through S-glutathionylation of NF-kB remains 
to be proven. We found that in HL-60 cells, S-glutathionylation is less marked on 
cytoplasmic proteins. This may be due to increased levels of GSH in the cytoplasm with 
resultant competition for reaction with JS-K. 
As demonstrated above, P123 micelles increase the stability of JS-K. Micelles also 
enhance nuclear translocation of JS-K with observable post-translational modification of 
nuclear proteins through S-glutathionylation. Post-translational modifications such as S-
glutathionylation and S-nitrosylation can have important consequences. These 
modifications can enhance or repress the activity of proteins and cause apoptosis (3). 
They can also cause activation of the unfolded protein response (UPR) due to 
accumulation of misfolded S-glutathionylated or S-nitrosylated proteins and result in 
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endoplasmic reticulum (ER) stress (27,28). If ER stress is strong and prolonged, 
apoptosis ensues (29). Induction of ER stress could therefore contribute to JS-K’s 
cytotoxic activity. 
S-glutathionylation of nuclear proteins by JS-K raises the possibility that the drug 
may be exerting some of its effect through a mechanism involving post-translational 
modification of these proteins. These proteins likely include transcription factors (soluble 
nuclear proteins) and histones (insoluble nuclear proteins). The latter finding raises the 
possibility that JS-K may affect leukemia cell growth through an epigenetic mechanism 
as has recently been reported for NO (30). Townsend et al. have shown that the JS-K 
analogue PABA-NO is a potent S-glutathionylating agent. They further demonstrated that 
one of the principal proteins that are S-glutathionylated by PABA-NO is Protein 
Disulphide Isomerase (28). Identification of proteins that are S-glutathionylated by JS-K 
will require further investigation. 
 
3.6 Conclusions 
We show here that JS-K likely affects leukemic cell viability by multiple 
mechanisms, including post-translational modification of nuclear proteins. While the 
drug by itself accumulates in different cellular compartments, a Pluronic® micelle 
formulation affects its cellular trafficking and leads to enhanced accumulation in the 
nucleus. JS-K-induced protein S-glutathionylation raises the possibility that it exerts part 
of its effect through the post-translational modification of key proteins that are yet to be 
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Fig. 3.1: Structure of JS-K 
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Fig. 3.2: Percent recovery of JS-K from cytoplasmic and nuclear fractions when 
cells were incubated in PBS: Values are expressed as percent of initial JS-K added. 
Cytosolic recovery of JS-K is low as compared to nuclear recovery. At any time 
point, JS-K recovery from the nucleus was higher when the drug was formulated 
in P123 Pluronic® micelles. Free Nuclei = JS-K recovery from nuclei with 
PBS/DMSO formulation. P123 Nuclei = JS-K recovery from nuclei with P123 
formulation. Free Cytosol = JS-K recovery from cytosol with PBS/DMSO 
formulation. P123 Cytosol = JS-K recovery from cytosol with P123 formulation. 
The plot shows averages and standard errors of the mean of at least two separate 







































Fig. 3.3: Percent recovery of JS-K from the nuclear fraction when cells 
were incubated in PBS/10% FBS. Values are expressed as percent of 
initial JS-K added. At any time point, JS-K recovery from the nucleus was 
higher when the drug was formulated in P123 Pluronic® micelles. The plot 
shows averages and standard errors of the mean of at least two separate 


































Fig. 3.4: Percent recovery of JS-K from the nuclear fraction when cells 
were incubated in RPMI/10% FBS: Values are expressed as percent of 
initial JS-K added. At any time point, JS-K recovery from the nucleus was 
higher when the drug was formulated in P123 Pluronic® micelles. The plot 
shows averages and standard errors of the mean of three separate 












Fig. 3.5: S-glutathionylation of cytosolic proteins by JS-K: HL-60 cells 
were treated with 5 µM JS-K and incubated for 30 minutes. Evaluation of 
S-glutahionylation of cytosolic proteins was conducted as detailed in the 
text. JS-K in either formulation causes minimal S-glutathionylation of 
cytosolic proteins. 30µg of protein was loaded into each lane of the gel. 
Lane 1: DMSO control; Lane 2: HL-60 cells treated with free JS-K; Lane 
3: P123 control; Lane 4: HL-60 cells treated with P123/JS-K. Actin was 













Fig. 3.6: S-glutathionylation of nuclear proteins by JS-K. HL-60 cells were 
treated with 5 µM JS-K and incubated for 30 minutes. Evaluation of S-
glutahionylation of nuclear proteins was conducted as detailed in the text. 
JS-K caused S-glutathionylation of nuclear proteins. The effect is more 
pronounced with P123/JS-K. Among the nuclear proteins, soluble nuclear 
proteins are S-glutathionylated to a greater extent than insoluble nuclear 
proteins. 30µg of protein was loaded into each lane of the gel. Lane 1: No 
treatment control for soluble nuclear proteins; Lane 2: S-glutahionylation 
of soluble nuclear proteins caused by free JS-K; Lane 3: P123 control for 
soluble nuclear proteins; Lane 4: S-glutahionylation of soluble nuclear 
proteins caused by P123/JS-K; Lane 5: No treatment control for insoluble 
nuclear proteins; Lane 6: S-glutahionylation of insoluble nuclear proteins 
caused by free JS-K; Lane 7: P123 control for insoluble nuclear proteins; 
Lane 8: S-glutahionylation of insoluble nuclear proteins caused by P123. 
PCNA was used as the loading control for soluble nuclear proteins and 
Histone 3 protein was used as the loading control for insoluble nuclear 






MULTIPLE STRESS RESPONSES INDUCED BY THE  
NITRIC OXIDE-RELEASING PRODRUG JS-K 
 
4.1 Abstract 
Cancer cell killing is challenging as most clinically approved chemotherapeutics 
show nonselective effects by killing normal cells as well (1-3). Also, most 
chemotherapeutics act through specific mechanisms (3), which is prone to development 
of resistance by cancer cells (4). The rapidly acquired mutations in cancer cells make 
them resistant to the single effect/stress produced. In the present chapter, we studied two 
major stress mechanisms produced by JS-K or P123/JS-K in HL-60 human AML cells. 
Oxidative stress and endoplasmic reticulum stress contribute to the apoptotic effects 
produced by the drug. We also tested the effect of the drug on normal hematopoietic cells 
(HSCs). JS-K or P123/JS-K did not evoke such a stress response in HSCs. This effect 
was also not triggered by the positive control used in the study. We conclude that JS-K or 
P123/JS-K enhanced intracellular reactive oxygen species/reactive nitrogen species thus 
causing oxidative stress. It also evoked endoplasmic reticulum stress-mediated cell death 
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4.2 Introduction 
The hallmarks of malignancies include uncontrolled cell proliferation, evasion of 
growth suppression and apoptosis, induction of angiogenesis, invasion and metastasis (5). 
Chemotherapeutics act on cancer cells in a diverse fashion. Generally, they act by 
damaging DNA (genotoxic), topoisomerase inhibition, mitotic inhibition or by interfering 
with key metabolic pathways. The overall strategy behind most chemotherapeutics is to 
generate some sort of cell stress in the cancer cells and drive them to apoptosis (6). The 
type of stress response generated and the extent of damage determines how effective the 
chemotherapeutic will be. This is because the cancer cell population is heterogeneous and 
distinct populations of sensitive and resistant cancer cells are present. Also, cancer cells 
can evoke repair mechanisms or efflux responses to the chemotherapeutics that limit their 
actions (7).  
Cancer cells are different from normal cells because of the above-stated hallmarks. 
The deregulated growth signals and altered metabolism supports the tumor 
microenvironment. Additionally, the property of stemness of cancer cells makes their 
complete eradication very hard. Therefore, it is necessary to target the tumor, the tumor 
microenvironment, the associated metabolic pathways and the associated cell death 
pathways in order to eradicate it completely (8-12).  
 
4.2.1 Endoplasmic reticulum stress 
 The endoplasmic reticulum (ER) is involved in a plethora of biological functions. ER 
is the site for biosynthesis of protein, steroids, cholesterol and other lipids. It is also the 
site for protein folding and assembly (13). It is also involved in posttranslational 
modifications such as glycosylation and disulfide bond formation (14). ER provides a 
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cellular store for calcium (15). Proteins translocated to the ER must be folded properly 
before translocating to the Golgi. Unfolded and misfolded proteins stay in the ER for 
refolding or degradation through ubiquitination. Accumulation of such unfolded or 
misfolded proteins or perturbations to any of the ER functions threatens ER integrity and 
cell survival (16). Such a condition is called ER stress. The adaptive response triggered as 
a result of ER stress is called the unfolded protein response (UPR). The ER therefore 
coordinates stress pathways maintaining the crosstalk between the cell’s intracellular and 
extracellular environment (17). ER stress has been implicated in several conditions, 
including diabetes (18), (19), cancer (13, 20-29), neurodegenerative disorders (30), (31), 
cardiovascular disorders (32) and other environmental insults and pathophysiological 
conditions such as hypoxia (33), calcium imbalance (13, 34), oxidative stress (13) and 
viral infections (35). The UPR re-establishes ER homeostasis by either shutting down 
general protein translation or by increasing protein folding through upregulation of 
components of the ER folding machinery and ER quality control, like the ER-associated 
degradation (ERAD) pathway. However, during severe ER stress that cannot be 
controlled by adaptive response, the UPR switches from a prosurvival to a prodeath 
response (36). 
 
4.2.1.1 Steps of UPR during ER stress 
 During the UPR, three ER stress sensors are triggered. PERK (pancreatic ER kinase), 
Ire1 (inositol requiring enzyme) and ATF6 (activating transcription factor) are present on 
the ER membrane (15). During the unstressed conditions, BiP/GRP78 (GRP78 from now 
onwards) is bound to these three ER stress sensors. GRP78 (glucose regulated protein) is 
an ER chaperone that is involved in the proper folding of proteins. During ER stress, due 
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to high demand of protein folding, GRP78 dissociates from the ER stress sensors and 
binds to the abnormal proteins. With GRP78 dissociation, the sensors are activated. 
While PERK and Ire1 are dimerized and autophosphorylated, ATF6 is transported to the 
Golgi and activated by two step cleavage by Site-1 and Site-2 proteases (37). These three 
sensors then act in a coordinated fashion to relieve the ER stress. In the first phase, 
general protein load is reduced by translational attenuation through phosphorylation of 
eIF-2α by PERK. In the second phase, induction of ER chaperones is observed that 
enhances the folding capacity of the ER. GRP78 is one such chaperone. The third phase 
is the ER associated degradation (ERAD), which involves degradation of unfolded or 
misfolded proteins accumulated in the ER through the ubiquitin-proteasome system in the 
cytosol. If all these adaptive responses fail and the ER homeostasis is not restored, then 
prosurvival UPR shifts to proapoptotic UPR to remove damaged cells. CHOP is the 
common proapoptotic protein activated by all three branches of UPR (15), (38), (39), 
(40). These phases are represented in Fig. 4.1. 
 
4.2.1.2 Conditions leading to and resulting from ER stress  
4.2.1.2.1 Misfolded/Unfolded protein accumulation 
 The cellular system is constantly challenged by environmental stresses that result in 
protein misfolding. Such a condition can arise inside the ER or outside the ER including 
the cytosol and nucleus (41). Such protein misfolding can result in pathological 
conditions.  
ER stress has been suggested as an early marker in neurodegeneration (42). 
Neurodegenerative disorders such as Alzheimers disease, Parkinsons disease and 
Huntington’s disease result from the accumulation of aggregated and misfolded proteins 
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(43). The misfolded proteins accumulated in ER transmit a toxic response in the form of 
disruption of synaptic function affecting neuronal function, calcium imbalance, free 
radical release causing redox imbalance, disruption in protein degradation pathway or 
programmed cell death as the eventual step. Such conditions arise due to deposition of 
misfolded proteins as inclusion bodies that enable interaction with cellular targets causing 
toxic response (44).  
Diabetes is a condition resulting from disturbed insulin regulation. In the β cell, ER 
serves important functions in the assembly and processing of insulin. During 
hyperglycemia, the transcription and translation of pro-insulin is increased, leading to 
accumulation of misfolded pro-insulin in the ER lumen thus causing ER stress (45), (46). 
Several cardiac disorders such as cardiac hypertrophy, cardiac failure, 
atheroscelorosis and ischemic heart diseases are associated with ER stress. In this section, 
only atheroscleosis will be discussed as only this condition results from protein synthesis 
overload. Macrophages and smooth muscle cells cause atherosclerosis development. 
During the initial phase of atherosclerosis, high levels of secretory proteins are produced 
by macrophages and smooth muscle resulting in ER overload and thus ER stress (32), 
(47). 
Cancer cells are highly proliferating cells and as a result have a high protein turnover. 
Such a demand for protein synthesis puts a load on the ER resulting in ER stress (48). ER 
stress response is triggered in the cancer cells as an adaptive response to cope with the 
external stress and high protein demand. It is prosurvival initially and in some solid 
tumors, it has been found to aid tumor progression (36). It can therefore be considered a 
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target for therapeutic intervention. Therapies aimed at enhancing ER stress can switch 
prosurvival ER stress to proapoptotic ER stress (36), (28). 
 
4.2.1.2.2 Calcium imbalance 
 The ER is involved in Ca signaling. Ca fluxes can evoke the UPR and contribute to 
the cell survival or cell death depending on the extent of ER stress.  Ca release from the 
ER has been linked with the proapoptotic response. Increased Ca release has been 
observed with Bcl2-deficient cells or proapoptotic Bcl2 members rich cells (49), (50), 
(51). The mechanism of ER stress response generated by Ca imbalance is related to 
sarco/endoplasmic reticulum calcium ATPase (SERCA) inhibition. This transmembrane 
protein pumps Ca ion into the ER, maintaining the gradient. Due to SERCA inhibition, 
Ca homeostasis is affected and UPR response triggered (52). In addition to tumors, ER 
stress caused by Ca imbalance is significant in cardiac pathologies. Recent evidence has 
suggested over expression of SERCA in failing hearts since heart failure is linked to Ca 
imbalance (32). 
 
4.2.1.2.3 Redox imbalance 
 Redox imbalance has been linked to ER stress. Generally, tumors support a hypoxic 
environment and thus redox imbalance is observed. Oxidative stress is linked with the ER 
stress that either precedes it or follows it. ER is the site of protein folding which is an 
energy intensive process requiring molecular oxygen (53). Also, ER is involved in 
disulfide bond formation requiring an oxidizing environment (48). Hyperglycemia is also 
associated with generation of reactive oxygen species that enhances ER stress (45). 
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4.2.1.2.4 Metabolic imbalance 
In solid tumors, poor vascularization leads to metabolic disorders because of acidosis 
and glucose starvation resulting in ER stress by activating glucose stress response 
through induction of glucose regulated protein 78 or GRP78 which is part of the UPR and 
thus ER stress (54). Apoptosis induced under metabolic stress is regulated by the Bcl2 
family of proteins (55).  Bim and PUMA, the proapoptotic Bcl2 family proteins, are 
expressed under ER stress caused by metabolic stress (56). Induction is caused by 
glucose imbalance that affects protein glycosylation and thus protein misfolding (57). 
 
4.2.2 Oxidative stress 
 Leukemic cells in general contain elevated levels of ROS (58). Elevated ROS levels 
are associated with oxidative damage leading to cell death due to genomic instability, 
lipid peroxidation and DNA damage (59). This could be enhanced by chemotherapeutics 
that increase ROS levels. Several FDA approved antileukemic chemotherapeutics utilize 
this strategy of generating/enhancing oxidative stress to cause cancer cell death (60). 
ROS or oxidative stress has been shown to play a part in cancer initiation and progression 
and in cancer cell death as well. Like ER stress, the extent of oxidative stress determines 
cell survival or cell death. It has been shown that a reducing environment promotes cell 
survival and an oxidizing environment promotes differentiation or cell killing (61). 
Therefore, oxidative stress has been considered as a strategy to induce cancer cell death 
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4.3 Materials and Methods 
4.3.1 Materials 
JS-K was synthesized as previously described (62). JS-K was synthesized at Richman 
Laboratories (Lower Gwynedd, PA) under conditions of Good Manufacturing Practice 
(cGMP). Tunicamycin was purchased from Sigma Aldrich (St. Louis, MO). Thapsigargin 
was purchased from Calbiochem (Billerica, MA). Pluronic® polymers were obtained from 
BASF (Florham Park, NJ). Radio immuno precipitation assay (RIPA) cell lysis and 
extraction buffer was purchased from Thermo Fisher Scientific (Rockford, IL). The 
following reagents and antibodies were purchased from the indicated suppliers: Anti-BiP/ 
GRP78 from BD Biosciences (San Jose, CA), Anti-CHOP from Cell Signaling 
Technology (Beverly, MA) or from Santa Cruz Biotechnology, Inc (Dallas, TX), Anti-
pJNK and anti-JNK were from Santa Cruz as well. 5-(and-6)-chloromethyl-2’, 7’-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA) was purchased from Invitrogen, 
Molecular Probes (Eugene, OR). All other antibodies or chemicals and reagents were 
from Sigma Aldrich (St Louis, MO) unless otherwise indicated. 
 
4.3.2 Cell culture 
Human myeloid leukemia HL-60 cells (ATCC, Manassas, VA) were cultured in 
RPMI-1640 supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin 
and mycozap. Cells were cultured at 37◦C in a 5% CO2 humidified atmosphere. Normal 
human CD34+ hematopoietic cells (HSC) were purchased from All Cells (Alameda, CA).  
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4.3.3 Preparation of JS-K loaded P123 micelles, free JS-K, Tunicamycin and 
Thapsigargin 
11.25% of P123 micelle stock solution was prepared in HPLC grade water (Fisher 
Scientific, Waltham, MA). The solution was further diluted to 2.25% in phosphate 
buffered saline (PBS) (pH 6.5). 1mM P123/JS-K was prepared by heating 3.34 mL of 
2.25% P123 at 50°C and adding 70µL of 50 mM JS-K. The weight loading of drug in 
P123 micelle is 1.7%. Further dilution was made in PBS (pH 6.5). For free JS-K, 5 mM 
JS-K stock was prepared in DMSO out of 50 mM JS-K stock in DMSO. Further dilutions 
were made in PBS. Tunicamycin (5mg/mL) and Thapsigargin (1mg/mL) stocks were not 
diluted. Final concentration was achieved in the cell culture. 
 
4.3.4 Western blot 
Cells were treated with free JS-K (5 µM) formulated in DMSO or micelle JS-K (5 
µM) formulated in 2.25% P123 for 4-12 h as indicated. The cells were also treated with 
Tunicamycin (25µg/mL) or Thapsigargin (3 µM) (as a positive control for ER stress) and 
a P123 and no drug control was established at 0 hour. After treatment, the cells were 
collected and washed with PBS. Following centrifugation, RIPA lysis buffer (25mM Tris 
HCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) 
supplemented with phenylmethylsulfonyl fluoride (PMSF) and protease and phosphatase 
inhibitors were added to the pellet. The lysates were sonicated (50% intensity for 15 
seconds), centrifuged and the supernatant was collected and protein concentration 
measured using the Bradford reagent (ThermoScientific) or BCA protein assay reagent 
(Pierce Biotechnology). Loading buffer and reducing agent (DTT, Invitrogen) were 
added to the samples and electrophoresed in a 10% polyacrylamide gel (Biorad). Proteins 
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were transferred to polyvinylidene difluoride (PVDF) membranes at 110 V for 95 min. 
(Biorad). The blots were blocked for 1.5 h in 2.5% nonfat dry milk diluted in tris-
buffered saline containing 0.2% tween (TBST) and washed with TBST (3X, 7 min. each). 
The membrane was then incubated with primary antibody (anti-CHOP or anti-GRP-78 or 
anti-actin) in 2.5% nonfat dry milk/TBST overnight. Membranes were washed (3X, 7 
min. each) and incubated with horseradish peroxidase-conjugated secondary antibody in 
2.5% nonfat dry milk in TBST for 2 h. The membrane was washed again in TBST thrice 
for 7 min. each and transferred proteins were detected with ECL substrate (GE 
Healthcare, Piscataway, NJ). 
 
4.3.5 Intracellular reactive oxygen/reactive nitrogen species 
Quantification of intracellular levels of reactive oxygen/nitrogen species (ROS/RNS) 
was performed using the ROS/RNS-sensitive fluorophore 5-(and-6)-chloromethyl-2’, 7’-
dichlorodihydrofluorescein diacetate or CM-H2DCFDA. Cells growing on 24 well plates 
(1x106 cells/well) were loaded with 5 µM CM-H2DCFDA in PBS at 37°C and 5% CO2 
for 30 min. (63), (64). The PBS-containing probe was removed by washing the cells with 
PBS and the cells were re-incubated in RPMI media only and treated with 5 µM JS-K or 
5µM P123/JS-K or 5µM P123 or H2O2 (positive control) or not treated for the indicated 
time periods. The treated or nontreated cells were then collected and fluorescence was 
measured at 488 nm excitation and 530 nm emission using a BD FACSCanto flow 
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4.4 Results 
4.4.1 JS-K and P123/JS-K enhances ER stress response in HL-60 cells 
We have previously shown that JS-K and P123/JS-K cause glutathionylation of 
nuclear proteins in HL60 cells (Chapter 3). Glutathionylation can result in deleterious 
post-translational modifications and cause accumulation of enough misfolded proteins to 
exceed the folding capacity of the ER. This response can result in activation of the UPR 
leading to ER stress (65). Several researchers have shown that due to high protein 
turnover in the tumor cells, the ER stress is already activated in cancer cells. A 
chemotherapeutic should be able to enhance the ER stress so as to shift the prosurvival 
signal to a proapoptotic response (66).  
 
4.4.1.1 GRP78/Bip expression 
Treatment of HL-60 cells with JS-K or P123/JS-K enhanced the expression of GRP-
78 from a 0 hour no treatment control. The expression of GRP78/BiP peaked at 6 h for 
both JS-K and P123/JS-K and showed a declining trend towards 8 h (Fig. 4.2). 
Densitometry analysis revealed that the effect produced by P123/JS-K was slightly lower 
than JS-K (results not shown). This could be attributed to the effect produced due to the 
use of Pluronics®. GRP-78 expression was also tested on normal human hematopoietic 
CD34+ cells (Fig. 4.3). None of the groups (treated or untreated or control) showed 
GRP78 expression. 
 
4.4.1.2 CHOP/GADD153 expression 
Basal levels of CHOP/GADD153 protein were low when a no treatment control was 
established in the HL-60 cells (Fig. 4.2). Treatment with both JS-K and P123/JS-K or the 
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positive control Tunicamycin enhanced the expression of this proapototic protein 
indicating the shift from a prosurvival response to a proapoptotic response. We did not 
see any expression of CHOP in HSC cells by neither the treatment group nor the positive 
control group (Fig. 4.3). 
 
4.4.1.3 Effects on the levels of intracellular ROS  
The fluorescent dye CM-H2DCFDA rapidly oxidizes to the fluorescent product 
dichlorofluorescein (DCF) in the presence of reactive oxygen or reactive nitrogen 
species. The intensity of fluorescence can therefore be regarded as proportional to the 
amount of intracellular reactive species generated. HL-60 cells were treated with JS-K or 
P123/JS-K or hydrogen peroxide (H2O2) as a positive control. We also prepared a 
combination of P123/JS-K and H2O2 to see the effect of the drug if oxidizing conditions 
already prevail inside the cells. The study was carried out over a period of 2 h (Fig. 4.4). 
JS-K caused a sustained increase in the release of ROS/RNS similar to the positive 
control H2O2. ROS/RNS levels did not change with P123/JS-K treatment for 2 h but the 
levels were higher as compared to no treatment control. This could be attributed again to 
the Pluronic effect as the treatment with Pluronics actually reduced the levels of 
ROS/RNS. Interestingly, treating the cells with H2O2 prior to the treatment with P123/JS-
K increased the overall level of ROS/RNS generation. The levels of ROS/RNS were 
higher than the H2O2 control or P123/JS-K treatment indicating a potentially additive 
effect or an effect produced by priming the cell with the oxidizing agent prior to the 
actual treatment. The fold change as compared to no treatment is shown in Fig. 4.4. One 
way ANOVA was ran on the data using Tukey post hoc analysis. The results were 
considered statistically significant for P<0.05. 
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4.5 Discussion 
The aim of the present study was to investigate different stress responses produced by 
the prospective chemotherapeutic drug JS-K. We also investigated potential differences 
that might arise due to Pluronic micelle formulation of the drug. JS-K is a nitric oxide 
releasing drug. The different biological metabolites formed as a result of JS-K 
degradation (apart from NO) include 2,4-dinitrophenyl-S-glutathione (SG-DNP) and 1-
carboethoxypiperazine (67). Subsequently, glutathione can dissociate from the 
dinitrophenyl ring separating glutathione from the aryl ring.  Protein S-glutathionylation 
is a phenomenon of mixed disulphide formation between glutathione and cysteinyl 
residues (68). However, under basal conditions, the reaction rate is slow and lacks any 
physiological relevance (68). The process is reversible under reducing conditions 
whereas it is permanent under oxidizing/stressed condition (69).  
We previously studied the cellular distribution of JS-K and P123/JS-K. As expected, 
P123/JS-K was more stable and localized to a greater extent than the free drug, which 
decomposed rapidly. The drug principally distributed to the nucleus. As the distribution 
study performed was a quantitative analysis based on actual drug quantification, it was 
concluded from the study that drug degrades in the cytosol if its not protected by a 
micelle shell. Secondly, it was also concluded that micelles aid in nuclear localization of 
the drug. The higher degradation of the drug in the cytosol could be attributed to the 
higher reducing environment in the cytosol (high GSH) as compared to the nucleus (70). 
This led to corollary that the drug degraded in the cytosol or in the nucleus generates NO 
or SG-DNP or also leads to protein glutathionylation. NO release can have several 
implications, including RNS in the form of radicals or nitrosylation of proteins (71). The 
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reduction of glutathione concentration also contributes to a more oxidizing environment 
leading to oxidative stress (10). With such conclusions and plausible ramifications, we 
next sought to investigate the process of protein glutathionylation in the cell. In the study 
carried out, JS-K glutathionylated nuclear proteins principally. Again, the extent of 
nuclear protein glutathionylation was higher in P123/JS-K treated HL-60 cells than the 
drug alone. Protein glutathionylation can produce certain unwanted posttranslational 
modifications leading to accumulation of glutathionylated proteins. Such a condition can 
result in ER stress (48). Also, the oxidative stress and changes in the redox environment 
of the cell can cause ER stress and contribute to the cell death cascade (72), (73).  
The ER is a critical subcellular compartment involved in execution of apoptosis (72), 
(40), (66). It is involved in protein synthesis and protein folding as well as calcium 
storage. All the proteins translocated to ER are subjected to posttranslational 
modifications. Only correctly folded proteins are exported out of the ER. Unfolded or 
misfolded proteins are retained inside the ER and are subjected to either refolding or 
degradation (74). Accumulation of such unfolded or misfolded proteins inside the ER 
generates the UPR to increase the folding capacity of the ER. This situation is 
particularly relevant in the cancer cell as the cancer cells require high protein turnover, 
compromising the ER capacity (48). Consequently, basal level UPR response is always 
present in cancer cells (66). Such a response is prosurvival initially, but if stress is 
enhanced beyond the ER capacity, apoptosis ensues. GRP-78/BiP is an ER chaperone 
that is involved in the protein folding mechanism. This chaperone keeps the transcription 
factors PERK, ATF6 and Ire-1 in an inactivated state till the induction of UPR. During 
UPR, GRP-78 dissociates from these transcription factors (75). All the three transcription 
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factors then work in a concerted fashion to relieve the stress either by increasing the ER 
capacity (through reducing the overall protein load by degrading the misfolded proteins 
or by enhancing the folding capacity of the ER) or by activating the apoptosis cascade. 
Several studies have been carried out to integrate the programmed cell death with ER 
stress. All the conditions that cause perturbations of ER functions or that stress the 
functional capacity of the ER can lead to ER stress. These include, protein synthesis or 
folding at a rate higher than ER’s capacity, calcium imbalance, oxidative stress or redox 
changes in the cell (73). Therefore, all the conditions can be integrated with the apoptotic 
cascade. The common apoptotic downstream target of the UPR branch is CHOP (C/EBP-
homologous protein) also known as GADD153 (growth arrest and DNA damage-
inducible protein-153). Prolonged CHOP expression has been linked to activation of 
apoptotic mechanisms involving activation of death receptors, outer mitochondrial 
membrane polarization, JNK phosphorylation and Bcl2 proteins interaction (73).  We did 
not get any CHOP or GRP-78 induction by JS-K in normal CD34+ cells (HSC-containing 
cells). However, we did not see any expression of ER stress markers with Tunicamycin 
(the positive control) either. This implies that either the CD34+ cells are resistant to the 
induction of ER stress or it implies that both the drugs are selective in killing cancer cells, 
thus sparing normal stem cells.  
With GRP-78 expression, it became clear that JS-K is enhancing ER stress in the 
cells. Prolonged CHOP expression suggested triggering of the apoptotic response. Further 
downstream, we investigated only the CHOP and oxidative stress pathway of ER stress-
induced cell death. Although oxidative stress or redox imbalance causes ER stress, it has 
been suggested that with prolonged ER stress, the lumen of the ER gets hyperoxidized 
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with release of H2O2 in the cytoplasm, leading to cell death.  In this pathway, ERO1α 
oxidase is involved which leads to either hyperoxidizing conditions in the cytosol or 
induction of NADPH oxidase subunit Nox2, resulting in generation of ROS and leading 
to oxidative stress (via CHOP-ERO1α-IP3R1-CaMKII pathway) (13). The common 
effector for both pathways is JNK activation which has been linked to oxidative stress 
and cell death (76). JS-K being a NO releaser and glutathione quencher is expected to 
cause redox imbalance leading to oxidative stress. Therefore, in our set of studies, we 
investigated the effect on ROS/RNS levels after JS-K or P123/JS-K treatment. As 
expected, a 2-4 fold increase in ROS/RNS level was observed as compared to controls 
after HL-60 cells were treated with JS-K or P123/JS-K. There was a sustained increase in 
ROS/RNS levels from 30 min. to 2 h after the cells were treated with JS-K. The levels of 
ROS/RNS levels did not increase drastically when cells were treated with P123/JS-K. 
This could be explained by results obtained from prior experiments. JS-K alone is 
sensitive to GSH present in the cells. Therefore, with time, drug degradation increased 
and therefore levels of ROS/RNS also increased. In contrast, P123/JS-K is stabilized in 
the micelle core and does not degrade as readily. Also, the drug translocates to the 
nucleus with time to a greater extent than free JS-K. The dye is intracellular and does not 
diffuse in the nucleus (77). Therefore, whatever degradation occurs inside the cytosol is 
reflected in the form of increased ROS/RNS as compared to the basal level. The reduced 
signal of P123 and P123/JS-K at 120 min. could be explained by considering the change 
in membrane permeability brought about by P123 (or Pluronic micelles) (78) causing dye 
leakage out of the cell and thus reduced response. 
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We also wanted to see the effect of cell priming with a known oxidizing agent. We 
primed the cells with H2O2 for 15 min. and treated the cells with P123/JS-K. The 
ROS/RNS levels were higher as compared to H2O2 or P123/JS-K alone. This means JS-K 
generates more ROS/RNS in the presence of an oxidizing agent.  
Following the above results, we then sought to integrate the ER stress response to the 
oxidative stress. Some studies have shown that ER stress leads to ROS production. 
Studies have suggested links between oxidative and ER stress. Malhotra et al. proposed 
two mechanisms of ROS generation (or oxidative stress) during UPR evocation. First, 
ROS is produced as a byproduct of mitochondrial oxidative phosphorylation during the 
binding of misfolded proteins to ER chaperone such as GRP-78. Second, ROS is 
generated during electron transfer from thiols to molecular oxygen generating hydrogen 
peroxide during disulfide bond formation. The authors showed that antioxidants 
attenuated ER stress and oxidative stress that inhibited apoptosis (79). A common 
effector in both pathways may be JNK protein (73). Although molecular pathways 
linking ER stress with oxidative stress have not been elucidated in detail, some studies 
have suggested JNK protein phosphorylation could be linked with oxidative stress and 
ER stress induced cell death (80, 81). The whole proposed mechanism is presented in the 
Fig. 4.5. Cancer cells have high levels of ROS and are under oxidative stress, which is 
essential for tumor progression (9). We could not observe consistent phosphorylation of 
JNK with JS-K treatment of HL-60 cells. However, the release of ROS/RNS with JS-K 
treatment indicate involvement of oxidative stress in producing its effect. If oxidative 
stress is linked to ER stress, this could be confirmed by studying the expression of Ero1α 
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as this chaperone is involved in apoptosis induced by pJNK due to oxidative stress caused 
by ER stress (72), (73). All the pJNK results have been reported in the Appendix A. 
 
4.6 Conclusions 
In this study, we showed that the NO releasing prodrug JS-K induces a differential 
stress response in HL-60 cells and/or primary AML cells. The stress response produced is 
affected by the Pluronic micelle formulation of JS-K. JS-K and P123/JS-K activates the 
endoplasmic reticulum stress response. We showed increased expression of ER stress 
specific markers GRP-78 and CHOP protein by JS-K treatment in HL-60 cells. The major 
reasons for induction of ER stress could be attributed to accumulation of misfolded 
glutathionylated proteins and possibly due to redox imbalance of the tumor cell caused by 
the release of RNS/ROS by JS-K.  We showed that intracellular ROS/RNS levels 
increased after JS-K treatment. The levels increased steadily for the free drug over a 
period of 2 h whereas they remained constant with P123/JS-K treatment. Free drug is 
likely more prone to attack by cellular thiols such as GSH and likely releases NO more 
quickly as compared to P123/JS-K. Reduction in the glutathione levels could create a 
more oxidizing environment and disturb the redox balance of the cell (82). We conclude 
that one of the mechanism of antileukemic activity of JS-K may involve induction of 
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Fig. 4.1: Phases and conditions of ER stress. Adapted and modified 
from Gotoh T and Mori M. Arterioscler Thromb Vasc Biol 2006, 26, 
1439-1446. 
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Fig. 4.3: Actin band seen on HSC cells. ER stress was not found to be 
activated in treated or nontreated cells. Therefore no bands observed.  
Thap: Thanpsigargin; Tun.: Tunicamycin; No t/t: No treatment 
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Fig. 4.4: Intracellular ROS levels after treatment with JS-K, P123/JS-K, P123, 
H2O2 or H2O2+P123/JS-K at 30, 60 and 120 min. Each point is a 
representative of the average and SEM of three independent experiments 
performed in triplicates. P<0.05 for all formulations except P123 control at 30 
and 60 min. when compared to no treatment. Color code: ☐  No treatment; ☐  
P123/JS-K; ☐  Free JS-K; ☐  P123 only; ☐  H2O2 only; ☐  H2O2+P123/JS-K 
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DEVELOPMENT AND VALIDATION OF A METHOD TO  
MEASURE LEVELS OF THE NITRIC OXIDE- 
 PRODUCING PRODRUG JS-K USING  





or JS-K is an anticancer lead compound of the arylated diazeniumdiolate class. JS-K is 
active against acute myeloid leukemia in in vitro and in vivo models. In this paper, we 
describe a sensitive and reproducible Ultra Performance Liquid Chromatography (UPLC) 
method JS-K measurement. We established linearity, accuracy, precision and specificity. 
We also developed a method to resolve, identify and quantify JS-K from its two major 
metabolites (2,4-dinitrophenol and S-(2,4-dinitrophenyl)-glutathione). We also compared 
two different extraction procedures and established the extraction efficiency of both. We 
compared a single step protein precipitation method/direct method with a two-step solid 
phase extraction procedure in blood and organic solvents. The recovery of JS-K 
demonstrated the extraction efficiency of both methods. The solid phase extraction 
procedure was more efficient as compared to the single step protein precipitation method. 
We also established the efficiency of solid phase extraction to determine if any drug loss 
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occurred during the extraction procedure. Insignificant loss of JS-K occurred with the 
final method developed. This method could be used for measurement of JS-K in clinical 
samples in the	  future. Also, this method lays the foundation for future studies in 
metabonomics and metabolomics. 
 
5.2 Introduction 
Acute myeloid leukemia  (AML) is a clonal, hematological malignancy characterized 
by proliferation and accumulation of myeloid blast cells in the bone marrow. It is the 
most common type of adult acute leukemia with a median age at diagnosis of 67 years 
(1). Current treatment regimens for AML rely primarily on cytarabine and anthracyclines 
(2). There is a need for new agents that effectively target leukemia cells and leukemic 
stem cells (3).  
Nitric oxide (NO) and NO donors have shown promise in producing cytotoxicity in 
cancer cells (4-7). O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-
ium-1,2-diolate or JS-K is a NO-donor that belongs to the arylated diazeniumdiolate 
class. This prodrug releases 2 molecules of NO upon nucleophilic attack by thiols. 
Mechanistically, JS-K releases NO upon attack by glutathione (GSH) (8), the most 
abundant cellular thiol (9). The reaction is catalyzed by glutathione-S-transferases (GST). 
This class of enzymes is overexpressed in several malignancies (10). Apart from the 
cytotoxic effects produced by NO release, JS-K’s cytolethality has also been speculated 
to involve arylation of key cellular proteins resulting in posttranslational modification 
leading to cell death (11). JS-K induces cytochrome-c release from mitochondria and 
activates caspase 3, 9 and 8 (12). In addition to AML, in vivo murine models have shown 
that JS-K is effective against prostate cancer (8), hepatoma (13), multiple	  myeloma (14), 
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non-small cell lung cancer (15) and glioma (16). JS-K also possesses anti-angiogenic 
activity both in vitro and in vivo (17). JS-K is selective in its toxicity towards malignant 
cells. It did not affect the growth of normal human peripheral blood mononuclear cells 
(14) and normal mammary epithelial cells (18). Thus, JS-K is a promising clinical 
candidate for cancer therapy.  
Advances in analytical instrumentation have led to the development of Ultra 
Performance Liquid Chromatography (UPLC). In contrast to High Performance	  Liquid 
Chromatography (HPLC), this chromatographic system ensures sensitive quantification 
with reduced analysis	  time. This is because	  the stationary phase of UPLC utilizes 2µm 
particles. Small particle size drastically improves resolution per unit time (19). 
As JS-K is a clinical lead, it was important to develop a protocol for its qualitative 
and quantitative analysis. We have developed a UPLC method to measure JS-K and its 
two major metabolites 2,4 dinitrophenol (2,4-DNP) and S-(2,4-dinitrophenyl)-glutathione 
(GS-2,4-DNP) (Fig. 5.1). The method developed could be used for quantification of the 
drug or its metabolites and to track its biodistribution.  It involves a two-step approach for 
JS-K quantification comprised of protein precipitation followed by solid phase extraction 
(SPE). Quantification was performed via UPLC. The method developed is sensitive to 
detect intact drug and its metabolites. It also offers high throughput adaptability enabling 
JS-K detection in patient samples once it enters clinical trials.  
 
5.3 Methods 
5.3.1 Chemicals and reagents 
JS-K was obtained from 2 different sources. One stock of JS-K (NCI JS-K) was 
synthesized at the National Cancer Institute by Dr. Joseph Saavedra as previously 
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described (20). For the purposes of this study, we treated this stock as an “unknown 
purity” compound. The other stock (Richman JS-K) was obtained from a scale-up batch 
produced at Richman Laboratories (Lower Gwynedd, PA) under conditions of Good 
Manufacturing Practice (cGMP). This JS-K was certified as 100% pure and therefore was 
used as a “standard” for quality control (QC) for the purposes of this study. In some 
experiments, JS-K was solubilized in micelles using Pluronic® P123 (Lot # WPYG535B) 
obtained from BASF (Florham Park, NJ). Solvents used for UPLC analysis were of 
HPLC-grade (Fisher Scientific, Waltham, MA). All other chemicals were from Sigma 
(St. Louis, MO) unless otherwise stated. 
 
5.3.2 Instrumentation and chromatographic conditions 
Solid phase extraction (SPE) C18 columns, 1g/8mL from Grace Davison Discovery 
Sciences (Deerfield, IL) were used for SPE of samples. Samples were analyzed on a 
Waters Acquity UPLC, Binary Solvent Manager (BSM) (Waters, Millford, MA) using 
Acquity UPLC BEH C18 columns (2.1 x 50 mm, 1.7 µm particle size) connected to a 
Waters Acquity UPLC PDA detector powered by Empower 2 software. For sample 
elution, we used an isocratic mobile phase (A and B), consisting of 10% acetonitrile 
(ACN) in 0.02M ammonium formate (pH~3) (A) and 100% ACN (B). It was used at a 
ratio of 70% A and 30% B for 4 min.  This was followed by gradient wash for an 
additional 2	  min. Flow rate was kept constant at 0.6mL/min for 6 min. The mobile phase 
was filtered through a 0.45 µm Teflon coated membrane filter (Millipore, Bilerica, MA). 
During chromatographic separation JS-K, 2,4-DNP and GS-2,4-DNP were monitored by 
absorbance at 300 nm.  
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5.3.3 Drug and sample preparation 
5.3.3.1 JS-K preparation 
50 mM JS-K stocks were prepared in DMSO. Free JS-K was formulated by diluting 
stock to 1/10 in DMSO. Subsequent dilutions were made in phosphate buffered saline 
(PBS) (pH~6.5) or DMSO as indicated. For JS-K preparation in P123 micelles (P123/JS-
K), 50 mM JS-K was diluted in 2.25% P123 to a final concentration of 1 mM P123/JS-K. 
Subsequent dilutions were made in PBS if required. 
 
5.3.3.2 Sample preparation  
To obtain 2,4-DNP and GS-2,4-DNP calibration curves, three 0.2 mM final 
preparations were made in DMSO in duplicate. For JS-K method validation, NCI JS-K or 
Richman JS-K solutions were prepared at 5 different concentrations (5, 50, 100, 150 and 
200 µM). The JS-K peak was obtained at 300 nm; the 2,4-DNP peak was obtained at 280 
nm; and the GS-2,4-DNP peak was obtained at 340 nm. For method validation, United 
States Pharmacopeia (USP) parameters were applied. 
 
5.3.4 Solid phase extraction efficiency 
We developed a solid phase extraction (SPE) procedure for the analysis of JS-K and 
its metabolites in in vivo samples. We established the efficiency of SPE by comparing 
recovery of JS-K from samples using SPE (two step extraction or TSE) to samples using 
a single step extraction (SSE) or protein precipitation (PP). The efficiency of SPE was 
established in JS-K samples prepared in relevant solvent or in mouse blood samples 
spiked with JS-K and then extracted using either a SSE via protein precipitation with 
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ACN/formate or a TSE via protein precipitation followed by SPE. For both techniques, 
JS-K standards were used. Both protocols are detailed as follows: 
 
5.3.4.1 Non-blood sample analysis  
3 mL of 10 µM or 100 µM JS-K or P123/JS-K were prepared from their respective 
stocks in 40% ACN/60% 0.02 M formate in water (pH~3). This preparation was divided 
into 2 halves. The first half was directly analyzed by UPLC. This was used as a baseline 
to calculate the loss of	  JS-K, if any, from SPE. The other half of the preparation was 
diluted with 0.02 M formate in water to reduce the final ACN percentage to 20% with a 
final volume of 3 mL. This dilution was used because in exploratory experiments we 
found that sample application with a high percentage of ACN (above 25%) led to loss of 
drug and its metabolites during washing steps. This 3 mL was then applied to SPE 
columns previously activated with methanol (MeOH) followed by 40% ACN/60% 
formate. The flowthrough was discarded. The columns were then washed with a weak 
solvent (2% ACN/98% 0.02M formate). The wash was discarded as well. Finally, 
columns were eluted with 100% MeOH twice. The eluates were collected and aliquoted 
for UPLC run. For the calculations, necessary adjustments were made based on the final 
amount of sample used in a particular experiment. 
 
5.3.4.2 Blood sample analysis 
 Mouse blood was collected in polypropylene tubes containing 0.3 mL 4% citrate 
(pH~5) using a protocol approved by the University of Utah Institutional Animal Care 
and Use Committee.  Samples were spiked with 1 mM P123/JS-K or 5 mM JS-K to 
obtain a final JS-K concentration of 0.5 mM. Area under the curve (AUC) was obtained 
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for these two preparations after extraction in 40% ACN/60% 0.02 M formate (total 
count). This total count was subsequently treated as actual JS-K added and the SPE 
treated and nontreated sample recovery was calculated relative to total count. The tubes 
were then placed for 2 min. at room temperature before centrifugation at 2500 rpm for 10 
min. The supernatant (SN) was extracted and divided equally into two sets for SSE or 
TSE.  For SSE, the sample set was spin filtered and the eluate was collected. The spin 
filtration was performed in order to avoid development of any backpressure of the UPLC 
BEH column leading to system overpressure. The spin-filtered samples were ran on the 
UPLC directly. For the TSE, the sample sets were diluted with 0.02 M formate to reduce 
ACN percentage to 20% and extracted with SPE as detailed above. Necessary 
dilutions/adjustments were made for calculation purposes. 
 
5.3.5 JS-K method validation parameters 
5.3.5.1 Accuracy and linearity 
 Accuracy is defined as “closeness of test results obtained by that procedure to the 
true value” (21). We analyzed the accuracy of the JS-K method by calculating	  the 
percentage recovery of JS-K samples of “unknown purity” (NCI JS-K) from JS-K 
standards of “known purity” (Richman JS-K). We evaluated percent recovery across a 
range of five different concentrations, namely 5, 50, 100, 150 and 200µM. We also 
conducted the analysis at two different injection volumes, namely 1 and 5 µL. In 
addition, we also analyzed accuracy by showing curve linearity and near 
superimposability of measurements obtained with NCI JS-K samples over Richman JS-K 
standards. The curve was obtained by plotting the peak AUC against the theoretical 
amount injected. 
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5.3.5.2 Precision 
 Precision of JS-K curve was analyzed in terms of repeatability and ruggedness 
(intermediate precision). We analyzed repeatability by running 5 different JS-K 
concentrations, each concentration in triplicate. Each set was injected twice at 2 different 
injection volumes. The standards and the samples were prepared in DMSO. Standard 
deviation (SD), relative standard deviation (RSD) and percentage of relative standard 
deviation (or coefficient of variation) was analyzed for each set of concentrations. 
Intermediate precision was analyzed by analyzing standards and samples on two different 
days with two sets of standards and samples prepared each day. The analyst, instrument 
and method were the same on both days. Samples and standards were prepared as 
detailed above. For statistical analysis, SD and RSD between two sets were calculated. 
 
5.3.5.3 Specificity 
 Specificity of the JS-K peak was analyzed by injecting standards prepared in DMSO 
or standards prepared in P123 Pluronic®  (P123/JS-K). Similar concentrations were 
prepared for each set (5, 50, 100, 150 and 200 µM) in DMSO in triplicate and evaluated 
at injection volumes of 1 and 5 µL in replicates. The AUC obtained at two different 
injection volumes was plotted against the amount injected and the linearity of the curve 
was established to show specificity of the method. 
 
5.4 Results and Discussion 
5.4.1 Recovery of JS-K and its metabolites 
Fig. 5.1 shows the structure of JS-K and its metabolites. We have developed a 
sensitive UPLC method to detect JS-K and its major metabolites in a single run. The 
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method is highly efficient and short enough to run multiple samples in 1 day. Fig. 5.2 
shows the recovery and resolution of JS-K and its metabolites peaks from a single run. 
 
5.4.2 Solid phase extraction (SPE) 
In order to develop the best and most sensitive method for analysis of JS-K and its 
metabolites, we compared two different extraction procedures. The single-step extraction 
(SSE) or protein precipitation (PP) method was compared to the two-step extraction 
(TSE) that involves PP followed by SPE. The SPE method was developed in order to 
analyze biological samples with high accuracy because drug detection can be limited by 
proteins or other blood components such as phospholipids (22). Consequently, the SPE 
method aims at getting rid of interfering blood components in order to enhance recovery 
of metabolites and the main analyte efficiently. 
We first determined the amount of JS-K or P123/JS-K lost during SPE. From the 
same pool, we analyzed one sample using direct extraction and the other one using SPE. 
Table 5.1 shows the percentage of JS-K lost with the use of SPE. As shown, negligible 
amounts of drug were lost with either formulation, suggesting the method works 
efficiently. 
Next, we analyzed a biological sample spiked with JS-K. The sample was extracted 
as summarized in the methods section using either SSE or TSE. Drug recovery was 
calculated based on the total amount of drug added and the amount measured. Results are 
shown in Table 5.2. One can conclude from these data that JS-K or P123/JS-K recovery 
from biological samples is significantly higher if the samples are processed with SPE. 
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5.4.3 Calibration curves 
We then prepared calibration curves for 2,4-DNP and GS-2,4-DNP (Figs. 5.3 and 5.4) 
as explained in the methods section. Both curves were linear with the following equations 
(5.1 and 5.2) for 2,4-DNP and GS-2,4-DNP, respectively:    
 
580958x – 44245 with R2 = 0.996        (5.1) 
895306x – 25328 with R2 = 0.999       (5.2) 
 
 Both curves have a correlation coefficient close to 1, showing the sensitivity of the 
method. The linearity obtained for metabolites is important for this study because during 
the clinical development of JS-K, metabolite detection will prove useful. 
 
5.4.4 JS-K method validation 
5.4.4.1 Accuracy and linearity  
The accuracy of JS-K measurements (calculated as percent recovery) was analyzed as 
explained in the methods section. As seen in Table 5.3, the percentage recovery is close 
to 100% for most of the samples. To further validate accuracy, we also compared the 
linearity of the JS-K standards from Richman (Richman JS-K) with JS-K samples from 
the NCI (NCI JS-K). The linearity of the two curves was established in terms of the slope 
of the lines. As seen in Figs. 5.5 and 5.6, the slopes of the obtained curves are: 
Fig. 5.5: injection volume of 1µL 
 
Richman JS-K: y = 3E+06x + 3096.8; R2 = 0.999               (5.3) 
NCI JS-K: 3E+06x + 4091.7; R2 = 0.999                             (5.4) 
 
Fig. 5.6: injection volume of 5µL 
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     Richman JS-K: y = 3E+06x +21060; R2 = 0.998                      (5.5) 
NCI JS-K: 3E+06x +19031; R2 = 0.999                                    (5.6) 
 
As is evident from both the figures and equations, the standard deviations are small 
and the correlation coefficients are close to one. Both standards and samples share similar 
slopes. 
The curves generated led to JS-K detection over a linear range of 0.001921 µg - 
0.07684 µg for 1µL injections and over a range of 0.01 µg - 0.384 µg for 5µL injections.  
Based on the linearity curve, the lower limit of detection (LLOD) and lower and lower 
limit of quantitation (LLOQ) is therefore below 1.921ng or 5 picomoles. 
 
5.4.4.2 Precision 
 Precision was calculated both in terms of intraday repeatability and interday 
reproducibility of the peaks. Table 5.4 shows intraday repeatability results calculated for 
Richman and NCI samples. As seen in the table, RSD values are small at high 
concentrations and deviations are evident at lower JS-K concentrations in both sets. This 
is typical for most assays as the variability in measurement of peak height or AUC is 
greater at such low concentrations. The interday precision or ruggedness results are 
shown in Table 5.5. Again, high RSD values are seen at lower concentrations. It is 
interesting to note that injection volume did not make much difference in the standard 
deviations or RSD obtained, reflecting the fact that standard deviation is a result of 
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5.4.4.3 Specificity 
 Specificity of the method was established by comparing free JS-K standards with JS-
K in P123 micelles as explained in the material and method section. At injection volumes 
of 1 or 5 µL, both standards were superimposable with JS-K in P123 indicating that 
addition of diluant/excipient did not cause changes in analyte detection. The curves are 
shown in Figs. 5.7 and 5.8. 
 
5.5 Discussion 
In this study, a method was developed and validated for the measurement of JS-K and 
its major metabolites (2,4-DNP and GS-2,4 DNP). The method was validated using a 
sensitive and rapid analysis provided by UPLC equipped with a UV detector. We 
compared two different extraction procedures that can be useful in the analysis of other 
agents than JS-K. Multiple studies have reported drug detection from biologics using 
HPLC or other analytical techniques with or without mass spectrometry analysis. For 
such studies, generally sample preparation is done using protein precipitation (23), (24), 
(25). The method is easy but lacks sensitivity and is time consuming. This method also 
requires larger sample volumes. Moreover, not all the proteins are precipitated by this 
method, which could lead to HPLC column clogging resulting in higher maintenance 
cost. Due to less sensitive resolution, longer sample runs are required on HPLC resulting 
in utilization of extensive mobile phase leading to higher costs and requiring more time. 
Advances in liquid chromatography with the introduction of UPLC have improved the 
performance for analysis substantially. High flow rate is obtained due to high operating 
pressure that cannot be achieved with HPLC (19).  
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Method validation was performed using lab-prepared JS-K (NCI) and standards from 
JS-K produced under cGMP conditions. We obtained good peak resolution and 
separation between JS-K and its metabolites. Unlike other bioanalytical assays, we did 
not establish the LOQ or LOD via signal/noise ratio as the noise detected was far below 
quantitation. We therefore established the range of LOQ based on the linearity curve. The 
accuracy and precision values calculated were in good agreement. The standard deviation 
or RSD calculated was slightly higher than expected in some concentrations. However, 
differences observed were between triplicates of the same sample/standard and not within 
the replicates. This indicates that the method developed is sensitive in peak detection and 
AUC calculation and the variability or deviations observed were due to user-based 




JS-K is an anticancer agent in preclinical development. We have developed a 
sensitive method to measure JS-K and its metabolites. The method has several potential 
applications. The method developed can therefore be used to perform bio-distribution, 
pharmacokinetic and toxicokinetic studies in animal models, which can guide dosing in 
humans. Also, this method can be combined with even more sensitive analytical 
techniques such as mass spectrometry (MS) and be applied for pharmacokinetic and 
elimination studies in patient samples. In the future, the method could be used for 
metabonomic studies. Metabonomic analysis is a comparatively new field and has wide 
applications such as toxicity analysis (26, 27), metabotyping, disease models (28, 29) and 
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“functional genomics” (30). Our method can serve as the basis for future 
pharmacokinetic studies of JS-K as an anticancer agent. 
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Fig. 5.1: Structure and metabolism of JS-K 
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Fig. 5.2: Chromatogram of JS-K and its metabolites. JS-K; 2,4-DNP and GS-
2,4-DNP (0.1 mM) were ran together as a single sample. The chromatogram 
shows clear and distinct peaks in a single 6-min. run. 	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Amount	  injected	  (nanomoles)	  
Fig. 5.3: 2,4-DNP standard curve using UV absorbance at 300 nm. Three 0.2 mM 
2,4-DNP samples were prepared in duplicate and run at 6 different injection 
volumes (0.5, 1, 2, 4, 6 and 8 µL). A linear curve was obtained. Each point is an 
average and SEM of 6 unique readings. As seen, error bars are small with a tight 
fit. The slope of the line and the R2 value obtained are y = 580958x – 44245, R² = 
0.99657. 	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Fig. 5.4: GS-2,4-DNP standard curve using UV absorbance at 300 nm. Three 0.2 
mM GS-2,4-DNP samples were prepared in duplicate and ran at 6 different 
injection volumes (0.5, 1, 2, 4, 6 and 8 µL). A linear curve was obtained. Each 
point is an average and SEM of 6 unique readings. As seen, error bars are small 
with a tight fit. The slope of the line and the R2 value obtained are y = 895306x – 
25328, R² = 0.99983. 	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Fig. 5.5: Linearity of Richman JS-K compared to NCI JS-K samples at 5, 50, 100, 150 
and 200 µM at 1 µL injection volume. Each concentration was made in triplicate and 
run in duplicate using UPLC. The injection volume was 1 µL. Each point on the curve 
is the average of peak area (n=6) with their standard deviations. For curve 
information, see text. Legend: ♦ = Richman JS-K; • = NCI JS-K. 	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Fig. 5.6: Linearity of JS-K standards compared to JS-K samples at 5, 50, 100, 
150 and 200 µM at 5 µL injection volume. For each concentration three 
replicates were made and each replicate was run in duplicate using UPLC. The 
injection volume was 5 µL. Each point on the curve is the average of peak area 
(n=6) with their standard deviations. For curve information, see text. Legend: 
♦ = Richman JS-K;  = NCI JS-K. 	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Fig. 5.7: Specificity of JS-K at 1 µL injection. JS-K standards at 5, 50, 100, 150 and 
200 µL were run in triplicate. Each set was injected twice. Similarly JS-K samples 
were prepared at 5, 50, 100, 150 and 200 µL in P123 diluant in triplicate. Again each 
set was injected twice. Area under the curve obtained for each set was plotted against 
the nanomoles injected. Each point on the curve is the average and SEM of six 
readings. Legend: ♦ = Richman JS-K; = NCI JS-K. 	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Fig. 5.8: Specificity of JS-K at 5 µL injection: JS-K standards at 5, 50, 
100, 150 and 200 µL were run in triplicates. Each set was injected twice. 
Similarly, JS-K samples were prepared at 5, 50, 100, 150 and 200 µL in 
P123 diluant in triplicates. Each set was injected twice. Area under the 
curve obtained for each set was plotted against the nanomoles injected. 
Each point on the curve is the average and SEM of six readings. Legend: 
♦ = Richman JS-K;  = NCI JS-K.	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Table 5.1 – Drug loss with solid phase extraction (SPE) 
Concentration 
(µM) 
% JS-K lost in SPE* % P123/JS-K lost in 
SPE* 
10 -2.263 ± 1.05 -3.331 ± 4.14 
100 -0.544 ± 3.3 -3.817 ± 5.72 
*Percentage drug loss was calculated based on the total initial amount of JS-K or 
P123/JS-K added. Reported is the average and SEM of 3 separate experiments. 	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Table 5.2 – Comparison of solid phase extraction (SPE) and direct extraction method 
efficiency 
Method % JS-K loss * % P123/JS-K loss * 
SPE 5.712±5.80 0.335±5.418 
Direct 33.778±3.69 39.424±4.316 
*Drug recovery from mouse blood was calculated based on the total initial amount of JS-K 
or P123/JS-K added.  Reported is the average and SEM of 3 separate experiments. 
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Average peak area 
(mAU)** ± SD*  
Accuracy 
(% Recovery)§ 
5 1 0.002 10965 ± 2254 137 
50 1 0.019 56126 ± 3669 96 
100 1 0.038 110855 ± 3642 102 
150 1 0.058 170597 ± 4567 105 
200 1 0.077 219143 ± 3190 100 
5 5 0.010 58270 ± 11329 123 
50 5 0.096 307904 ± 24230 88 
100 5 0.192 612312 ± 20099 101 
150 5 0.288 943774 ± 22920 103 
200 5 0.384 1216464 ± 29646 97 
**Three standards or samples were prepared for each concentration and injected in 
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5 1 8051 1705 21.18 0.21 
50 1 58626 11057 18.86 0.19 
100 1 108282 6522 6.02 0.06 
150 1 161794 6779 4.19 0.04 
200 1 218218 10464 4.8 0.05 
5 5 47174 16315 34.59 0.35 
50 5 348560 82553 23.68 0.24 
100 5 607231 18590 3.06 0.03 









200 5 1250103 49650 3.97 0.04 
5 1 10964 2254 20.55 0.20 
50 1 56125 3669 6.54 0.06 
100 1 110855 3641 3.28 0.03 
150 1 170597 4567 2.67 0.02 
200 1 21914 3190 1.45 0.01 
5 5 58270 11330 19.44 0.19 
50 5 307904 24230 7.87 0.08 
100 5 612312 20099 3.29 0.03 







200 5 1216464 29646 2.44 0.02 
**Three standards or samples were prepared for each concentration and injected in 
duplicate. SD*: Standard Deviation; CV*: Coefficient of Variation; RSD*: Relative 
Standard Deviation.  	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Table 5.5 – Intermediate precision for Richman JS-K samples (formulated in DMSO) 
prepared and analyzed on two different days 





5 1 9191 2871 0.31 
50 1 57309 8023 0.14 
100 1 116636 9965 0.09 
150 1 173972 13608 0.08 
200 1 240587 29086 0.12 
5 5 49978 18839 0.38 
50 5 343490 72768 0.21 
100 5 649859 42502 0.07 
150 5 988835 50218 0.05 
200 5 1367869 171209 0.13 
**Three standards or samples were prepared for each concentration and injected in 






SUMMARY OF RESEARCH, CRITIQUES AND 
SUGGESTED FUTURE WORK 
 
In this final chapter, each scientific chapter has been summarized succinctly to 
highlight the major hypothesis, findings and the goal achieved. Also, each chapter has 
been critically analyzed and based on those criticism, future work has been summarized. 
 
6.1 Chapter 2- Development and Characterization of a Pluronic® P123  
Formulation for the Nitric Oxide-generating Agent JS-K 
6.1.1 Hypothesis and motivation 
JS-K, an arylated diazeniumdiolate (ADZD), is a nitric oxide (NO)-releasing prodrug. 
NO donors have shown promising anticancer effects (1-10). Past studies with JS-K 
showed encouraging results (11-14). However, the instability of the drug in the presence 
of nucleophiles limits its applicability. Due to the above stated reasons, polymeric 
Pluronics® were screened in order to develop a formulation that would allow the clinical 
development of JS-K. The choice of using Pluronics® as compared to other polymeric 
systems were their ease of availability, cost effectiveness and comparative nontoxicity. 
Several Pluronics® have been approved by FDA and regarded as “Generally Recognized 
as Safe” (GRAS) (15). To start with our studies, we characterized the Pluronic® P123 
formulation of JS-K, and then tested it in vivo. 
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After the development of the P123/JS-K formulation, the first step was to analyze the 
overall utility of the formulation. Since JS-K rapidly degraded in the presence of GSH, 
we hypothesized that Pluronic micelles stabilized JS-K. We also hypothesized that 
Pluronic did not impart major toxicity on their own. Finally, we hypothesized that the 
formulation P123/JS-K will be effective in vivo. 
 
6.1.2 Summary of research 
After the initial comparison of four different poloxamers based on the drug loading, 
drug retention and formulation toxicity in HL-60 and U-937 myeloid leukemia cells, we 
performed the major stability analysis of JS-K and P123/JS-K. The stability was tested 
using, RPMI media with 10% fetal bovine serum, normal human blood and plasma, and 
4mM GSH. All the experiments showed that P123/JS-K was more stable than free JS-K. 
We then analyzed the protein binding of the free and Pluronic formulation, of JS-K. After 
the stability and the protein binding studies of the formulation, we characterized the 
poloxamer before starting the in vivo part. We measured the size (blank and formulation) 
of the Pluronic® micelles using dynamic light scattering. The size of the formulation was 
slightly smaller than the blank micelles. This could be because of the stabilization of both 
the drug and the unimers inside the micelle core. The micelles formed are very dynamic 
in nature and JS-K incorporation inside the core of the micelles stabilized the structure, 
thus reducing the size. The shape of the formulation was found to be spherical as 
obtained from transmission electron microscopy (TEM). The zeta potential measurement 
of the formulation was also carried out in distilled water. We also performed the critical 
micelle concentration (CMC) measurement and analyzed the specific gravity, cloud point 
and viscosity of the Pluronic. All the values were well within the range as reported by the 
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manufacturer. The in vivo tumor regression study was carried out on NOD/SCID 
IL2Rgnull mice. The mice were treated with 4 µmol/kg JS-K or 4 or 5 µmol/kg P123/JS-K 
or P123 only or were not treated at all. The treatment was performed every other day and 
was continued until the tumor size was greater than 10% of the body weight or when the 
mice became moribund. Interestingly, nearly 50% of the tumor regression was observed 
when treated mice (JS-K or P123/JS-K) were compared to untreated mice (no treatment 
or control treatment). Not much difference was observed between the free drug and the 
formulation initially, but a statistically significant difference was seen on the last day of 
the treatment. We expect the difference to go higher past that but we could not continue 
the treatment due to ethical reasons. The in vivo study clearly indicates that JS-K is an 
effective chemotherapeutic for the treatment of AML. The Pluronic formulation works as 
effectively as free drug with no observed major toxicity of the Pluronic by itself. 
 
6.1.3 Critical analysis and suggested future work 
This chapter of dissertation discussed the formulation prepared for JS-K. The major 
goals achieved with the formulation design were: a) stability of JS-K and b) increased 
solubility of the drug. The major assumption in the use of Pluronic was the polymer 
obtained from BASF was pure and ready to use. cGMP or medical grade Pluronic® P123 
is not available commercially but it could be made to produce by cGMP labs. At this 
point, the major goal was to confirm if the prepared formulation will work and is shown 
to be effective in in vitro and in vivo studies. In regards to Pluronic characterization, 
studies were performed based on physical parameters like specific gravity, cloud point, 
viscosity, critical micelle concentration, size and shape. All the parameters tested 
conformed with the previously reported values available in the literature or from the 
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manufacturer. We also performed some qualitative/quantitative studies based on the peak 
area by measuring the refractive index of the polymer on HPLC. 
 
6.1.3.1 Negative zeta potential 
While poloxamer P123 is a neutral polymer, the zeta potential analyzed was negative. 
The study performed by a different lab also showed negative zeta potential and our value 
is close to theirs (16). One of the possible explanations for such a value calculated by 
different labs could be the purity of the Pluronic available commercially. Therefore, it is 
suggested that in the future, Pluronic purity should be analyzed via chromatography. 
 
6.1.3.2 In vivo tumor model 
The tumor cell implantation in NOD/SCID IL2Rγnull mice to study tumor regression is 
an old model and does not mimic the actual clinical disease. As the drug is expected to 
enter the clinic study, a model that more closely reproduces the disease needs to be 
established. Broadly two models could be generated: 
6.1.3.2.1 Implantation of bioluminescent leukemia cells in irradiated NOD/SCID 
IL2Rγnull mice. Leukemia is a hematological malignancy. The older xenograft mouse 
models require the subcutaneous implantation of the leukemia cells, which does not 
reflect that actual disease involving the bone marrow (17). Therefore, a suitable model 
would be a systemic leukemia model with bioluminescent leukemia cells. This will have 
two major advantages. First, disease evolution will be close to the actual disease in 
humans with involvement of hematopoietic organs. Second, with the use of 
bioluminescent leukemia cells, tumor tracking will be reliable and quicker.  
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6.1.3.2.2 Leukemia stem cell mouse model. It has been found that chemotherapy 
resistant AML stem cells home in the endosteal region of the bone marrow (18). Since 
our focus is to establish specificity of P123/JS-K at the cancer stem cell level, it would be 
appropriate to generate an AML stem cell model in NOD/SCID IL2Rγnull mice. 
 
6.2  Chapter 3 −  Cellular Distribution Studies of the Nitric  
Oxide-generating Antineoplastic Prodrug JS-K,  
Formulated in Pluronic® P123 Micelles 
6.2.1 Hypothesis and motivation behind the study 
Polymeric micelles have been found to affect cellular penetration and cellular 
distribution (19). The polymers could have acidic functional groups, basic functional 
groups or be neutral polymers. Depending on the polymer type, drug release from the 
polymer could be acidic release, basic release or by simple diffusion (20). As it has been 
reported in the literature that micelles affect cellular penetration and the cellular 
distribution of the drug, focusing on such a result, we were motivated to analyze the 
variable distribution of our drug and formulation system. Rapaport et al. reported the 
nuclear penetration of their Pluronic/drug system. The drug used in the study was also 
hydrophobic like JS-K and the Pluronic system they used was P105 (21). Keeping this 
result in mind, we carried out our studies. Also, past studies have shown that JS-K 
stability is compromised in complex media such as RPMI with or without FBS as these 
media have free cysteine groups that could release NO from JS-K. This encouraged us to 
study if the stability of JS-K affected the cellular distribution of the drug. This 
experimental set up was also instrumental in answering a corollary observation, namely if 
the type of formulation affected the stability and thus the distribution. From the 
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mechanistic point, we wanted to address the post-translational modifications produced by 
the drug and the formulation. PABA-NO, an arylated diazeniumdiolate (ADZD), has 
shown extensive glutathionylation in human leukemia HL-60 cells (22). JS-K is also an 
ADZD and therefore, JS-K is also expected to glutathionylate proteins to different 
extents. The cellular distribution study was also important from future studies point of 
view. With cellular distribution study carried out, it was easier to hypothesize and 
analyze the cell death mechanism of JS-K. 
The polymeric formulation stabilized JS-K appreciably as explained in the previous 
chapter. The next step was to study the cellular distribution of the drug. The cellular 
distribution of the drug could be affected by the type of formulation and type of media 
used for incubation. We hypothesized that cell distribution will be different for the free 
JS-K and P123/JS-K. Also, the incubation media used for the cells and the drugs will 
affect their stability and thus the distribution. We further hypothesized that the 
distribution will affect the glutathionylation response induced by JS-K or P123/JS-K. 
Such a differential effect produced affects posttranslational modifications produced by 
the drug or the formulation in the proteins of various cell compartments finally affecting 
cell death. Posttranslational modifications such as glutathionylation are critical in cell 
survival (23). Such modifications induced are dependent on the type of the protein 
involved in the posttranslational modification and the cellular function carried out by that 
protein. This might work in favor or against the cell survival process. Also 
glutathionylation posttranslational modification has been particularly associated with 
cellular stress conditions such as oxidative stress and endoplasmic reticulum stress. Both 
the stress condition can result in the cell death response (24-33). 
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6.2.2 Summary of research 
This study was carried out with two clear objectives. The first objective was to 
analyze the differential distribution of the free drug compared to micelle formulated 
P123/JS-K. This is because micelles have been shown to affect the intracellular 
distribution and localization of several drugs. Also, with JS-K stability determined by the 
type of incubating solutions, we wanted to confirm if that affects the cellular distribution 
of the two formulations. The second objective was to explore the mechanistic effect of 
the free drug and the formulation and thus the effect produced due to the polymer used. 
This study was important in order to carry out future mechanistic studies of JS-K and the 
formulation P123/JS-K.  
In this study, the initial exploratory experiments were carried out to confirm the free 
drug or P123/JS-K uptake by human leukemia HL-60 cells. These initials experiments 
were positive and therefore, we moved to the next step of the differential distribution of 
the drug when incubated in different media. This study was carried out by treating HL-60 
cells with either JS-K or P123/JS-K when incubated in PBS that does not contain any 
proteins or amino acids that might lead to drug degradation. The incubated cells were 
then fractionated into cytosolic and nuclear isolates after indicated time points. The intact 
drug recovered from each compartment was calculated as percentage recovery of the 
actual amount of the drug added. We found that at each time point P123/JS-K recovery 
was higher than free JS-K. Also, nuclear drug recovery was higher than the cytosolic 
drug recovery. With this study, we were confident that the drug translocates primarily to 
nucleus. We then moved forward with more complex media where the HL-60 cells were 
incubated in RPMI/10% FBS media or PBS/10% FBS media. As postulated, the drug 
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recovery was lower as the drug degraded. RPMI/10% FBS media is the most complex 
media as it contains free cysteines and serum. PBS/10% FBS on the other hand, was a 
system with intermediate complexity. While it is not as gentle as PBS, it is not as harsh as 
RPMI/10% FBS. The studies also revealed that regardless of the incubating media, 
P123/JS-K recovery was higher than free JS-K from the nucleus. 
The glutathionylation studies carried out confirmed the nuclear entry of the drug as 
the nuclear proteins were glutathionylated to a higher extent as compared to the cytosolic 
proteins. Again, glutathionylation induced by P123/JS-K was higher than the free JS-K, 
again indicating polymeric micelles modulate drug’s function. 
 
6.2.3 Critical analysis and suggested future work 
6.2.3.1 High concentration of drug used  
In the study carried out, we used 50 µM of JS-K or 50 µM of P123/JS-K that was 
added to HL-60 cells and fractionated at different time points. While the IC50 of free JS-K 
is 0.5 µM, it could be argued that 100X times higher concentration should not have been 
used for the distribution study. The prime reason to start with such a high concentration 
was due to the limitation of the assay and sensitivity of the instrument. We used HPLC to 
quantify whole JS-K. We tried a lower concentration of the drug, but detection was an 
issue. Later, we developed a method on UPLC. When we used 5 µM JS-K or P123/JS-K, 
again we could not detect intact drug. Therefore, high concentration of the drug was used 
for cell uptake experiments. Another critique of the study was the degradation of the drug 
to its metabolites. We can justify the use of high concentration, as our aim was to detect 
the whole intact drug as it distributes. We were not analyzing any pharmacological effect 
produced by the drug, therefore we did not worry about the concentration or the 
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metabolites produced. Also, there are several clinically available drugs that have very low 
IC50 but are used at high concentrations when exploring pharmacological effects 
produced in vitro (34). 
 
6.2.3.2 Pluronic® uptake not quantified 
 P123/JS-K showed higher nuclear distribution and higher nuclear protein 
glutathionylation. The polymeric micelles affected the cell translocation. We analyzed the 
distribution of JS-K or P123/JS-K; in both the studies, whole JS-K was quantified and the 
effect of polymer was inferred from the higher recovery of P123/JS-K. We still need to 
determine whether the drug is still inside the micelle core when it is taken up by the cell. 
Also, how soon does the drug come out of the micelle core? Also, are the micelles 
differentially distributed? The corrolary question could be whether P123 (micelles or 
unimers) is taken up by cells. Additionally, we have shown differential protein binding 
between JS-K and P123/JS-K. This raises the possibility of interaction between P123 
unimers (or micelles) with albumin in addition to existing interaction between JS-K or 
P123/JS-K and albumin. If such a complex interaction is taking place, then this could 
affect the local concentration of JS-K. All these possibilities will require labeling of the 
Pluronic micelles with a dye and then tracking them via fluorescence. Also, in order to 
determine how soon JS-K is released from the micelle core or if P123/JS-K as a whole 
distributes in the nuclei, we will have to prepare labeled Pluronics® and then quantify 
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6.2.3.3 Types of proteins glutathionylated not identified 
 In this study, the aim was to analyze global glutathionylation of cytosolic and nuclear 
proteins. With the confirmed result that both JS-K and P123/JS-K cause glutathionylation 
of the cytosolic and the nuclear proteins, the next step should be to analyze the types of 
nuclear (soluble and insoluble nuclear proteins) and cytosolic proteins glutathionylated 
by running the relevant markers and generating hypothesis for the possible proteins that 
could be glutathionylated. 
 
6.3 Chapter 4- Multiple Stress Response Induced by the  
Nitric Oxide-releasing Prodrug JS-K. 
6.3.1 Hypothesis and motivation behind the work 
Nitric oxide has been associated with pro-apoptotic and anti-apoptotic effects. As 
explained in detail in the chapter, the delivery and site of NO release determines the type 
of the effect produced. Initial studies have confirmed that NO released due to JS-K or 
other ADZD has been associated with their pro-apoptotic effects. This motivated us to 
further explore the possible mechanisms that might be involved in producing such 
effects. There are several effects produced by JS-K as shown by past studies. There are 
certain effects that are tumor type specific and some are due to properties of JS-K. The 
major effects produced by JS-K could be attributed possibly to a) release of NO, b) 
ability to undergo nucleophilic substitution reaction with GSH, c) catalysis by GST 
enzyme system, d) specificity towards cancer cells due to targeting of pathways elevated 
in cancer, e) posttranslational modifications induced due to S-nitrosylation, S-
glutathionylation and arylation, f) oxidative stress or nitrosative stress (redox imbalance) 
caused by consumption of GSH or release of NO, g) endoplasmic reticulum stress caused 
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by accumulation of proteins as a result of S-glutathionylation or S-nitrosylation or due to 
oxidative stress. Therefore, apoptotic effects produced by JS-K could be attributed to 
either one or all the possible mechanisms stated above. In order to achieve complete 
remission from cancer, the drug should produce multiple effects so that even if one 
possible target gains resistance, a chemotherapeutic should be able to work effectively in 
killing tumor cells. An effective chemotherapeutic should be able to modulate the 
intrinsic and the extrinsic components of cell survival. While the intrinsic component 
includes targeting of multiple stress responses such as the survival pathways and the self-
renewal pathways (of cancer stem cells), the extrinsic components is comprised of the 
tumor microenvironment, adhesion factors and angiogenic factors (35). In addition to 
these factors, it is also important for the chemotherapeutic to not cause any nonspecific 
toxicity to normal cells or noncancer cells. As stated in the introduction chapter, JS-K 
was found to be nontoxic in normal peripheral blood mononuclear cells, normal 
mammary cells, normal renal cells, normal murine hematopoietic stem cells and normal 
human CD34+ hematopoietic cells. 
With past studies indicating that JS-K possessed a broad mechanism of action, we 
based our hypothesis to carry out this project. We hypothesized that JS-K caused ER 
stress due to glutathionylation, nitrosylation, arylation, oxidative stress or nitrosative 
stress. We hypothesized that JS-K activated several components of intrinsic pathways of 
cell survival by producing multiple stress responses, thus acting through a broad 
mechanism of action. 
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6.3.2 Summary of research 
In this chapter, we presented our results showing that both JS-K and P123/JS-K 
caused ER stress and oxidative stress. We showed that when HL-60 cells were treated 
with 5 µM of JS-K or P123/JS-K for 4-8 hours, the unfolded protein response (UPR) 
sensitive chaperone GRP-78 was activated. GRP-78 is also considered a sensor of ER 
stress as this chaperone is involved in the refolding of misfolded proteins. This chaperone 
splits from the other ER stress markers- PERK, ATF6 and IRE1 and gets involved in the 
refolding of the misfolded proteins. CHOP, a gene and DNA damaging protein (GADD 
153), is considered the effector of ER stress. We also found that by treating HL-60 cells 
with 5 µM JS-K or P123/JS-K for 6-8 hours, CHOP activation was seen with Western 
blots. With positive results obtained in both experiments, we concluded that JS-K or 
P123/JS-K activated ER stress response. We then continued our studies to analyze the 
oxidative stress response. When HL-60 cells were treated with 5 µM JS-K or P123/JS-K, 
Western blot showed activation of JNK protein in some experiments and negligible 
activation in others. JNK protein activation (or JNK protein phosphorylation) is generally 
linked to oxidative stress response. To confirm if JS-K actually caused any sort of 
oxidative stress response or nitrosative response, we treated the cells with JS-K or 
P123/JS-K for 30, 60 or 120 minutes and later treated them with a reactive 
oxygen/reactive nitrogen species sensitive fluorescent dye for 30 minutes. The results 
showed that free JS-K had highest intracellular ROS/RNS which did not change 
significantly after 30 minutes of treatment. This could be due to the immediate release of 
NO from the free JS-K that was not sheltered in the micelle core. P123/JS-K on the other 
hand showed comparatively low levels of intracellular ROS/RNS. Again this could be 
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due to sheltering of the drug inside the micelle core thus stabilizing the drug for a period 
of time. When the cells were treated with both positive control (H2O2, a ROS generator) 
and P123/JS-K, the ROS/RNS levels were higher than the individual ROS levels of only 
H2O2 treated cells or only P123/JS-K treated cells, suggesting that ROS/RNS levels could 
be increased if the cells are pretreated with a ROS generator. Interestingly, P123 only 
treated cells, showed lower levels of ROS/RNS when compared to nontreated cells. Even 
though the results were not statistically significant, this suggests that either P123 reduced 
levels of ROS/RNS acting as a quencher or did not produce any effect at all. This also 
explains the reason for reduced levels of ROS/RNS detected for P123/JS-K cells. We 
next carried out our studies on AML patient cells. These cells were isolated from two 
relapsed AML patients and we carried out our ER stress-related studies. We obtained 
positive results in one set of patient cells and negative results in the other set. Several 
reasons could explain this observation. To start with, we had archived samples collected 
several years prior to the experiments and thus may have been altered during storage. The 
second could be differences in the phenotype of each individual leukemia as AML is a 
heterogenous disease. With further study, this could lead to a personalized medicine 
strategy. Another explanation could be the inherent ER stress response variability. It has 
been shown that in patient cell isolates where ER stress response was seen in the 
nontreated cells, such patients had increased survival chances as compared to patients 
with negative ER stress markers to start with (36). This may be because leukemias with 
baseline elevated levels of ER stress markers could be pushed beyond their threshold 
level switching the cancer cell survival response to cell death response. In the next set of 
studies, we tried to analyze JS-K’s effect on normal human CD34+ hematopoietic cells, a 
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population of cells that is rich in normal hematopoietic stem cells (HSC). The HSC were 
treated with JS-K or P123/JS-K and an MTT cell survival assay was carried out. Neither 
of the groups (treated or untreated) showed any difference. This result indicated that JS-K 
did not show any nonspecific toxicity towards the normal HSC. We then carried out our 
study to explore if JS-K activated ER stress response in normal HSC. The cells were 
treated with either JS-K or P123/JS-K or P123 only or positive control of ER stress 
response tunicamycin or not treated at all. Western blot analysis was then carried out on 
the treated or nontreated cells. Interestingly, none of the groups showed any activation. 
This could imply that none of the drugs were active on HSC or triggered the ER stress 
response. This could also imply that the treatment time was not enough as HSC are 
generally nonresponsive to any kind of stress response generated. More work is required 
in that area. 
 
6.3.3 Critical analysis and suggested future work 
In Chapter 4 of this dissertation, mechanistic effects of JS-K were studied in detail 
and an attempt was made to explore the broad pharmacological effects produced by the 
drug. The hypotheses for the proposed experiments were based on previous studies 
performed on JS-K and ADZD. In general, the confirmatory experiments to validate the 
hypothesis were performed and the conclusions were made based on the results obtained.  
 Several hypotheses could be proposed to a particular result obtained and therefore, 
specific experiments should be performed for the proposed hypothesis as explained later. 
Also, in the studies performed, although we used positive controls, we did not use 
negative control in any study. This is due to the fact that the mechanism explored could 
be activated by several pathways. Our intent was to establish the activation of the 
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mechanism in general. With more specific future studies, appropriate negative controls 
should be included. Also, other AML cell lines with different phenotypes (example U937 
cells) should also be tested. 
 
6.3.3.1 Accumulation of S-glutathionylated or S-nitrosylated  
proteins lead to ER stress 
 When the ER stress experiments were started, S-glutathionylation and S-nitrosylation 
caused by JS-K was considered a prime reason for causing accumulation of unfolded or 
misfolded proteins leading to ER overload thus causing ER stress. While global S-
glutathionylation has been showed in a set of experiments as explained in Chapter 3, we 
did not study the S-nitrosylation response produced by JS-K or P123/JS-K. Specific 
proteins glutathionylated or S-nitrosylated should be analyzed and their effect on ER 
stress activation should be studied. 
 
6.3.3.2 Link up of oxidative stress and ER stress 
 A very broad assumption could be made linking up ER stress with oxidative stress. 
While in the literature, there are several studies that link up both the stresses (37-41), in 
our case, confirmatory experiments should be performed. Induction of ERO1 (ER 
oxidoreductase enzyme) has been correlated with ER stress caused by oxidative stress. 
This further leads to activation of JNK protein and finally results in apoptosis. 
 
6.3.3.3 Inconclusive JNK activation 
 JNK activation should be confirmed with follow-up experiments testing for the 
activation of ERO1. Also, HL-60 cells could be pretreated with JNK inhibitors and then 
treated with JS-K followed by either an MTT experiment (to show if JNK involved in 
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cell death), an ER stress experiment (by testing for GRP-78 and CHOP to show if JNK is 
involved in ER stress) or a ROS/RNS generation experiment (to show if JNK is involved 
in oxidative stress). 
 
6.3.3.4 Consumption of GSH related to oxidative stress 
 Another hypothesis proposed in the study was induction of oxidative stress in HL-60 
cells due to consumption of GSH. Again, confirmatory experiments should be performed. 
Although GSH consumption studies have been done in past (14, 42), in the study 
proposed, a link would be established between GSH (anti-oxidant), oxidative stress and 
ER stress. For the study, GSH levels should be monitored before and after JS-K and 
P123/JS-K treatment in HL-60 cells. This should be followed by another experiment 
where HL-60 cells are pretreated with the GSH precurson N-acetyl-cysteine. The cells 
should be then treated with JS-K or P123/JS-K. After appropriated time, reactive 
oxygen/nitrogen species generation should be tested. This should be followed by ER 
stress activation experiments. This will confirm if glutathionylation caused by JS-K or 
P123/JS-K treatment led to accumulation of misfolded proteins thus leading to ER stress. 
This will also show any possible link between oxidative stress and ER stress. 
 
6.3.3.5 Effect on HSC 
 The effect on HSC should be analyzed in more detail by carrying out experiments at 
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6.3.4 Additional suggested future work 
6.3.4.1 Effect on leukemic stem cell (LSC) 
 In order to investigate the complete intrinsic pathway activated by JS-K, its effect on 
LSC should be analyzed. These can be challenging experiments because of the small 
number of LSCs in any given isolate and because of the heterogeneity of the phenotype 
of LSCs. 
 
6.3.4.2 Combination studies 
 Combination studies with clinically used ER stress generating drugs should be 
performed. One such drug is Bortezomib used for the treatment of multiple myeloma and 
mantle cell lymphoma. This drug is a proteasome inhibitor and causes both oxidative and 
ER stress generating cell death. 
 
6.3.4.3 Cell senescence experiments 
It is possible that JS-K caused cell death through other pathways than programmed 
cell death. A number of studies have shown that the drugs causing oxidative stress cause 
cell death due to senescence. Confirmatory studies with JS-K should be performed. 
 
6.3.4.4 Personalized medicine 
 JS-K specificity for one patient type suggests JS-K might be helpful in personalized 
medicine. The genes upregulated and down regulated by JS-K should be explored to use 
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6.3.4.5 Cell survival pathways 
 Nuclear factor kappa B (NF-kB) has been shown to be upregulated in leukemia and 
LSC and provide survival factors to leukemic cells and LSC (35, 43).  
 
6.4 Chapter 5- Development and Validation of a Method to Measure  
Levels of the NO-producing Prodrug JS-K Using Ultra  
Performance Liquid Chromatography (UPLC) 
6.4.1 Motivation behind the work 
In this chapter, a rapid and robust quantitative method was developed to analyze JS-K 
and its metabolites (2,4-dintrophenol and S-(2,4-dinitrophenyl)-Glutathione). The method 
was developed using Ultra Performance Liquid Chromatography (UPLC). This method 
holds importance as P123/JS-K is a clinical candidate. Therefore, this method could be 
used for the clinical study of pharmacokinetic parameters such as elimination, half-life, 
metabolite generation and tissue distribution. Also, the method could be used for dosage 
designing and future metabolomic and metabonomic studies. This is the fist assay 
developed for the simultaneous measurement of JS-K and its metabolites. The detection 
of metabolites is important as JS-K degrades to its metabolites rapidly. Information about 
metabolites could help in studies related to toxicity, elimination and drug tracking. 
Because of JS-K’s reactivity, the method used to extract JS-K from plasma and tissues is 
extremely important.  
 
6.4.2 Summary of research 
In this chapter, method development and validation of JS-K were discussed. For all 
the validation studies carried out, United States Pharmacopoeia (USP) parameters were 
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followed. The chromatogram of JS-K and its metabolites was obtained in a single run 
with all the three peaks separated from each other. A total run time of 6 minutes was 
developed. An isocratic followed by isogradient solvent system was utilized. We 
compared two extraction systems that lead to maximum drug recovery. We compared 
direct protein precipitation (PP) method with solid phase extraction (SPE) followed by 
protein precipitation method. 
JS-K spiked blood samples or JS-K prepared in solvent systems was used to calculate 
the percentage recovery using either extraction procedure. The results indicated that SPE 
followed by PP showed higher extraction of JS-K. After the extraction procedure 
development and method development, we validated the whole method. Validation was 
conducted by determining the linearity, specificity, accuracy, robustness and precision of 
the developed method. For the validation studies, we considered the lab prepared JS-K as 
“samples” and cGMP prepared JS-K as “standards”.  
 
6.4.3 Suggested future work 
6.4.3.1 Pharmacokinetic (PK) study 
This is one of the major and the direct application of the developed method. During 
the PhD, I have performed several PK experiments but the drug could not be recovered, 
even in the shortest time interval of 2 minutes. Also, those experiments were performed 
on HPLC, which is less sensitive as compared to UPLC. Therefore, it was important to 
develop a sensitive method with an efficient extraction procedure. While we did not 
perform a full PK analysis with the new method developed on UPLC, method 
development studies were carried out on mouse organs treated with JS-K for 2 minutes. 
The results obtained from UPLC were then validated by running the same samples on the 
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mass spectrometer and similar results were obtained. Full PK analysis will therefore be 
possible in future studies. 
 
6.4.3.2 Metabonomic study 
 The method developed could be used for future metabolomic and metabonomic 
analysis by coupling UPLC to a mass spectrometer. This could be helpful in toxicity 
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ACTIVATION OF ENDOPLASMIC RETICULUM STRESS IN  
PRIMARY CELLS AND ACTIVATION OF JNK PROTEIN  
BY JS-K OR P123/JS-K− A POTENTIAL MISSING LINK  
BETWEEN ENDOPLASMIC RETICULUM STRESS  
AND OXIDATIVE STRESS 
 
A.1 Introduction 
Endoplasmic reticulum (ER) is involved in a plethora of biological and physiological 
functions (1-7). One important role played by ER is in protein disulphide bond formation. 
If during the process, protein disulphide bond formation goes awry, it not only leads to 
accumulation of misfolded proteins evoking the unfolded protein response (UPR) and 
causing ER stress, but also leads to oxidative stress due to the continuous reductive and 
oxidative cycles generating H2O2 (8). Oxidant levels in the cell are controlled by the 
intracellular anti-oxidants including glutathione (GSH). Oxidative stress can be enhanced 
if the anti-oxidants get depleted in the process as well (9). The classes of oxidoreductases 
(Er oxidoreductase) and isomerases (protein disulfide isomerase) enzyme systems are 
involved in the disulphide bond formation between the proteins. Any modification to the 
enzymes involved also induces conditions of ER stress and oxidative stress (10, 11). 
Several attempts have been made to link ER stress with oxidative stress. Even then, no 
confirmatory pathway has been elucidated that links both stresses (12). Malhotra and 
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Kaufman suggested four different reasons of oxidative stress caused by ER stress. They 
suggested two pathways of reactive oxygen species  (ROS) generation during disulfide 
bond formation and two pathways independent of disulfide bond. The first case is the 
production of ROS as a byproduct during the transfer of electrons from thiol groups (in 
proteins) to molecular oxygen when the reaction is catalyzed by protein disulfide 
isomerase and ER oxidoreductase. In the second case, ROS production occurs due to 
depletion of GSH during improper disulfide bond formation. ROS production could also 
result independently of disulfide formation. This could happen either due to calcium leak 
into the cytosol or during mitochondrial oxidative phosphorylation (12). It has been 
shown that ER stress can follow (9) or precede (13) oxidative stress. 
Jun N terminal kinase (JNK) protein belongs to the class of mitogen activated protein 
kinase (MAPK). This protein has been found to be involved in the apoptotic response by 
inactivation of the anti-apoptotic protein Bcl-2. Phosphorylation or activation of the JNK 
protein to p-JNK has been found to be brought about by the UPR transducer-Ire1 (14). 
During the ER stress, Ire1 has been found to interact with tumor necrosis factor type 2 
receptor associated protein (TRAF2) to form a complex with mitogen activated kinase 
kinase kinase protein- apoptosis signal regulating kinase 1 (ASK1) which then activates 
JNK by phosphorylation of JNK protein (15). Oxidative stress has been linked with a 
similar molecular pathway. ROS has been found to activate pJNK through oxidation of 
thioredoxin which forms a complex with ASK1. Due to the disruption of the complex, 
free ASK1 activates JNK and other MAPK involved in the cell death (16). Therefore, 
JNK activation could be considered a common pathway that links oxidative stress and ER 
stress (12). 
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The supplementary chapter of the thesis is an attempt to explore and link the two 
stresses observed with JS-K treatment. Also, this chapter has been devoted to show some 
incomplete studies that hold potential if investigated fully in the future. As shown in 
Chapter 4, ER stress was triggered by JS-K or P123/JS-K treatment in HL-60 cells. We 
extended our study to patient AML cell isolates. We tested the stress response in primary 
cells obtained from relapsed AML patients. We found that out of the two AML patient 
samples tested, one showed activation of ER stress. In the other set of the study carried 
out, we tested a common link between ER stress and oxidative stress. Oxidative stress 
and ER stress can be linked due to the anti-oxidant systems involved. As JS-K causes 
oxidative stress and hypothetically depletes GSH, the process of ER stress and oxidative 
stress might be linked. 
 
A.2 Materials and Methods 
A.2.1 Materials 
JS-K was synthesized as previously described (17). Pluronic® polymers were obtained 
from BASF (Florham Park, NJ). Radio immuno precipitation assay (RIPA) cell lysis and 
extraction buffer was purchased from Thermo Fisher Scientific (Rockford, IL). Anti-
pJNK and anti-JNK antibodies were obtained from Santa Cruz Biotechnology, Inc 
(Dallas, TX). All other antibodies or chemicals and reagents were from Sigma Aldrich 
(St Louis, MO) unless otherwise indicated. Densitometric analysis were performed by a 
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A.2.2 Cell culture 
Human myeloid leukemia HL-60 cells (ATCC, Manassas, VA) were cultured in 
RPMI-1640 supplemented with 10% fetal bovine serum (FBS), penicillin/streptomycin 
and mycozap. Cells were cultured at 37◦C in a 5% CO2 humidified atmosphere. Primary 
AML patient samples were obtained from two relapsed AML patients and were frozen 
under liquid nitrogen under a protocol approved by the University of Utah Institutional 
Review Board. 
 
A.2.3 Western blot 
HL-60 cells or AML patients samples were treated with free JS-K (5 µM) formulated 
in DMSO or micelle JS-K (5 µM) formulated in 2.25% P123 for 6-18 h for ER stress 
experiments on AML patient sample cells or for 4-6 h for pJNK experiments in HL-60 
cells. The cells were also treated with JNK or pJNK positive control and a P123 and no 
drug control was established. After treatment, the cells were collected and washed with 
PBS. Following centrifugation, commercially available RIPA lysis buffer (25mM Tris 
HCl (pH 7.6), 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) 
supplemented with phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor was 
added to the pellet. The lysates were sonicated (50% intensity for 15 seconds), 
centrifuged and the supernatant was collected and protein concentration measured using 
the BCA protein assay reagent (Pierce Biotechnology). Loading buffer and reducing 
agent (DTT, Invitrogen) were added to the samples and electrophoresed in a 10% 
polyacrylamide gel (Biorad). Proteins were transferred to polyvinylidene difluoride 
(PVDF) membranes at 110 V for 95 min. (Biorad) for ER stress experiments or at 30 V 
for 120 min. (Invitrogen) for pJNK experiments. The blots were blocked for 1 h in 2.5% 
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nonfat dry milk diluted in tris-buffered saline containing 0.2% tween (TBST) and washed 
with TBST (3X, 7 min. each). The membrane was then incubated with primary antibody 
(anti-GRP-78 or anti-CHOP or anti-JNK or anti-pJNK or anti-actin) in 2.5% nonfat dry 
milk/TBST overnight. Membranes were washed (3X, 7 min. each) and incubated with 
horseradish peroxidase-conjugated secondary antibody in 2.5% nonfat dry milk in TBST 
for 2 h. The membrane was washed again in TBST thrice for 7 min. each and transferred 
proteins were detected with ECL substrate (GE Healthcare, Piscataway, NJ). 
 
A.3 Results and Discussion 
This study was also carried out on 2 archived AML patient samples. We saw 
enhanced GRP-78 expression in 1 of the 2 patient samples (Fig. A1). We also showed 
prolonged CHOP expression by JS-K or P123/JS-K treatment in 1 of 2 AML patient 
samples (Fig. A1). Basal level GRP-78 and CHOP expression was also observed in the 
same sample. The expression in an AML patient sample has two implications. First, JS-K 
or P123/JS-K treatment could induce ER stress in some patients. In fact, we observed that 
even basal level of GRP-78 or CHOP expression was not observed in patient 2 sample. It 
has been suggested that basal level of ER stress protein expression is essential for 
enhancing the stress and driving them towards the apoptotic response. In one study 
carried out on patient samples, it was found that patient samples with basal level 
expression of ER stress proteins were associated with a better prognosis and survival 
(18). In the case of JS-K, further investigation with a larger number of patient samples is 
necessary in order to confirm our preliminary observations. One factor to take into 
account as well is the effect of prolonged storage on archived patient samples. 
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The kinase protein c-JNK (c-JUN-NH2-terminal kinase) was activated when the HL-
60 cells were treated with JS-K or P123/JS-K (Fig. A.2). JNK activation leads to 
phosphorylation of the JNK protein, which then is involved in the apoptotic cascade. We 
obtained variable results with Western blots (Fig. A.3). Densitometric analysis showed 
some differences between the different treatment and control groups (Table A.1). 
However, results were variable and not uniformly reproducible. In some, JNK activation 
increased from 4 to 6 hours. Therefore, JNK activation could not be treated as the link 
connecting ER stress response with oxidative stress. To establish any link, more 
conclusive studies are required. 
As explained in Chapter 4, the JNK study was carried out to explore a link, if any, 
between ER stress and oxidative stress. JNK activation has been previously shown by JS-
K treatment in lung cancer (19), liver cancer (20) and multiple myeloma (21). However, 
all the studies showed JNK activation in response to MAPK or oxidative stress. This was 
the first time we tried to link the two pathways activated by JS-K. Although the results 
obtained with JNK activation are inconclusive at this point, more direct study such as 
activation of Ire-1 and Ero-1 could confirm if ER stress and oxidative stress are linked. 
 
A.4 Conclusions 
We showed increased expression of ER stress markers in 1 of 2 AML primary 
samples studied. The study discussed yielded inconclusive results about the involvement 
of JNK protein for mediating apoptotic response. It could not be ascertained from the 
study if JNK could be considered a link between ER stress and oxidative stress. 
Therefore, more investigation would be needed in order to determine whether JS-K 
produces apoptosis by producing oxidative stress followed by ER stress in AML. 
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Fig. A.1: Activation ER stress by JS-K. Primary AML cells 
from patient 1 were treated with the indicated drugs for the 
indicated period of time. Induction of GRP-78 or CHOP was 
verified when compared to No treatment. No t/t: No treatment 
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Fig. A.2: JNK protein phosphorylation after 4 hr or 6 hr 
treatment of HL-60 cells with JS-K or P123/JS-K. No t/t: no 
treatment; JNK ctrl: positive JNK control 
No t/t     P123    P123/JS-K        JS-K                   JNK ctrl 
0 hr       6 hrs     4 hrs   6 hrs   4hrs  6 hrs 
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Fig A.3: JNK protein phosphorylation after 4 hr or 6 hr treatment of 
HL-60 cells with JS-K or P123/JS-K treatment. Not much difference 
was observed in no treatment and treatment. No: No treatment; P/JS-K: 
P123/JS-K; pJNK and JNK: positive controls 
	   214	  
 
 
Time (hrs)/Exp# Formulation pJNK JNK JNK/pJNK Actin 
0/1 No Treatment 22984 71820 0.320022278 116964 
4/1 No Treatment 23426 72960 0.321080044 121068 
4/1 P123 23426 70680 0.331437465 116964 
4/1 JSK 24310 71820 0.338485102 125856 
4/1 P123/JS-K 26078 72960 0.357428728 130644 
6/1 No Treatment 27404 71820 0.381565024 132696 
6/1 P123 25194 74100 0.34 131328 
6/1 JSK 26962 77520 0.347807018 130644 
6/1 P123/JS-K 31382 77520 0.404824561 123804 
6/1 p-JNK Control 28288 160740 0.175986064 786600 
6/1 JNK Control 26520 109440 0.242324561 119700 
0/2 No Treatment 67716 179860 0.376492828 66640 
4/2 No Treatment 52668 173604 0.303380106 81340 
4/2 P123 45828 159528 0.287272454 69090 
4/2 JSK 47196 162656 0.290158371 70070 
4/2 P123/JS-K 46512 172040 0.270355731 66640 
6/2 No T 45828 176732 0.259307879 72520 
6/2 P123 49932 189244 0.263849845 70560 
6/2 JSK 51300 204884 0.250385584 79380 
6/2 P123/JS-K 46512 204884 0.227016263 77420 
6/2 p-JNK Control 75240 273700 0.274899525 25480 
6/2 JNK Control 65664 237728 0.276214834 75950 
Table A.1: JNK, pJNK and actin levels in two separate experiments. Notice the 
difference in pJNK levels in the two experiments when treatment is compared to no 
treatment. 
